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Abstract
Human pluripotent stem cells (PSCs) provide a powerful model system for the study of early human
development, disease modeling and physiology. We chose to focus our studies on monogenic diabetes using
this model system. Within the pancreas, β cells are one of the most critical endocrine cells as loss of this cell
type disrupts blood glucose homeostasis, leading to diabetes. Due to the limited availability of primary human
cells it is difficult to study them in vitro, especially in the context of genetic disease where patient material is
even more difficult to obtain. Here, we characterize endodermal progenitor (EP) derived β-like cells as a
model system for studying β cell development and function in vitro. EP cells are a population of endodermal
stem cells, which can self-renew and be differentiated into multiple endodermal cell lineages. EP derived β-like
cells are mono-hormonal for insulin and express a number of genes important for insulin processing and
secretion. By use of both static stimulations and perifusion assays we show that EP derived β-like cells are
responsive to both glucose and a number of other know secretagogues. Next, we demonstrate that genome
editing with a zinc finger nuclease at the AAVS1 safe harbor locus can generate stable gene expression in PSCs
during differentiation. We then combine these tools and describe the use of PSCs as an in vitro model system
to study GATA6. Heterozygous mutations in this gene are the leading cause of pancreas agenesis while studies
in mice do not replicate the human phenotype. Induced pluripotent stem cells were created from a pancreas
agenesis patient with a heterozygous mutation in GATA6. Using genome editing technology, additional stem
cell lines with mutations in both GATA6 alleles were generated and demonstrate a severe block in definitive
endoderm induction. Re-expression of GATA6 or other GATA family members can rescue this endoderm
phenotype. Partial rescue could also be achieved by treatment with a basic fibroblast growth factor. Using the
EP cell culture system to bypass the developmental block at the endoderm stage, cell lines with mutations in
one or both GATA6 alleles were differentiated into β-like cells. The mutant cells were shown to be functionally
defective by failure to secrete insulin upon glucose stimulation. Decrease in retinoic acid concentrations used
during the differentiation lead to decreased β-like cell differentiation efficiency of the heterozygous GATA6
mutants suggesting a possible mechanism for the patient phenotypes. These data show that GATA6 plays a
critical role in endoderm specification and β-like cell functionality in humans while in mice it is dispensable,
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Human  pluripotent  stem  cells  (PSCs)  provide  a  powerful  model  system  for  the  study  of  
early   human   development,   disease   modeling   and   physiology.  We   chose   to   focus   our  
studies  on  monogenic  diabetes  using  this  model  system.  Within  the  pancreas,  β  cells  are  
one  of   the  most   critical  endocrine  cells  as   loss  of   this   cell   type  disrupts  blood  glucose  
homeostasis,  leading  to  diabetes.  Due  to  the  limited  availability  of  primary  human  β  cells  
it   is   difficult   to   study   them   in   vitro,   especially   in   the   context   of   genetic   disease  where  
patient   material   is   even   more   difficult   to   obtain.   Here,   we   characterize   endodermal  
progenitor   (EP)  derived  β-­like  cells  as  a  model  system  for  studying  β  cell  development  
and  function  in  vitro.  EP  cells  are  a  population  of  endodermal  stem  cells,  which  can  self-­
renew   and   be   differentiated   into   multiple   endodermal   cell   lineages.   EP   derived   β-­like  
cells  are  mono-­hormonal  for  insulin  and  express  a  number  of  genes  important  for  insulin  
processing  and  secretion.  By  use  of   both   static   stimulations  and  perifusion  assays  we  
show  that  EP  derived  β-­like  cells  are  responsive  to  both  glucose  and  a  number  of  other  
know   secretagogues.   Next,   we   demonstrate   that   genome   editing   with   a   zinc   finger  
nuclease  at  the  AAVS1  safe  harbor  locus  can  generate  stable  gene  expression  in  PSCs  
during  differentiation.  We  then  combine  these  tools  and  describe  the  use  of  PSCs  as  an  
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in   vitro   model   system   to   study   GATA6.   Heterozygous   mutations   in   this   gene   are   the  
leading   cause  of   pancreas  agenesis  while   studies   in  mice   do  not   replicate   the   human  
phenotype.   Induced   pluripotent   stem   cells   were   created   from   a   pancreas   agenesis  
patient   with   a   heterozygous   mutation   in   GATA6.   Using   genome   editing   technology,  
additional   stem   cell   lines   with   mutations   in   both   GATA6   alleles   were   generated   and  
demonstrate  a  severe  block  in  definitive  endoderm  induction.    Re-­expression  of  GATA6  
or   other   GATA   family   members   can   rescue   this   endoderm   phenotype.   Partial   rescue  
could  also  be  achieved  by  treatment  with  a  basic  fibroblast  growth  factor.  Using  the  EP  
cell  culture  system  to  bypass  the  developmental  block  at  the  endoderm  stage,  cell  lines  
with  mutations   in   one   or   both   GATA6   alleles   were   differentiated   into   β-­like   cells.   The  
mutant   cells  were   shown   to  be   functionally  defective  by   failure   to   secrete   insulin  upon  
glucose   stimulation.   Decrease   in   retinoic   acid   concentrations   used   during   the  
differentiation  lead  to  decreased  β-­like  cell  differentiation  efficiency  of  the  heterozygous  
GATA6  mutants   suggesting   a   possible  mechanism   for   the   patient   phenotypes.   These  
data   show   that   GATA6   plays   a   critical   role   in   endoderm   specification   and   β-­like   cell  
functionality   in   humans   while   in   mice   it   is   dispensable,   highlighting   the   importance   of  
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CHAPTER  1  
Introduction  and  Overview  
  
1.1  Characteristics  and  Function  of  Pancreatic  β-­cells  
β   cells   reside  within   the  endocrine  portion  of   the  pancreas.  They  are   important   for   the  
maintenance  of  blood  glucose  and  a  loss  of  their  functionality  leads  to  diabetes  mellitus.  
As  this  thesis  will  first  focus  upon  the  characterization  of  an  in  vitro  system  for  the  study  
of  β  cells  and  then  apply  this  system  to  the  study  monogenic  diabetes  caused  by  GATA6  
mutations,  we  will  first  review  the  characteristics  and  functionality  of  β  cells.    
  
1.1.1  The  Pancreas    
The   human   pancreas   is   an   organ   consisting   of   exocrine,   ductal   and   endocrine   cells.  
Exocrine   cells   constitute   the   majority   of   the   pancreatic   tissue   and   function   to   secrete  
digestive  enzymes  such  as  amylase,  proteases,  lipases  and  nucleases  to  the  duodenum  
via   the   pancreatic   duct   that   runs   through   the  middle   of   the   pancreas.   These  enzymes  
function   in   nutrient   digestion   by   catalyzing   the   breakdown   of   lipids,   proteins   and  
carbohydrates   (Shih  et  al.,   2013).  Endocrine  cells  are   located   in   small   tight   clusters   in  
structures   known  as   the   Islets   of   Langerhans   found   scattered   throughout   the  exocrine  
tissues.  Within   the   islets  of  Langerhans   in  addition   to   the  endocrine  cells,   there   is  also  
vasculature,   neurons   and   mesodermal   derived   stromal   cells   (Pan   and   Wright,   2011).  
Endocrine   cells   function   mostly   independent   of   the   exocrine   pancreas.   Each   type   of  
endocrine   cell   within   the   islet   produces   a   specific   type   of   hormone.   α-­cells   secrete  
glucagon,  β-­cells  secrete  insulin,  δ-­cells  secrete  somatostatin,  ε-­cells  secrete  ghrelin  and  
γ-­cells  secrete  pancreatic  polypeptide  (PP)  (Cleaver  and  Melton,  2004).  The  α-­cells  and  
β-­cells  in  the  endocrine  pancreas  function  to  maintain  glucose  homeostasis  by  secretion  
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of  glucagon  when  blood  glucose   is   low  and  secretion  of   insulin  when  blood  glucose   is  
high   from   their   respective   cell   types.   δ-­cells,   ε-­cells   and   γ-­cells   function   to   regulate  
nutrient  metabolism.    Human  islets  are  composed  of  55%  β-­cells,  35%  α-­cells  and  10%  
δ-­cells  with  all  cell   types   intermixed  within   the   islet  architecture.  An  adult  pancreas  can  
contain  between  300,000  and  1,500,000  islets  (Brissova  et  al.,  2005).    
  
1.1.2  Development  of  the  Pancreas  
In   vitro   differentiation   protocols   for   pluripotent   stem   cells   (PSCs)   to   β-­like   cells   are  
informed  by  the  events  of  in  vivo  development.  By  mimicking  known  signaling  pathways  
that   are   important   at   each   stage   of   development   in   vivo,   PSCs   can   be   directed   to  
differentiate   toward   a   specific   lineage.   To   determine   whether   a   stage   of   development  
has  been  achieved  through  in  vitro  differentiation,  markers  that  are  expressed  in  vivo  are  
often  assayed.  Throughout   this   thesis,  different   stages  of  β-­cell   development  will   often  
be  referred  to  along  with  their  marker  expression.  Thus,  we  present  here  a  summary  of  
pancreatic  development.    
  
During  early  development,  the  region  of  the  foregut  endoderm  from  which  the  pancreas  
will  arise   is  prepatterned.  This   region  has  a   lack  of  expression  of  sonic  hedgehog  and  
requires   the   expression   of   retinoic   acid.   The   presumptive   pancreatic   endoderm   is  
characterized  by   the  expression  of  Pdx1,  Ptf1a  and  Sox9.  At   this  stage   the  pancreatic  
epithelium  is  tightly  surrounded  by  mesenchyme  which  highly  expresses  FGF10.  FGF10  
regulates   expression   of   Ptf1a   and   Sox9   and   is   important   for   cell   proliferation   and  
expansion  of   the  early  pancreatic  buds  once  they   form  (Pan  and  Wright,  2011;;  Shih  et  
al.,  2013).    
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The  pancreas  begins  to  develop  by  forming  as  two  epithelial  buds,  a  ventral  and  a  dorsal  
pancreatic   bud   at   opposite   sides   of   the   foregut   endoderm   by   evagination   into   the  
surround  mesenchyme.   In  both  mouse  and  human,   the  dorsal  bud   forms   first   from   the  
dorsal  foregut  endoderm.  The  emergence  of  the  dorsal  bud  appears  to  be  regulated  by  
extrinsic   cues   from   the   surrounding   vascular   endothelial   cells.   The   evagination   of   the  
ventral   pancreatic   bud   along  with   the   liver   from   the   ventral   foregut   endoderm   follows.  
The  ventral  pancreatic  bud   receives  cues   form   the  cardiac  mesoderm  and   the  vitelline  
veins  (Gittes,  2009;;  Pan  and  Wright,  2011).  At  this  stage  of  development,  the  majority  of  
the  buds  are  composed  of  multipotent  pancreatic  progenitor  cells   that  express   the  key  
transcription   factors   Nkx6.1,   Nkx6.2   and   Ptf1a.   Also   present   in   the   buds   are   a   small  
subset  of  cell   from  the  ‘first  wave’  of  endocrine  cells  which  are  either  glucagon  positive  
or  double  positive  for  insulin  and  glucagon.  These  cells  eventually  contribute  to  a  small  
subset  of  the  mature  α  cell  population  (Herrera,  2000).    
  
As   the   multipotent   pancreatic   progenitor   cells   continue   to   proliferate   there   is   a  
segregation   and   change   in  morphogenesis   of   the   pancreatic   buds   (Shih   et   al.,   2013).  
The  buds  elongate  and  as   the  gut   tube   rotates,   the  ventral  and  dorsal  buds  come   into  
contact  and  fuse  together.  Multiple  small  protrusions  then  begin  to  form  from  the  edge  of  
the  of  the  pancreatic  bud  (Gittes,  2009).  Cells  that  are  located  toward  the  edge  of  these  
protrusions  are  in  the  tip  domain  and  express  Ptf1a,  c-­Myc  and  Cpa  (Shih  et  al.,  2013).  
Tip   domain   cells   are   fated   to   become  acinar   cells.  As   development   progresses   acinar  
cells   will   continue   to   proliferate   and   increase   in   cell   number   by   duplication   (Pan   and  
Wright,   2011).      Cells   that   are   located   toward   the   inside   of   the   buds   are   in   the   trunk  
domain   and   are   characterized   by   the   expression   of   Nkx6.1,   Nkx6.2,   Sox9,   Tcf2,  
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Oncecut-­1,   Prox1   and   Hes1.   Trunk   domain   cells   are   bipotential   and   give   rise   to  
endocrine  and  ductal  cells  (Shih  et  al.,  2013).  
  
Endocrine  progenitor  cells  in  the  trunk  domain  form  the  primitive  duct  (or  also  known  as  
the  epithelial  cord),  which  is  characterized  by  tubules  lined  by  a  single  layer  of  polarized  
epithelial  cells.  At  this  stage  a  subset  of  cells  within  the  primitive  ducts  express  transient  
high   levels   of   Neurogenin3   (Ngn3),   which   indicates   the   onset   of   endocrine   cell  
differentiation.  Cells  that  lack  the  expression  of  Ngn3  will  become  the  ductal  cells.  Ngn3  
positive   endocrine   precursors   then   delaminate   from   the   primitive   ducts,   converting   to  
non-­epithelial   cells   through   a   process   thought   to   involve   an   epithelial-­to-­mesenchymal  
transition   (Pan   and   Wright,   2011;;   Shih   et   al.,   2013).   These   cells   migrate   into   the  
surrounding   area   and   coalesce   into   aggregates   that   become   the   islets   of   Langerhans  
(Gittes,  2009).  Each  endocrine  precursor  cell  will  further  differentiate  into  one  of  the  five  
types   of   hormone   expressing   cells.   The   mature   endocrine   cells   that   the   endocrine  
precursor  will  become  is  temporally  determined  and  is  dependent  on  the  developmental  
stage  at  which  their  differentiation  occurs.  At  this  stage  a  large  numbers  of  β  cells  and  α  
cells   begin   to   appear.  α   cell   fate   is   determined   by   the   expression   of   Arx   while   β   cell  
identity  is  determined  by  Pax4,  Pdx1  and  Nkx6.1  (Shih  et  al.,  2013).  
  
1.1.3  Insulin  Biosynthesis    
β-­cells   function   to   produce,   store   and   regulate   the   secretion   of   insulin   (Rhodes   et   al.,  
2005).  In  experiments  with  in  vitro  differentiated  β-­like  cells  we  examine  the  ability  of  the  
cells   to   process   insulin   as   a   method   to   determine   the   cells   maturity   and   similarity   to  
functional  adult  β  cells.    
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Frederick  Banting  and  Charles  Best   first  discovered   insulin   in  1921  by   treating  diabetic  
dogs  with  extracts  of  the  pancreas  that  did  not  contain  any  digestive  enzymes  (Banting  
et  al.,  1922).  Upon  treatment  both  blood  glucose  levels  and  sugar  excreted  in  the  urine  
of   the  dogs  were   lowered.     Based  upon   these   results,   the   first   human  diabetic   patient  
was  successfully  treated  with  insulin  in  January  of  1922  (Banting  et  al.,  1922).    
  
Insulin  consists  of  two  peptide  chains,  the  A  chain  and  the  B  chain  that  are  connected  by  
three  disulphide  bonds  (Fu  et  al.,  2013).   Insulin   is   initially  synthesized  as  the  precursor  
molecule  preproinsulin,  consisting  of  an  A-­chain  connected  to  the  B-­chain  via  a  C-­chain  
and   a   signal   peptide   located   at   the   end   of   the   B-­chain   peptide   (Figure   1-­1A).    
Preproinsulin   is   trafficked   through   the   rough   endoplasmic   reticulum   where   the   signal  
peptide   is   cleaved   and   the   remaining   proinsulin   is   folded   into   its   three   dimensional  
conformation   (Figure   1-­1B).   Proinsulin   is   then   loaded   into   immature   granules   and   the  
conversion  of  proinsulin  to  insulin  occurs  in  these  granules.  The  immature  granules  are  
acidified   as   the   prohormone   processing   enzymes   prohormone   convertase   2   (PCSK2)  
and  prohormone  convertase  1/3   (PCSK1/3)  have  optimal  enzymatic  activity  at  a  pH  of  
5.0   to  5.5.  Proinsulin   is  cleaved  at   two  sites  by  PCSK2  and  PCSK1/3   releasing   the  C-­
chain  that  is  also  known  as  c-­peptide.  Cleavage  by  the  prohormone  processing  enzymes  
results   in   the   exposure   of   the   C-­terminal   basic   amino   acids   on   the   insulin   molecule.  
These  residues  are  then  cleaved  by  carboxypeptidase  E  (CPE)  (Figure  1-­1C)  (Rhodes,  
2004a;;  Rhodes  et  al.,  2005).  As   the  granule  matures,   the  high  concentration  of   insulin  
causes  the   insulin  monomers  to  crystalize   into  hexamers  associated  with   two  zinc   ions  
(Bilous   and   Donnelly,   2010;;   Fu   et   al.,   2013).   When   viewed   by   electron   microscopy  
mature  insulin  granules  often  appear  as  crystalline  dense  core  granules  surrounded  by  a    
  







A	  	    
B	  	    
C	  	    
Figure  1-­1.  Processing  of   the   Insulin  Molecule.      (A)  Preproinsulin   is  synthesized  
with  the  signal  peptide,  A  chain,  Bchain  and  C-­peptide  connected.  (B)  The  signal  
pepetide  (C)  Upon  cleavage  of  insulin,  mature  insulin  consists  of  the  A  chain  and  
B   chain   connected   via   disulphide   bonds.      (PCSK1:   prohormone   convertase   1,  
PCSK2:  prohormone  convertase  2,  CPE:  carboxypeptidase  E).  
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clear  halo.  These  insulin  granules  are  ready  to  be  released  by  exocytosis  from  the  β-­cell  
upon  stimulation  (Bilous  and  Donnelly,  2010).  
  
1.1.  4  Insulin  Secretion    
Glucose  is  one  of  the  critical  stimulants  of  insulin  secretion.  When  human  blood  glucose  
levels  are  higher   than  5mmol/L  (90  mg/dL),  β-­cells  begin   to  release   insulin.  To  study  β  
cell   functionality,   in   vitro  differentiated  β   cells   should  express   the  appropriate  genes   in  
order   to   sense   increased   glucose   concentrations   as   well   as   respond   with   insulin  
secretion.    
  
Glucose   enters   the   β-­cell   through   glucose   transporters   such   as   glucose   transporter   1  
(GLUT1  encoded  by  SLC2A1)   or   glucose   transporter   2   (GLUT2  encoded  by  SLC2A2)  
(De   Vos   et   al.,   1995;;   McCulloch   et   al.,   2011),   where   it   is   then   phosphorylated   by  
glucokinase  (GCK).  The  glucose  is  then  metabolized  by  glycolysis,  causing  an  increase  
in   the   ratio   of   ATP   relative   to   ADP.   This   causes   the   ATP   sensitive   potassium   (KATP)  
channels   which   are   normally   open   to   close   (Henquin,   2000).   The   KATP   channel   is   an  
octamer  composed  of  tetramers  of  the  two  subunits:  the  sulfonylurea  receptor  (SUR1  or  
ABCC8)  and  an  inwardly  rectifying  K+  channel  (Kir6.2  or  KCNJ11)  (Koster  et  al.,  2005).  
The   closing   of   the   KATP   channel   results   in   the   depolarization   of   the   cell   surface  
membrane   and   the   opening   of   the   voltage   gated   calcium   channels   allowing   calcium  
influx  into  the  cytoplasm.  The  increased  cytoplasmic  calcium  stimulates  the  exocytosis  of  
insulin   granules   from   the   cell   (Greeley   et   al.,   2010).      In   addition   to   stimulating   insulin  
release   in   β-­cells,   high   glucose   levels   also   induce   proinsulin   biosynthesis.   Within   20  
minutes   of   glucose   stimulation,   the   increase   in   insulin   biosynthesis   can   be   observed.  
With  prolonged  stimulation,  by  60  minutes  the  maximal  rate  of  insulin  biosynthesis  is    



















     
Figure   1-­2.   Insulin   Secretion.      Glucose   enters   the   β   cell   via   either   GLUT1   or  
GLUT2   glucose   transporters   and   is   phosphorylated   by   GCK.   This   causes   an  
increase  in  ATP  to  ADP  ratio  and  results  in  the  closure  of  the  postassium  channel  
(Kir6.2   and  Sur1  are   the   subunits).  Depolarization  of   the  plama  membrane   then  
follows.   This   leads   to   the   opening   of   the   calcium   channels   and   increase   in  
cytoplasmic  calcium  concentrations  triggering  the  exocytosis  of  insulin  from  the  β  
cell.    
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reached.   This   can   to   30   to   40   fold   compared   to   basal   levels   (Alarcón   et   al.,   2002;;  
Rhodes,  2004b).  In  contrast,  when  unstimulated,  β-­cells  are  constantly  releasing  a  basal  
level  of   insulin.  The  glucose   that  undergoes  oxidative  glycolysis   is   low  enough  that   the  
ATP   to   ADP   ratio   does   not   change   significantly   and   the   KATP   channels   remain   open  
(Henquin,  2009).  
  
When  β  cells  are  stimulated  in  vivo  or  in  vitro,  insulin  release  is  biphasic.  During  the  first  
phase,   large  amounts  of   insulin  are   rapidly   released   from  a   ‘readily   releasable  pool’  of  
insulin  granules.  These  granules  are   located  near   the  cell   surface  membrane  and  can  
quickly  undergo  exocytosis.    The  first  phase  of  insulin  release  lasts  a  few  minutes  from  
the   time   of   stimulation.   With   prolonged   stimulation,   during   the   second   phase   of  
secretion,   there   is   a   decelerated   rate   of   insulin   secretion   and   the   amount   plateaus   or  
gradually  increases  lasting  as  long  at  the  stimulus  is  applied  (Bilous  and  Donnelly,  2010;;  
Henquin  et  al.,  2006;;  Lacy  et  al.,  1972).  Insulin  released  during  the  second  phase  comes  
from  a  reserved  pool  of  insulin  granules  that  can  account  for  up  to  90%-­95%  of  the  total  
granules  present  within  the  β-­cells.  These  granules  are  located  further  away  and  need  to  
be   modified   and   transported   to   the   cell   surface   membrane   in   order   to   undergo  
exocytosis  (Rorsman  et  al.,  2000;;  Seino  et  al.,  2009).  In  addition  to  high  glucose  levels,  
insulin   secretion   can   also   be   stimulated   by   glucagon,   gastric   inhibitory   peptides,  
epinephrine,  and  amino  acids  such  as  arginine  (Cleaver  and  Melton,  2004).    
  
Insulin  functions  to  lower  blood  glucose  levels  by  stimulating  a  10  to  40-­fold  increase  in  
glucose   uptake   by   cells   throughout   the   body   with   the   liver,   skeletal   muscles,   cardiac  
muscles,   central   nervous  system  and  adipose   tissue  being   important   sites.   In   the   liver  
and  muscles,   glucose  either   undergoes  glycolysis   to   produce  pyruvate,   be  oxidized   to  
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generate   ATP   or   is   stored   in   the   form   of   glycogen   and   tryiglycerides.   In   the   adipose  
tissues,  glucose  is  stored  in  the  form  of  triglycerides  (Saltiel,  2001).  
  
Full   functionality   of   β   cells   requires   a   combination   of   correct   insulin   synthesis   and  
development  of   the  appropriate  mechanisms   to   respond   to   insulin   secretion.  During   in  
vitro  differentiation  of  PSCs,  functionality  of  β-­like  cells  is  determined  by  insulin  secretion  
in   response   to   various   stimuli,   the  most   important   being   glucose.   Furthermore,   insulin  
granule  morphology  is  often  examined  as  an  indicator    
  
1.2  Diabetes  Mellitus  
Diabetes  Mellitus  is  a  disease  that  characterized  by  the  dysregulation  of  insulin  secretion  
and/or   responsiveness   in   the   body.   Patients   with   this   disease   typically   display  
abnormally  high   levels  of  circulating  glucose  (Rhodes  et  al.,  2005;;  Saltiel,  2001).  While  
type   I   and   type   II   diabetes  mellitus  are   the  most   common   forms  of  diabetes  and  have  
been   immensely  studied   (reviewed   in  Atkinson  et  al.,  2014;;  Kahn  et  al.,  2014;;  Lin  and  
Sun,  2010;;  Nolan  et  al.,  2011;;  Olokoba  et  al.,  2012;;  Tuomi  et  al.,  2014;;  Van  Belle  et  al.,  
2011),  this  thesis  will  focus  upon  the  less  studied  form  of  diabetes  mellitus  which  results  
from  monogenetic  mutations  in  GATA6.      
  
1.2.1.  Characteristics  and  Types  of  Diabetes  Mellitus  
In  humans,  physiological  levels  of  blood  glucose  prior  to  meals  are  typically  3.9  mmol/L  
to  7.2  mmol/L  (or  70  to  130  mg/dL)  and  two  hours  after  a  meal  should  not  be  higher  than  
10  mmol/L  (or  180  mg/dL).  Blood  glucose  levels  in  the  body  are  regulated  by  the  release  
of  the  antagonistic  hormones  from  α-­cells  and  β-­cells.  During  regular  homeostasis,  when  
blood   glucose   is   low,   α-­cells   secrete   glucagon   stimulating   the   hepatic   conversion   of  
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glycogen  to  glucose,  which  is  then  released  into  the  blood  stream.  When  blood  glucose  
levels   are  elevated,  β-­cells   respond  by   releasing   insulin   causing   the  uptake,   utilization  
and   storage   of   glucose.   Furthermore,   insulin   also   subdues   the   hepatic   production   of  
glucose   resulting   in   the   lowering   of   blood   glucose   levels   (Rhodes   et   al.,   2005;;  Saltiel,  
2001).  
  
Diabetes  Mellitus  can  be  categorized   into   four  main  categories,   type   I  diabetes,   type   II  
diabetes,  gestational  diabetes  and  diabetes  as  a  result  of  other  causes.  Other  causes  of  
diabetes   include  monogenic  mutations,  diseases  of   the  exocrine  pancreas  and  drug  or  
chemical  induced  diabetes  (American  Diabetes  Association,  2016).    
  
1.2.2  Type  I  and  Type  II  Diabetes  Mellitus  
Type   I   and   Type   II   diabetes   are   the   most   common   forms   of   diabetes.   In   2014,   an  
estimated   22   million   people   in   the   United   States   were   diagnosed   with   diabetes.  
Approximately   5%  of   those   diagnosed  with   diabetes   have  Type   I   diabetes  while   90%-­
95%  of  those  diagnosed  have  Type  II  diabetes  (Centers  for  Disease  Control  Prevention,  
2015).  Type  I  diabetes   is  an  autoimmune  disease  that  causes  the  selective  destruction  
and   loss  of  β-­cells.  An  absence  of   c-­peptide  occurs  as   the  disease   further  progresses  
and  eventually   there   is  complete   loss  of  β-­cells  within   the   islets  of  Langerhans.  Type   I  
diabetes   is   treated   by   rigorously  monitoring   glucose   levels   and   daily   insulin   injections.  
(American   Diabetes   Association,   2016;;   Murphy   et   al.,   2008).   Type   II   diabetes   is   a  
complex  metabolic   syndrome  with  multiple   causes   that   are   still   being   elucidated.  Risk  
factors  for  the  development  of  type  II  diabetes  include  aging,  obesity,  a  lack  of  exercise  
and  a  genetic  predisposition.  Management  of  type  II  diabetes  initially  includes  regulating  
diet  and  increasing  exercise  (Bilous  and  Donnelly,  2010;;  Saltiel,  2001).  While  Type  I  and  
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type  II  diabetes  continued  to  be   immensely  studied  (Atkinson,  2014,  2012;;  Kahn  et  al.,  
2014;;  Lin  and  Sun,  2010;;  Nolan  et  al.,  2011;;  Olokoba  et  al.,  2012;;  Röder  et  al.,  2016;;  
Todd,   2010;;   Tuomi   et   al.,   2014;;   Van   Belle   et   al.,   2011),   this   thesis   will   focus   upon  
investigating  monogenic  diabetes,  a  rarer  and  less  studied  form  of  diabetes.    
  
1.2.3  Monogenic  Diabetes  
Patients   with  monogenic   diabetes   have   a  mutation   in   a   single   gene   involved   in  β-­cell  
development   or   functionality.   These   mutations   can   be   inherited   as   dominant   or  
recessive,  or  arise  spontaneously.  Monogenic  diabetes  occurs  approximately  in  1  to  2  in  
100,000  live  births  (Anik  et  al.,  2015;;  Greeley  et  al.,  2010)  which  accounts  for  1%-­4%  of  
diabetes   that   are   diagnosed   in   children   (Rubio-­Cabezas   et   al.,   2014).   Monogenic  
diabetes   can  be   subcategorized   into  neonatal   diabetes  and  maturity   onset   diabetes  of  
the  young  (MODY)  (American  Diabetes  Association,  2016).    
  
A   total   of   13   types   of   MODY   have   been   described   in   the   literature.   The   four   most  
common   types   of   MODYs   result   from  mutations   in   either   HNF1α   or   MODY3   (30%   to  
50%  of  the  cases),  GCK  or  MODY2  (20%  to  50%  of  the  cases,  HNF1β  or  MODY5  (5%  
of   the   cases)   or  HNF4α   or  MODY1   (5%   of   the   cases)   (Kim,   2015;;   Steck   and  Winter,  
2011).   Patients   with  MODYs   typically   do   not   have   the   presence   of   pancreatic   or   islet  
autoantibodies,  have   low   insulin   requirements  and  detectable  c-­peptide   levels   (Murphy  
et  al.,  2008;;  Rubio-­Cabezas  et  al.,  2014).  
  
A  distinguishing  feature  of  patients  with  neonatal  monogenic  diabetes  is  that  the  majority  
of   these  patients   are   diagnosed  with   diabetes   prior   to   6  months   of   age   (Edghill   et   al.,  
2006;;   Iafusco   et   al.,   2002).   Patients   with   neonatal   diabetes   can   be   divided   into   two  
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subcategories:  those  that  have  transient  neonatal  diabetes  mellitus  which  resolves  after  
a   few   weeks   to   months   and   those   who   have   permanent   neonatal   diabetes   mellitus  
(Steck   and  Winter,   2011).   In   addition   to  mutations   that   can   result   in   non   functional   β  
cells,   permanent   neonatal   diabetes   can   also   be   a   result   of   pancreatic   agenesis.  
Pancreatic  agenesis   is  a  rare  congenital  disease  caused  by  heterozygous  mutations   in  
PDX1   (Schwitzgebel   et   al.,   2003;;   Stoffers   et   al.,   1997),   PTF1A   (Sellick   et   al.,   2004;;  
Weedon   et   al.,   2014),   GATA4   (Amato   et   al.,   2010;;   Shaw-­Smith   et   al.,   2014)   or  most  
commonly  GATA6   (Bonnefond  et  al.,  2012;;  Chao  et  al.,  2015;;  De  Franco  et  al.,  2013;;  
Lango  Allen  et  al.,  2012;;  Nakao  et  al.,  2013;;  Stanescu  et  al.,  2014;;  Suzuki  et  al.,  2014;;  
Yorifuji  et  al.,  2012).    
  
1.3  GATA6  
Human   GATA6   heterozygous   mutations   are   the   most   common   cause   of   pancreatic  
agenesis.  Due  to  discrepancies  in  the  phenotype  of  currently  available  mouse  models  of  
a  heterozygous  loss  of  GATA6  and  human  patient  phenotypes,  this  thesis  focuses  upon  
addressing  this  issue  by  development  of  an  in  vitro  human  based  model  system  to  study  
a  loss  of  GATA6.  
  
1.3.1  Characteristics  of  GATA6  
GATA6   is   a   part   of   the   six  member  GATA   family   of   transcription   factors   that   share   a  
conserved   DNA   binding   motif.   GATA   family   members   recognize   and   bind   to   the  
consensus   sequence  A/T-­GATA-­A/G.  While  GATA1,  GATA2  and  GATA3  are   primarily  
expressed   in   the  hematopoietic   cell   linages,  GATA4,  GATA5  and  GATA6  are   found   in  
endodermal  derived  tissues,  the  heart  and  gonads  (Molkentin,  2000;;  Viger  et  al.,  2008).  
GATA6  consists  of  7  exons  with  a  total  of  3770  base  pairs,  it  contains  two  transactivation    
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Figure  1-­3.  GATA6  protein  structure.  A  schematic  representation  of  GATA6  
protein  structure  with  the  alternative  transcriptional  start  site  indicated.  
(TAD:  Transcriptional  activation  domain,  ZnF:  Zinc  Finger  DNA  binding  domain,  
NLS:  nuclear  localization  signal).  
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domains  followed  by  a  DNA  binding  domain  and  a  nuclear  localization  signal  (Figure  1-­
3).  GATA6  has  two  transcriptional  start  sites,  both  located  in  the  second  exon  resulting  
in  the  production  of  two  isoforms  of  GATA6,  one  which  is  595  amino  acids  in  length  and  
the  other  449  amino  acids  long  (Brewer  et  al.,  1999).  In  mice,  GATA6  is  expressed  in  the  
primitive   streak,   heart,   lung,   intestine,   gonads,   adrenal   and   pancreatic   tissues  
(Koutsourakis  et  al.,  1999;;  Liu  et  al.,  2002;;  Sartori  et  al.,  2014).    
  
1.3.2  The  Function  of  GATA6    
GATA6   is  a   transcription   factor   that   is   critically   important   for  normal  human  pancreatic  
development.   Heterozygous   mutations   in   GATA6   are   the   most   common   cause   of  
pancreatic   agenesis   (Amato   et   al.,   2010;;   Shaw-­Smith   et   al.,   2014).   Patients   with   a  
heterozygous  mutation  in  GATA6  have  been  found  with  a  range  of  phenotypes  from  no  
pancreatic  defects   to  adult  onset  diabetes  and  pancreatic  agenesis   (De  Franco  et.  al.,  
2013).   The   majority   of   GATA6   mutations   in   patients   with   pancreatic   agenesis   are   de  
novo  mutations.  However,   in  rare  cases  where  the  mutation  has  been   inherited,  not  all  
patients   with   the   same   mutation   display   the   same   phenotype   suggesting   incomplete  
penetrance.   There   have   been   studies   of   pancreatic   agenesis   patients   and   family  
members   with   identical   GATA6  mutations   who   have   adult   onset   diabetes   or   even   no  
abnormalities  of  the  pancreas  (Bonnefond  et  al.,  2012;;  De  Franco  et  al.,  2013;;  Yu  et  al.,  
2014).  In  addition  to  the  pancreatic  defects,  GATA6  heterozygous  patients  often  have  a  
combination  of   other   additional   defects   including  gut   abnormalities,   intrauterine  growth  
retardation  and  congenital  heart  defects  (Chao  et  al.,  2015).      
  
In  murine  studies,  mice  with  heterozygous  loss  of  GATA6  are  fertile  and  phenotypically  
normal   (Carrasco   et   al.,   2012;;   Morrisey   et   al.,   1998;;   Xuan   et   al.,   2012).      Mice   with  
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homozygous  GATA6  null  alleles  are  embryonic  lethal  by  embryonic  day  7.5  (Morrisey  et  
al.,  1998).  Tetraploid  complementation  studies  have  shown  that  GATA6  is  essential   for  
extra   embryonic   endoderm   formation   and   thus   explains   the   embryonic   lethality   of  
GATA6  null  mice  However,   it  has  also  been  shown  that  GATA6  null  ES  cells  can  form  
definitive  endoderm  and  contribute   to   the  primitive  gut   tube   (Koutsourakis  et  al.,  1999;;  
Zhao  et  al.,  2005).  These  studies  were  based  upon  a  global   loss  of  GATA6  within   the  
mouse.  As  human  patients  with  a  heterozygous  loss  of  GATA6  have  phenotypes  of  the  
pancreas,   mouse   models   with   a   pancreatic   specific   loss   of   GATA6   are   beneficial   in  
gaining  an  understanding  of  the  function  of  GATA6  in  the  pancreas.    
  
During  the  development  of  the  mouse  pancreas,  GATA6  is  found  to  be  expressed  in  the  
pancreatic  epithelium  and  eventually  becomes  restricted  to  the  endocrine  pancreas  and  
ductal   cells   (Decker   2006).  Mice  with   a  homozygous   conditional   loss  of  GATA6   in   the  
pancreas   during   embryonic   development   driven   by   either   the   PDX1   or   the   PTF1a  
promoter  were  born  normal  and  had  a  normal  life  span.  Furthermore,  the  loss  of  GATA6  
in   these  mice  did  not  affect  glucose   tolerance   test  or   insulin   levels  when  examined  as  
adults   (Carrasco  et  al.,   2012;;  Martinelli   et  al.,   2013;;  Xuan  et  al.,   2012).  Additionally,  a  
conditional   loss   of   GATA6   in   adult   β-­cells   leads   to   increased   endoplasmic   reticulum  
stress  and  minor  β-­cell   death   but   does  not   have  any  effect   on  β-­cell  mass  or   glucose  
homeostasis   (Sartori   et   al.,   2014).   This   suggest   that   GATA6   is   not   required   in   the  
endocrine   compartment   in   mice   during   the   later   stages   of   development   and   in   the  
pancreas   of   adult   mice,   GATA6   plays   a   non   essential   role   in   β-­cell   functionality.  
However,   GATA6   is   required   in   the   exocrine   pancreas   for   the   maintenance   and  
functionality  of  acinar  cells.  In  mice  with  a  lack  of  GATA6,  the  acinar  cells  are  gradually  
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lost   resulting   in   the   majority   of   the   pancreas   being   replaced   by   fat   (Martinelli   et   al.,  
2013).  
  
In   an   alternative   experimental   system   to   study   GATA   family   function   in   pancreas  
development,  GATA6  was  fused  to  an  engrailed  dominant  negative  repressor  and  driven  
by   the  PDX1  promoter.  Expression  of   the  GATA6-­engrailed  dominant   negative  protein  
lead  to  the  majority  of  embryos  having  either  the  complete  absence  of  a  pancreas  or  the  
presence   of   a   partial   pancreas  with   disrupted  morphology.      Utilizing   this  more   severe  
method  to  inhibit  targets  of  GATA6  further  demonstrates  the  importance  of  GATA  family  
members  in  pancreatic  development  (Decker  et  al.,  2006).    
  
1.3.3  Functional  Redundancy  of  GATA6  
GATA4   and   GATA6   have   been   demonstrated   to   have   functional   redundancy   in   the  
development  of  the  heart  (Zhao  et  al.,  2008),  gonads  (Padua  et  al.,  2015,  2014),  adrenal  
glands  (Tevosian  et  al.,  2015)  and  intestine(Walker  et  al.,  2014)  in  the  mouse  and  in  liver  
and   pancreatic   development   in   the   zebra   fish   (Holtzinger   and   Evans,   2005).   A  
conditional   loss  of   both  GATA4  and  GATA6  during  pancreatic  epithelium  development  
leads   to  mice  being  born  with  growth   retardation  and  hyperglycemia.  These  mice  died  
shortly   after   birth   and   upon   examination   were   found   to   completely   lack   a   pancreas  
suggesting   functional   redundancy  between  GATA4  and  GATA6  (Carrasco  et  al.,  2012;;  
Xuan   et   al.,   2012).   This   functional   redundancy   was   further   studied   by   substituting  
GATA6  cDNA  in  place  of  the  GATA4  coding  sequence.  GATA6  was  able  to  compensate  
for   a   loss   of   GATA4   during   early   development   replacing   the   function   of   GATA4   and  
allowing  the  formation  of  the  extra  embryonic  endoderm.  Additionally,  at  embryonic  day  
10.5   the   heart   precursor   cells   could   form   and   were   comparable   to   wild   type   cells  
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suggesting  that  at   this  stage  GATA6  could  compensate  for  a   lack  of  GATA4.  However,  
by   embryonic   day   12.5   the   embryos   displayed   severe   cardiac   malformations.  
Furthermore,  examination  of   the  embryos  revealed  that   there  was  agenesis  of   the   liver  
and  ventral  pancreas  indicating  a  necessity  for  GATA6  in  the  maturation  of  these  organs  
(Borok  et  al.,  2015).  
  
In  human  patients  a  heterozygous  loss  of  GATA6  results  in  more  severe  phenotypes  in  
comparison   to  murine  models.  Additionally,   in  humans,   there   is   incomplete  penetrance  
of  GATA6  mutations  as  patients  have  a  range  of  phenotypes  from  adult  onset  diabetes  
to  pancreatic  agenesis  with  other  organ  deficiencies.  Haploinsufficiency  of  GATA6  may  
be  occurring  in  human  patients  while  this  is  not  the  case  in  murine  models.  Additionally,  
GATA4  and  GATA6  may  have  greater  functional  redundancy  in  the  mouse  as  compared  
to   humans   and   thus   in   mouse   models,   a   heterozygous   loss   of   GATA6   can   be  
compensated  for  with  GATA4.  To  study  a  loss  of  GATA6  in  a  human  based  system  we  
chose  to  use  the  differentiation  of  pluripotent  stem  cells.      
  
1.4  Pluripotent  Stem  Cells    
Pluripotent  stem  cells  (PSC)  are  cells  that  have  the  ability  to  indefinitely  self  renew  in  an  
undifferentiated  state  and  have  the  potential  to  be  differentiated  into  any  cell  type  in  the  
body.   Embryonic   stem   (ES)   cells   can   be   derived   from   the   inner   cell   mass   of   the  
blastocyst   while   induced   pluripotent   stem   (iPS)   cells   are   generated   by   introduction   of  
pluripotency   factors.   PSCs   have   the   potential   to   give   rise   to   unlimited   supplies   of  
functional  human  cells  that  can  be  used  in  the  study  of  developmental  biology,  disease  
mechanisms,  drug  discovery  and  therapeutics  (Girlovanu  et  al.,  2015;;  Irion  et  al.,  2008;;  
Murry  and  Keller,  2008).  In  this  thesis,  we  describe  the  further  development  of  a  protocol  
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for  differentiation  of  human  PSCs  through  an  endoderm  progenitor  cell  intermediate  to  β-­
like  cells.  We   then  utilize   these  cells  as  a  model  system   to  study  human  monogenetic  
diabetes  and  pancreas  agenesis  caused  by  heterozygous  mutations  in  GATA6.    
  
1.4.1  Mouse  Embryonic  Stem  Cells  
Pluripotent   cells   were   first   studied   in   vitro   through   the   use   of   mouse   teratocarcinoma  
stem  cells  or  also  known  as  embryonal  carcinoma  cells  (ECCs)  (Strickland,  1981).  ECCs  
are  formed  by  either  grafting  a  11  to  12-­day  old  fetal  germinal  ridge  or  a  1  to  6-­day  old  
fertilized   egg   into   the   testes   of   adult   of   mice.   The   grafted   cells   then   spontaneously  
proliferate   and   can   be   isolated   as   ECCs   (Stevens,   1970).   ECCs   are   pluripotent   and  
single   cells   can   be   transplanted   in   vivo   to   form   teratomas   (Kleinsmith   and  Pierce,   Jr.,  
1964).  Teratomas  are  benign  tumors  that  grow  in  vivo  and  contain  tissues  derived  from  
all  three  germ  layers,  the  ectoderm,  mesoderm  and  endoderm.  Due  to  these  properties,  
teratoma  formation  is  often  used  to  prove  the  pluripotency  of  a  cell  (Zhang  et  al.,  2012).  
In   vitro,   ECCs   can   also   be   differentiated   to   multiple   cell   lineages   by   formation   of  
embryoid   bodies   or   through   use   of   chemical   induction   (Strickland,   1981).   However,  
ECCs  often  have  multiple   chromosomal   rearrangements,   have  an  abnormal   karyotype  
and  in  some  lines  have  presence  of  only  one  X  sex  chromosome  (Evans,  1981).    Based  
on   the   pluripotency   of   ECCs   it   was   hypothesized   that   ECCs   were   derived   from   a  
population  of  embryonic  pluripotent  stem  cells  and  if  these  cells  would  be  experimentally  
advantageous  if  they  could  be  isolated  (Evans,  1981).    
  
Murine  embryonic  stem  (ES)  cells  were  first  isolated  in  1981  by  Martin  Evans,  Matthew  
Kaufman   and   independently   in   the   same   year   by   Gail   Martin.   In   their   experiments,  
mouse   ES   cells   were   derived   from   the   inner   cell   mass   of   either   blastocysts   that   had  
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been  delayed   in   implantation  or   the   late  mouse  blastocyst   (Evans  and  Kaufman,  1981;;  
Martin,  1981).  These  cells   form  colonies   that  proliferate  and  could  be  maintained  on  a  
feeder   layer   of   mouse   embryonic   fibroblasts.   Alternatively,   mouse   ES   cells   can   be  
maintained  and  propagated   in  culture  without   feeder  cells   in   the  presence  of   leukemia  
inhibitory  factor  (LIF)  (Smith  et  al.,  1988)  or  bone  morphogenetic  protein  (BMP)  signaling  
as  these  two  factors  can  suppress  differentiation  (He  et  al.,  2009)  .  Mouse  ES  cells  have  
a  normal  karyotype  that  can  be  stability  maintained  during  in  vitro  culture.  They  can  form  
teratomas   containing   ectoderm,   mesoderm   and   endoderm   germ   layers   when  
transplanted   into   immune   compromised   mice,   have   high   telomerase   activity,   stable  
karyotype  and   can   contribute   to   the   formation   of  mouse   chimeras   (Ginis   et   al.,   2004).  
The  discovery  of  the  mouse  ES  cells  laid  the  ground  work  for  the  genetic  engineering  of  
the  mouse  and  derivation  of  human  ES  cells.    
  
1.4.2  Human  Embryonic  Stem  Cells  
In  1998,  James  Thomson  first  described  the  derivation  of  primate  and  human  ES  cells.  
Human   ES   cells   were   derived   from   the   inner   cell   mass   of   the   human   blastocyst   and  
could  be  maintained  as  colonies  on  a  feeder   layer  (Thomson  et  al.,  1998).  The  optimal  
culture   conditions   for   the   long-­term   maintenance   of   pluripotency   with   basic   fibroblast  
growth  factor  (bFGF)  were  established  allowing  the  maintenance  of  human  ES  cells  in  in  
vitro  cultures   (Yamanaka,  2012).  Similar   to  mouse  ES  cells,  human  ES  cell   lines  were  
shown   to   have   high   telomerase   activity,   be   karyotypically   stable   and   displayed  
pluripotency  as  they  are  able  to  form  all  three  germ  layers  in  a  teratoma  assay.  Human  
ES  cells  express  the  transcription  factors  NANOG,  OCT4  and  SOX2.  They  also  express  
the   extracellular   markers   SSEA-­3,   SSEA4,   TRA-­1-­60   and   TRA-­1-­81   (Thomson   et   al.,  
1998).    
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Mouse  ES  cells  that  are  derived  from  the  pre-­implantation  epiblast  described  to  be  in  a  
naïve   state   of   pluripotency   while   cells   derived   from   the   post   implantation   epiblast   are  
termed  epiblast   stem  cells   (EpiSCs)   described   to   have  a   primed   state   of   pluripotency.  
Both   ESCs   and   EpiSCs   share   the   characteristics   of   the   ability   to   form   teratomas   and  
express   the  same  core  markers  of  pluripotency,  Oct4,  Sox2  and  Nanog.  Naïve  mouse  
ES  cells   can  be   incorporated   into  blastocysts   to   form  chimeras  and  colonize   the  germ  
line,   are   amenable   to   gene   targeting,   can  be   cloned  and  propagated   from  single   cells  
and   in   female   cells   do   not   have   an   inactivated   X   chromosome.   In   contrast,   EpiSCs  
cannot   contribute   to   germ   line   chimeras,   are  more   difficult   to   genome   engineering   via  
homologous  recombination,  do  not  propagate  well  as  single  cells,  have  higher  levels  of  
DNA   methylation   and   have   one   inactivated   X   chromosome.   While   mouse   ES   cells  
require  LIF  and  BMP  or  GSK3  and  MEK  inhibition  to  remain  pluripotent,  mouse  EpiSCs  
require  FGF  and  Activin/TGF-­β  signaling.  Although  human  ES  cells  are  derived  from  the  
preimplantation  blastocyst,   their   characteristics  and  methods  of  maintenance   in  culture  
are  more  similar  to  mouse  EpiSCs  leading  to  the  interpretation  that  human  ES  cells  are  
at  a  later  stage  of  development  than  mouse  ES  cells  (Davidson  et  al.,  2015;;  Ginis  et  al.,  
2004).    
  
1.4.3  Induced  Pluripotent  Stem  Cells  
In   addition   to   the   discovery   of   mouse   and   human   ES   cells,   there   are   other   major  
scientific   breakthroughs   that   have   together   contributed   to   the   development   of   induced  
pluripotent   stem   (iPS)   cell   technology.      In   1962,   John   Gurdon   demonstrated   the   first  
reprogramming   of   cells   by   somatic   cell   nuclear   transfer.   A   nucleus   from   the   intestinal  
epithelium  cell  of  a  swimming   tadpole  stage  was   transferred   to  an  unfertilized  egg  and  
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shown   that   the   egg   could   successfully   develop   into   a   tadpole   demonstrating   that  
development  could  be  reverted  to  an  earlier  stage  (Gurdon,  1962).  Additionally,  in  1989  
Harold  Weintraub  described  the  transcription  factor  myosin  D  as  a  master  regular  whose  
expression  could  convert  the  cell  fate  of  multiple  cell  lines  to  muscle  cells  (Weintraub  et  
al.,   1989).  This  was  a  very  early  demonstration   that   the   introduction  and  expression  a  
transcription  factor  could  change  cell  fate  (Yamanaka,  2012).  
  
Based  upon  these  ideas,  in  2006,  Takahashi  and  Yamanaka  described  the  generation  of  
iPS  cells   from  both  embryonic  and  adult  mouse   fibroblast  cells.  They   initially  screened  
24   transcription   factors   known   to   play   roles   in   maintaining   pluripotency   by   retroviral  
expression  and  then  narrowed  this  list  down  to  4  necessary  factors,  Oct3/4,  Sox2,  c-­Myc  
and   Klf4.   The   iPS   cells   were   demonstrated   to   express   markers   of   pluripotency,   they  
could  form  teratomas  and  contribute  to  adult  chimeric  mice  (Takahashi  and  Yamanaka,  
2006).   Their  work   demonstrated   that   adult   differentiated   cells   could   be   reprogrammed  
back  to  an  embryonic  stem  cell  state.    
  
The  following  year,  human  iPS  cells  were  derived  from  adult  human  fibroblast.  While  the  
Yamanaka  group  utilized  the  same  four  transcription  factors  that  were  used  to  generate  
mouse  iPS  cells  (Takahashi  et  al.,  2007),  James  Thomson  and  colleagues  demonstrated  
that   an   alternate   set   of   four   transcription   factors,   replacing   c-­Myc   and  Klf4  with   LIN28  
and  NANOG,  could  be  utilized  (Yu  et  al.,  2007).   In  both  studies  human   iPS  cells  were  
shown  to  be  karyotipically  normal  and  pluripotent.  The  discovery  of  iPS  cells  was  a  large  
advancement  in  the  field,  as  it  provides  a  potential  for  studying  pluripotency  without  the  
ethical  complications  that  may  be  associated  with  the  derivation  of  human  ES  cells  and  
also  a  method  to  generate  patient  specific  stem  cells.    
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Multiple  studies  have  now  demonstrated  that  there  is  flexibility  in  the  transgenes  that  can  
be  used  to   induce  pluripotency  from  both  mouse  and  human  somatic  cells.   In  addition,  
chemical  induction  of  pluripotency  that  has  resulted  from  screens  of  compound  libraries  
provides  an  alternative  method  for  the  generation  of  transgene  free  iPS  cells.  This  may  
be   beneficial   and   a   safer   alternative   if   iPS   cells   are   to   be   used   in   a   clinical   setting  
(Theunissen  and  Jaenisch,  2014).    
  
1.4.4  Human  Pluripotent  Stem  Cells  as  a  Model  System  
The  differentiation  of  human  PSCs   is  advantageous  as   they  provide  an   in  vitro  human  
based  model  system.  Upon  differentiation  to  different  cell  lineages,  PSCs  can  be  utilized  
to  study  basic  biology  such  as  human  development  and  the  effects  of  a  gain  or   loss  of  
gene  function.  Differentiated  cells  can  also  be  used  to  elucidate  disease  mechanism  and  
to  develop  and  test  new  drugs.  Furthermore,  human  PSCs  provide  a  source  of  unlimited  
cells   that   once  differentiated   could  be  used   for   cell   replacement   therapies   (Irion  et   al.,  
2008).  
  
One  powerful  model  system  that  has  been  intensely  studied  (Johannesson  et  al.,  2015)  
is   the   in  vitro  differentiation  of  β   cells.  Differentiation  of   this  cell   type   is   important   for  a  
better  understanding  of   the  development  and  functionality  of  β  cells  as  well  as  for   their  
potential   use   in   therapeutics.   In   humans,   β   cells   have   negligible   proliferation   with   the  
exception   of   the   first   year   of   life   where   β   cells   proliferate   at   a   rate   of   1%   to   3%   and  
during  pregnancy  (Wang  et  al.,  2015).  β  cells  are  difficult  to  maintain  in  vitro  and  cannot  
be  cultured  long  term  as  they  quickly  lose  functionality  (Pellegrini  et  al.,  2016).    
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Over  the  years  a  number  of  attempts  to  generate  a  β  cell  line  have  been  made,  however  
the  majority  of  human  β  cell  lines  that  were  generated  have  low  insulin  content  and  are  
not  glucose  responsive  (Skelin  et  al.,  2010).  To  date,  a  total  of  3  functional  human  β-­cell  
lines   have   been   generated   from   human   fetal   pancreases.   These   cells   are   glucose  
responsive,  express  β-­cell  specific  markers  and  can  be  cultured  for  extended  periods  of  
time.   The   first   β-­cell   line,   EndoC-­βH1   was   generated   by   transducing   fetal   pancreatic  
buds   with   lenti   viruses   expressing   SV40LT   and   human   telomerase   transcriptase  
(hTERT)  followed  by  in  vivo  transplantation  for  expansion  of  the  cells  (Ravassard  et  al.,  
2011).      Subsequent   β-­cell   lines,   EndoC-­βH2   and   EndoC-­βH3,   were   generated   by   a  
similar   method   with   the   added   capability   to   CRE-­excise   the   SV40LT   and   hTERT  
resulting   in  enhanced   functionality  and  β-­cell   specific  gene  expression   (Benazra  et  al.,  
2015;;  Scharfmann  and  Pechberty,  2014).    While  these  cells  contain  many  properties  of  a  
β  cell,  there  are  limitations  for  the  utilization  of  these  cells  because  they  are  immortalized  
cell   lines  and  may  not  perfectly  mimic  real  beta  cells.  Furthermore,   they  are  unsuitable  
for  therapeutics.    
  
Based  upon  these  limitations  the  differentiation  of  PSCs  to  β  cells  is  advantageous  as  it  
provides   an   unlimited   supply   of   β   cells   for   studies   of   β   cell   biology   as   well   as   the  
potential   to   be   used   in   the   clinic   for   treatment.   Additionally,   any   genome   editing   or  
genetic   manipulation   that   may   be   needed   can   be   readily   performed   in   PSCs   prior   to  
differentiation  overcoming  the  difficulty  posed  by  the  slow  proliferation  rate  of  terminally  
differentiated  cells.    
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1.4.5  Differentiation  of  Pluripotent  Stem  Cells  
In   vitro   differentiation   of   PSCs   is   achieved   by   sequential   exposure   of   PSCs   to   growth  
factors  based  on  known  signaling  pathways  and  mechanisms  of  development.  During  in  
vivo   embryonic   development   the   process   of   gastrulation   leads   to   the   formation   of   the  
primary  germ  layers,  ectoderm,  mesoderm,  and  endoderm  (Tam  and  Behringer,  1997).  
Tissues  and  organs   in   the  body  are  then  derived  from  one  of   the  three  germ  layers.   In  
the  mouse  embryo,  the  primitive  streak  forms  during  gastrulation  in  the  posterior  side  of  
the  embryo  at  the  border  between  the  epiblast  and  extraembyronic  tissue.  Uncommitted  
epiblast  cells   that  will  eventually  become   the  mesoderm  and  definitive  endoderm  germ  
layer  undergo  an  epithelial  to  mesenchymal  transition  and  migrate  through  this  structure.  
Epiblast  cells   that  migrate   through   the  more  posterior   region  of   the  primitive  streak  will  
form   the   mesoderm   while   cells   that   migrate   through   the   more   anterior   region   of   the  
primitive  streak  will  form  definitive  endoderm.  Ectoderm  cells  are  derived  from  the  most  
anterior  region  of  the  epiblast  and  do  not  migrate  through  the  primitive  streak  (Gadue  et  
al.,  2005;;  Murry  and  Keller,  2008).  
  
1.4.6  Definitive  Endoderm  and  Endodermal  Progenitor  Cells  
As   development   progresses,   the   endodermal   germ   layer   of   cells   forms   as   a   sheet   of  
cells  and  folds  into  a  primitive  gut  tube  along  an  anterior  to  posterior  axis.  The  primitive  
gut  tube  can  be  divided  into  three  main  regions:  the  foregut,  the  midgut  and  the  hindgut.  
The  thyroid,  esophagus,  lung,  liver,  pancreas  and  stomach  are  derived  from  the  foregut,  
the  small   intestine  develops  from  the  midgut  and  the  hindgut  will  eventually  give  rise  to  
the   colon   (Zorn   and   Wells,   2009).   In   vitro   primitive   streak   differentiation   is   first  
established   by   the   addition   of   Wnt3a.   Cells   are   then   sequentially   differentiated   to  
definitive   endoderm   by   the   activation   of   Nodal   signaling   through   the   addition   of   high  
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concentrations  of   the  Nodal  surrogate  Activin  A.  Activin  A  acts  by  binding   to   the  Nodal  
receptor  (D’Amour  et  al.,  2005;;  Gadue  et  al.,  2006;;  Kubo  et  al.,  2004).  
  
The  generation  of  an  expandable  PSC-­derived  endodermal  cell  population   is  desirable  
as   it   would   create   cells   with   a   greater   restricted   differentiation   potential   and   would  
provide  a  pure  population  of  cells   that  do  not  have  contamination  with  cells   from  other  
germ  layers  (Cheng  et  al.,  2013).  One  such  cell  population  that  has  been  described  by  
our  lab  is  the  endodermal  progenitor  (EP)  cell  (Figure  1-­4).  EP  cells  are  a  population  of  
endodermal  stem  cells  that  are  derived  from  human  ES  or   iPS  cells.  EP  cells  have  the  
ability   to   self-­renew  and  be  maintained   for  many  months   in   culture  with   trillions  of   fold  
expansion   potential.   They   express   markers   of   endoderm   including   SOX17,   FOXA1,  
FOXA2,   GATA4   but   low   levels   of   GATA6.   Upon   transplantation   into   immune  
compromised  mice,  EP  cells  do  not  form  teratomas  and  can  differentiate  spontaneously  
endodermal  derived  tissues  such  as  the  gut  epithelial  and  liver.  In  vitro,  EP  cells  cannot  
be  differentiated  in  mesodermal  or  ectodermal  lineages  and  have  been  demonstrated  to  
differentiate   into  multiple   endoderm   derived   lineages   including   the   pancreas,   liver   and  
intestine  (Cheng  et  al.,  2012).      
  
1.4.7  Pluripotent  Stem  Cell  Derived  β  Cells    
As   development   of   the   endodermal   germ   layer   proceeds,   the   primitive   gut   tube   forms  
organs   buds  which   will   proliferate   and   eventually   differentiate   into   the  mature   organs.  
One  of  these  organs  is  the  pancreas  that  initially  forms  as  two  distinct  buds  in  the  ventral  
foregut  endoderm  and  eventually  join  together  (Zorn  and  Wells,  2009).  By  mimicking  the  
signaling   pathways   that   occur   in   vivo,   multiple   protocols   have   been   established   to  
differentiate  PSCs  to  β  cells  in  vitro.  Although  many  of  these  early  protocols  claim  to    
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Figure  1-­4  
  
          
Figure   1-­4.   Endodermal   Progenitor   Cells.   A   schematic   illustration   of   the  
generation  of  EP  cells   from  pluripotent  stem  cells  is  shown.  EP  cells  are  capable  
of   differentiating   into   cells   of  many   endodermal   organs   including   liver,   pancreas  
and   intestine   that   in   vivo   are   derived   from   the   foregut,  midgut   and   hindgut.   It   is  
currently   unknown   if   EP   cells   have   the   potential   to   give   rise   to   all   endodermal  
derivatives   including   the   thymus,   thyroid   and   lungs   (ESC:   embryonic   stem   cell;;  
iPSC:  induced  pluripotent  stem  cell;;  EP  cell:  Endodermal  progenitor  cell).  
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generate  β   cells,   these   cells   often   failed   to   respond   to   glucose   stimulation  with   insulin  
secretion.   Analysis   of   gene   expression   revealed   that   there  was   expression   of   ARX,   a  
gene   that   is   typically   expressed   in   α   cells,   and   a   lack   of   NKX6.1,   a   β-­cell   specific  
transcription   factor   important   in  β   cell  maturation  and  maintenance.  Additionally,   these  
cells  are  also  polyhormonal  expressing  a  combination  of  insulin  and  glucagon  or  insulin,  
glucagon  and   somatostatin   (Basford  et   al.,   2012;;  D’Amour  et   al.,   2006;;  Micallef   et   al.,  
2012;;  Nostro  et  al.,  2011).  Studies  in  mouse  embryos  show  that  during  early  endocrine  
cell   development   in   vivo   in   the   ‘first   wave’   of   endocrine   cell   development,   cells   co-­
expressing   insulin   and   glucagon   have   been   observed.   These   polyhormonal   cells  may  
contribute   to   a   small   proportion   of   the  mature  α   cells   but   are   not   the   precursor   of   the  
mature  monohormonal  β   cells   (Herrera,   2000;;  Herrera   et   al.,   1994;;  Nostro   and  Keller,  
2012).  Only  during   the   ‘second   transition’  of  endocrine  development  do  mature  β   cells  
develop  and   these  cells  are  distinguished  by   their  expression  of  NKX6.1.  This  suggest  
that   the   endocrine   cells   that   were   differentiated   are   more   reminiscent   of   the   first  
transition  of  endocrine  cell  development  rather  than  a  mature  β  cell  (Nostro  and  Keller,  
2012).   In   these   earlier   protocols,   the   only   way   to   generate   functional   β   cells   was   to  
transplant  pancreatic  progenitors  into  an  immune  compromised  mouse  and  allow  3  to  4  
months   for   their  maturation   in   vivo   to  become  glucose   responsive   (Kroon  et   al.,   2008;;  
Rezania  et  al.,  2012;;  Schulz  et  al.,  2012).        
  
Our   lab  was   the   first   to   describe   a   differentiation   protocol   to   generate  monohormonal,  
glucose   responsive   β-­like   cells   by   utilizing   an   EP   cell   intermediate.      EP   cells   were  
differentiated  toward  β-­cells  utilizing  a  previously  established  protocol  designed  for  PSC  
differentiation  starting  from  the  primitive  gut  tube  stage.  EP  derived  β-­like  cells  express  
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insulin  and  do  not  express  glucagon.  Furthermore,  upon  glucose  stimulation,  the  kinetics  
of  insulin  secretion  was  comparable  to  that  of  an  adult  human  islet  (Cheng  et  al.,  2012).    
  
By   further  manipulation  of  pathways   involved   in  β-­cell  development  and  utilization  of  a  
three  dimensional  culture  system,  recently  three  groups  were  able  to  differentiate  PSCs  
to  functional  β  cells  in  vitro.  While  two  of  the  groups  cultured  and  differentiated  PSCs  in  
suspension,  the  other  aggregated  cells  at  the  pancreatic  progenitor  stage.  The  majority  
of  the  PSC  derived  β  cells  are  monohormal  for  insulin  and  a  subpopulation  of  the  insulin  
positive  cells  co-­express  two  β-­cell  specific  transcription  factors  PDX1  and  NKX6.1.  The  
PSC  derived  β  cells  can  respond  to  glucose  stimulation  with  a  2  fold  increase  in  insulin  
secretion  over  basal,  similar  to  the  primary  islet  controls  that  were  used.  The  cells  could  
respond   to   multiple,   sequential   glucose   stimulations   with   the   secretion   of   insulin,  
however,  in  these  studies  insulin  response  to  stimulation  was  poor  in  perifusion  systems  
and  displayed  abnormal  calcium  flux.  Upon  transplantation  into  nondiabetic  mice,  human  
c-­peptide  was   detected  within   2  weeks.   Transplantation   into   streptozotocin   induced   or  
Akita   diabetic   mice   could   reduce   the   hyperglycemia   more   quickly   than   in   previous  
publications  (Pagliuca  et  al.,  2014;;  Rezania  et  al.,  2014;;  Russ  et  al.,  2015a).    
  
The  ability  to  differentiate  PSCs  to  functional  β  cells  in  vitro  is  important  for  the  study  of  
the  mechanisms  of  β-­cell  failure.  PSCs  with  specific  mutations  can  be  obtained  through  
genome  editing  of  ES  cells  or   from  diabetic  patient  derived   iPS  cells.   In  vitro  derived  β  
cells  can  also  be  utilized  to   investigate  β  cell  proliferation,  maintenance,   in  drug  testing  
and  provide  the  potential  for  the  generation  of  an  unlimited  supply  of  β  cells  if  these  cells  
are  to  be  used  in  tissue  replacement  therapy.    
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1.5  Overview  of  Research  Goals  
The   goals   of   the   work   presented   in   the   following   chapters   are   to   use   the   human  
pluripotent  model  system  to  study  human  beta  cell  development  and  disease,  optimize  
beta   cell   in   vitro   development   and   enhance   genome   engineering   technologies   to   help  
achieve   these  goals.  Chapter  3  establishes  and  further  characterizes  EP  derived  β-­like  
cells  as  an  in  vitro,  human  based  model  system  to  study  the  development  and  function  
of   β-­cells.   We   confirm   the   functionality   of   EP   derived   β-­like   cells   and   explore   the  
similarities  and  differences  of  these  cells  to  adult  β  cells.  Chapter  4  describes  a  proof  of  
principal   study   for   the  utilization  of   the   zinc   finger  nuclease  at   the  AAVS1  safe  harbor  
locus  as  a  genome  editing  technique  in  pluripotent  stem  cells.  We  describe  the  creation  
of   a   GFP   reporter   line   by   utilization   of   a   lineage   specific   promoter   region   as   well   as  
knock  down  of   transcription  factor  by  expression  of  short  hairpins.  The  tools  previously  
described  are   then  utilized   in  Chapter   5   to   study   the   role   that  GATA6  plays   in   human  
endoderm  development  and  pancreatic  β  cells.  We  studied  the  role  of  GATA6  by  use  of  
a   GATA6   patient   derived   iPS   cell   line   with   a   heterozygous   mutation   and   a   genome  
edited   ES   cell   line   with   a   compound   heterozygous   mutation.   We   show   that   while   a  
heterozygous   loss   of   GATA6   does   not   affect   definitive   endoderm   specification,   PSCs  
with  a  complete  loss  of  both  alleles  do  not  differentiate  efficiently  to  definitive  endoderm.    
The   role  of  other  GATA   family  members  can  compensate   for   this   loss.  We   then  utilize  
EP  derived  β-­like  cells  to  show  that  while  a  loss  of  GATA6  is  not  absolutely  required  to  
differentiate  to  β-­like  cells  in  vitro,  the  presence  of  GATA6  is  required  for  the  β-­like  cells  
to   be   glucose   responsive.   In   these   studies,   we   demonstrate   that   the   differentiation   of  
PSCs  and  EP  cells  can  be  utilized  as  a  means  to  study  human  monogenetic  diabetes  in  
vitro.      
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CHAPTER  2  
METHODS  AND  MATERIALS  
  
2.1  Maintenance  of  Human  Pluripotent  Stem  Cells  
The  H9  human  ES  cells  (NIH  code  WA09)  were  obtained  from  Wicell  Research  Institute,  
Madison,  WI.  The  Mel1-­INS-­GFP  ES  cells  were  obtained  from  Ed  Stanley  and  Andrew  
Elafanty   at   the   Murdoch   Children’s   Research   Institute   (Micallef   et   al.,   2012).   The  
CHOP.Panagenesis1  (patient  iPS+/indel)   iPS  cells  were  generated  from  a  lymphoblastoid  
cell   line  (Stanescu  et  al.,  2014)  by  reprogramming  using  episomal  vectors  (Okita  et  al.,  
2011)  by  the  Stem  Cell  core  at  the  Children’s  Hospital  of  Philadelphia.    
  
Human  ES  cells  were  maintained  in  human  ES  cell  maintenance  media  in  gelatin  coated  
6-­well   tissue  culture  plates   (Thermo  Fisher  Scientific)  with   irradiated  mouse  embryonic  
fibroblast.   The   composition   of   the   human   ES   cell   media   consist   of:   DMEM/F12  
containing   15%   knock-­out   serum   replacement,   2mM   glutamine,   50U/mL   penicillin,  
50µg/mL  streptomycin,  100µM  Non-­essential  amino  acids,  0.075%  sodium  bicarbonate,  
1mM  sodium  pyruvate  (all  from  Invitrogen,  Grand  Island,  NY),  10-­4M  β-­mercaptoethanol  
(Sigma,   St.   Louis,  MO)   and   5ng/mL   or   10ng/mL   human   bFGF   (Stemgent).      The   cells  
were  passaged  every  3  to  6  days  by  treating  with  TrypLE  (Invitrogen)  for  3  minutes  and  
replating  in  ROCK  inhibitor  (R&D)  or  thiazovivin  (R&D).  
  
2.2  Primary  Human  Islets  (Chapter  3)  
Isolated   non   diabetic   human   islets   were   obtained   from   Prodo   Laboratories   and  
maintained  on    Prodo  Islet  Media-­  Standard  for  1  to  3  days  prior  to  use  for  experiments.    
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2.3  Vector  Construction  For  AAVS1  Targeting  
ZFNs   targeting   the  AAVS1   loci   (Hockemeyer   et   al.,   2009)  were   synthesized   and   sub-­
cloned   into   a   PGK   promoter   expression   vector   (ZFN-­left   and   ZFN-­right).   The   CD43  
targeting   construct   was   generated   using   the   AAVS1-­SA-­2A-­puro-­pA   donor   plasmid  
(Addgene,  Cambridge,  MA).  A  2136  base  pair  (bp)  sequence  from  -­1386  to  +750  of  the  
transcription  start  site  of  the  human  CD43  gene  (transcript  ID:  ENST00000395389)  was  
used.  This  region  includes  the  first  exon,  first  intron  and  the  second  exon  up  to  the  ATG  
of  the  CD43  transcript.  The  CD43  promoter  construct  was  cloned  out  by  PCR  using  the  
fusion   kit.   This   promoter   construct   was   followed   by   GFP   and   the   rabbit   globin   poly-­
adenylation   sequence   to   create   AAVS1-­SA-­2A-­puro-­CD43   promoter-­GFP-­PA   (Figure  
1A.1)  Generation  of   the  shPU.1  set  1  and  set  2  constructs  were  carried  out  by  cloning  
pairs   of   shRNA   against   PU.1   (Open   Biosystems)   into   a   miR-­30   backbone   (Wang,  
Theunissen,  &  Orkin,  2007)  into  the  AAVS1-­CAGGS-­eGFP  plasmid  (Hockemeyer  et  al.,  
2009).  The  expression  of  the  hairpins  are  driven  by  the  CA  promoter  to  create  AAVS1-­
SA-­2A-­puro-­CApromoter-­GFP-­shPU.1-­PA.   (Figure   1A.2).   ShPU.1   set1   contains   2  
hairpins,  one  against  exon  2  and  one  against  exon  5.  Both  hairpins  in  shPU.1  set2  are  
targeted  against  two  regions  of  PU.1  in  exon  5.    
  
2.4  Gene  targeting  of  the  AAVS1  locus    
Six-­well   tissue   culture   plates   (Thermo   Fisher   Scientific)   were   pre-­coated  with  matrigel  
(1:3   dilution)   (BD   Biosciences)   followed   by   plating   of   1x106   irradiated   puromycin-­
resistant  mouse  embryonic  fibroblast  cells.  H9  ES  cells  were  plated  at  a  density  of  1.2-­
1.8x106  cells  per  6-­well  dish  in  human  ES  cell  media  containing  10  µM  Rho-­associated  
kinase   (ROCK)   inhibitor   (Cayman   Chemical,   Ann   Arbor,   MI).   The   next   morning,   3-­4  
hours   prior   to   transfection,   the   medium   was   changed   to   human   ES   cell   medium  
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containing  20  µg/ml  bFGF  (Stemgent),  without  penicillin  and  streptomycin.  The  targeting  
vector  plasmid  (0.6  µg),  the  ZFN-­left  plasmid  (0.2  µg)  and  the  ZFN-­right  plasmid  (0.2  µg)  
were  added   to  100  µL  of   IMDM  (Mediatech)   followed  by  addition  of  X-­tremeGENE9  (3  
µL)   (Roche  Diagnostics).   The   transfection  mixture  was   gently  mixed   and   incubated   at  
room  temperature  for  20  minutes  before  it  was  added  drop  wise  into  one  well  of  H9  ES  
cells.  The  next  day,   the  medium  was  changed   to  human  ES  cell  maintenance  medium  
and  48-­72  hours  post  transfection,  puromycin  (0.5  µg/mL)  (Sigma)  was  added  with  each  
media   change.  Approximately   7   to   10   days   later,   single   clones  were  manually   picked.  
The   clones   were   passaged   and   expanded   before   being   screened   by   Southern   blot  
analysis.    
  
2.5  PCR  Screen  For  ZFN  Construct  Integration  (Chapter  4)  
PCR  was  carried  out  using  the  JumpStart  AccuTaq  LA  DNA  polymerase  kit  (Sigma).  The  
primers  used  were  homologous   to   regions   in   the  both   the   left  ZFN  and   the   right  ZFN.  
The   forward   primer   sequence   is   5’-­GCTTTTCCCAAGGCAGTC-­3’   and   the   reverse  
primer  sequence  is  5’-­GGGTCGACTTGCAGGTCG-­3’.  The  amount  of  plasmid  used  was  
equivalent   to   the  genomes  of  DNA  present   from  the  cells.  The  PCR  products  were  run  
on  a  1%  agarose  gel  at  100  volts  for  45  minutes.      
  
2.6  Genome  Editing  Using  CRISPR/Cas  (Chapter  5)  
The   gRNA  was   cloned   into   the   vector   (Addgene,   #41824)   as   described   by  Mali   et   al.  
(Mali   et   al.,   2013).   PSCs   were   plated   onto   gelatin   coated   6-­well   plates   with   mouse  
embryonic  fibroblasts  (MEF)s  24  hours  prior  to  transfection  and  were  transfected  at  40%  
to  60%  confluency.  1  µg  CAS9-­GFP  (Addgene,  plasmid  #44719),  1  µg  gRNA  and  3  µL  
X-­tremeGENE9   (Roche)   was   added   to   100   µL   IMDM   and   gently  mixed   together.   The  
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mixture  was  incubated  at  room  temperature  for  20  minutes  and  added  drop  wise  into  1  
well  of  cells.  18  to  24  hours  post  transfection,  cells  were  harvested  with  TrypLE  and  cell  
sorted   for  GFP  positive  cells.  These  cells  were  plated  at   low  density   in  human  ES  cell  
maintenance  media  with  ROCK  inhibitor  (Cayman  chemicals)  onto  a  1:3  matrigel  coated  
10  cm  tissue  culture  dishes  containing  MEFs.  Approximately  10  to  12  days   later  single  
colonies  were  manually   picked   and   screened.   To   screen   for  mutations,   genomic  DNA  
was  extracted  from  the  clones  by  resuspending  the  cells  in  20  µL  of  Accutaq  PCR  buffer  
(Sigma-­Aldrich)   with   0.1   µg/mL   proteinase   K   (Qiagen)   and   incubated   at   55°C   for   60  
minutes   followed   by   95°C   for   10   minutes.   Cell   debris   was   spun   down   and   5   µL   of  
supernatant  was  used  for  PCR.  PCR  primers  were  designed  to  flank  the  region  that  the  
gRNA  was   targeted  resulting   in  a  124  base  pair  product.  The  sequence  of   the  primers  
can  be  be  found  in  Table  S1.  Phusion  High  Fidelity  DNA  polymerase  was  used  for  PCR  
(New   England   Biolabs   Inc.).   The   PCR   products   were   analyzed   by   3.5%   agarose   gel  
electrophoresis  and  mutations  were  confirmed  by  sub-­cloning  PCR  products  using   the  
TOPO   TA   cloning   kit   (Life   Technologies)   following   manufacturers   instructions   and  
sequencing.    
  
To   create   a   wild   type   isogenic   line   from   the   patient   iPS+/indel,   a   200   base   pair  
oligonucleotide  with  wild   type  sequence  was  synthesized  with  5  silent  mutations  at   the  
guide  RNA  site  and  two  silent  mutations  to  cause  the  loss  of  a  PstI  restriction  site.  The  
sequence  of   the  oligonucleotide  can  be   found   in  Table  S1.  GATA6+/indel   iPS  cells  were  
treated   as   described   above   for   the   generation   of   the   compound  heterozygous  GATA6  
mutations  with  the  addition  of  3  µg  oligonucleotide  during  the  transfection.  To  screen  for  
the   incorporation  of   the  oligonucleotide,  clones  were  expanded  and  genomic  DNA  was  
isolated   from   clones   using   PureLink   Genomic   DNA   kit   (Invitrogen)   following   the  
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manufacturers  protocol.  PCR  primers   (Table  2-­1)  were  designed   to  amplify  a   region  of  
1046  base  pairs  flanking  the  oligonucleotide.  The  PCR  was  run  as  described  above  and  
a  PCR  cleanup  (Invitrogen)  was  done  prior  to  digestion  with  PstI  (New  England  Biolabs)  
overnight  at  37°C.  Samples  were   run  on  an  agarose  gel  and  clones   that  did  not  have  
digested  PCR  products  were   sent   for   sequencing   to   verify   the   correct   incorporation  of  
the  oligonucleotide.    
  
2.7  Differentiation  Of  Human  Pluripotent  Stem  Cells  
For  the  monolayer  adherent  hematopoietic  differentiation,  PSCs  were  feeder  depleted  by  
plating   onto   1:3   matrigel   (BD   Biosciences,   Bedford,   MA)   coated   6-­well   plates.   The  
differentiation   was   started   24   to   48   hours   later   when   the   cells   had   achieved  
approximately   70%   confluency.   The   procedure   for   differentiation   has   been   previously  
described   (Mills   et   al.,   2013;;   Paluru   et   al.,   2013).   Hematopoietic   progenitors   were  
expanded   in   cytokine   cocktails   to   drive   expansion   of   myeloid   cells:   10ng/mL   IL-­3,  
100ng/mL  SCF  and  200ng/mL  GM-­CSF;;  erythroid  cells:  2  units  of  EPO  and  100ng/mL  
SCF;;  and  megakaryocytes:  100ng/mL  TPO  and  100ng/mL  SCF.    All  cytokines  from  R&D  
Systems  (Minneapolis,  MN).  
  
For  monolayer   definitive   endoderm   differentiation,   cells   were   plated   into   a   1:3   coated  
matrigel   coated   6-­well   plate   with   human   ES   cell   media   and   ROCK   inhibitor  
approximately  24  hours  prior  to  differentiation.  The  differentiation  was  started  once  cells  
reached  80%   to   90%  confluency.  Cells  were   differentiated   toward   definitive   endoderm  
utilizing  the  following  protocol.  Day  0:  RPMI  supplemented  with  2mM  glutamine,  50U/mL  
penicillin,  50µg/mL  streptomycin,  2  µM  Chir99021   (Cayman  Chemicals)  and  100ng/mL  
Activin  A  (R&D).  Day  1  and  Day  2:  RMPI  supplemented  with  2mM  glutamine,  50U/mL    
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Table  2-­1:  Primers  utilized  in  generation  of  GATA6  compound  heterozygous  mutations  
and  correction.  
  
Purpose   Sequence  
Screening  and  sequencing  primers  for  
GATA6  indel  mutations  
Forward:  5’-­TCCATGCTGCCCGGCCTAC-­3’  
Reverse:  5’-­TGCCGTATGGAGGGCTGT-­3’  




Sequencing  primers  for  GATA6  
GATA6  IPS+/indel  correction  
5’-­AGGAGATGTACCAGACCC-­3’  
5’-­TGCCGTATGGAGGGCTGT-­3’  
200  base  pair  oligonucleotide  for  









     
	   37	  
penicillin,   50µg/mL   streptomycin,   100ng/mL   Activin   A,   20ng/mL   VEGF,   5ng/mL   bFGF  
and  0.25ng/mL  BMP4.  Day  3  onward:  SFD  supplemented  with  2mM  glutamine,  50U/mL  
penicillin,   50µg/mL   streptomycin,   100ng/mL   Activin   A,   20ng/mL   VEGF,   5ng/mL   bFGF  
and  0.25ng/mL  BMP4.  For  experiments  with  the  GATA6  mutant  PSC  lines  (Chapter  IV),  
the  base  media  was  switched  to  SFD  on  day  2  instead  of  day  3.  
  
For   the   monolayer   neuroectoderm   differentiation,   undifferentiated   PSCs   were   plated  
onto  1:3  matrigel  coated  12-­well  plates  one  day  prior  to  starting  the  differentiation.  Cells  
were   differentiated   for   8   days   in   media   composed   of:   DMEM/F12   (Corning)  
supplemented   with   1%   B27   without   retinoic   acid   (Gibco),   2mM   glutamine,   50U/mL  
penicillin,   50µg/mL   streptomycin,   100   µM   non-­essential   amino   acids,   10-­4M   β-­
mercaptoethanol,   250ng/mL   Noggin,   0.15   µM   SB431542   (Stemgent)   and   0.1   µM  
PD0325901   (Stemgent)   (Greber   et   al.,   2011).  Neuroectoderm   cells   were   harvested   at  
day  4  and  day  8  by  trypsinization.  
  
2.8  Endodermal  Progenitor  (EP)  Cell  Generation  And  Maintenance  
EP  cells  were  generated  and  maintained  as  previously  described   (Cheng  et  al.,  2012).  
Briefly,  EP  cells  were  generated   from   the  majority  of   the  cell   lines  by  differentiation   to  
day  5  definitive  endoderm  and  1.5x106  cells  were  replated  onto  EP  cell  conditions.  For  
cells   that   resulted   in   poor   definitive  endoderm  differentiation,   definitive  endoderm  cells  
were  harvested  on  day  5  and  cell  sorted  for  double  positive  CXCR4  and  CKIT.  For  cell  
sorting,  0.25%  trypsin/EDTA  was  utilized  to  create  a  single  cell  suspension.  Cells  were  
then   stained   with   conjugated   antibodies   on   ice,   in   the   dark   for   30   minutes   in   presort  
media  consisting  of  IMDM  supplemented  with  15%  FBS  and  1%  DnaseI  (Roche).  Cells  
were   sorted   in   presort   media   and   plated   into   EP   cell   conditions.   EP   cells   were  
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maintained  on  a  matrix  of  undiluted  matrigel  with  300,000  MEFs  per  10cm  dish  in  media  
consisting  of:  75%  homemade  IMDM  (GIbco),  25%  Hams  F-­12  (Corning),  0.5%  BSA  in  
DPBS,  1%  Glutamine  (Corning),  1%  Penicillin/Streptomycin  (Corning),  100ng/mL  human  
BMP4,  10ng/mL  human  bFGF,  10ng/mL  human  VEGF  and  10ng/mL  human  EGF.  The  
cells   were   passaged   every   6   days   with   1mg/mL   dispase   (Gibco)   followed   by   0.25%  
trypsin/EDTA  (Invitrogen)  and  replated  with  rock  inhibitor  (Cayman  Chemicals).  
  
2.9  Pancreatic  β  Cell  Differentiation    
Differentiation   was   started   5   days   after   the   splitting   of   EP   cells.   Differentiation   to  
pancreatic  β-­like  cells  was  performed  as  described  (Cheng  et  al.,  2012;;  D’Amour  et  al.,  
2006)  with  modifications  at   the  end  stage  of   the  protocol  as   follows:  Day  12:  SFD  with  
50ng/mL   noggin,   SB431542   (Stemgent),   50ng/mL   IGF-­1,   50ng/mL   HGF,   GLP-­1,  
1.25mg/mL   nicotinamide   (Sigma-­Aldrich)   and   insulin   (Sigma-­Aldrich).   Day   15   onward:  
SFD  with  50ng/mL   IGF-­1,  50ng/mL  HGF,  GLP-­1,  1.25mg/mL  nicotinamide  and   insulin.  
At   day   13   of   the   differentiation,   cells   were   reaggregated   by   treatment   with   1mg/mL  
dispase   for   15  minutes.   Cells   were   replated   into   1   well   of   low   adherent   6-­well   plates  
(Corning).   Following   the   reaggreation,   the   aggregates  were   spun   down   and   fed   every  
other  day  with  the  appropriate  media.    
  
2.10  Glucose  Stimulated  Insulin  Secretion  Assay  
Kreb  Ringers  Buffer  with  HEPES  (KRBH)  prepared  as  three  separate  stock  solutions  as  
follows:   (A)   1.83M   sodium   chloride   (Sigma-­Aldrich)   (B)   80mM   potassium   chloride,  
384mM  NaHCO3  and  62.55mM  MgCl2H2O  (C)  35.2mM  CaCl2H2O.  Prior  to  use,  62.5mL  
of  each  solution,  0.25%  w/v  bovine  serum  albumin  (2.5g)  and  10mM  HEPES  (2.38g)  is  
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mixed   together   and   the   total   volume   is   bought   up   to  1L  with   tissue   culture  grade  H2O  
(Corning),  the  pH  is  adjusted  to  7.4  and  the  medium  warmed  to  37°C.  
  
β-­like  cell  aggregates  were  washed  twice  with  KRBH  and  incubated  in  1mL  KRBH  for  1  
hour.   Cells   were   placed   into   500µL   of   1mM   glucose   in   KRBH   for   20   minutes   and  
stimulated   in   500µL   of   20mM   glucose   in   KRBH   for   20   minutes.   For   stimulation   with  
secretagogues   and   inhibitors   of   insulin   secretion,  β-­like   cells  were   placed   in   500µL   of  
1mM   glucose   in   KRBH   for   20   minutes   then   stimulated   in   500µL   of   10mM   with   the  
addition  of  the  secretagogue  for  20  minutes.  The  secretagogues  and  inhibitors  included  
10mM   arginine,   100µM   glibenclamide,   100nM   xxtendin-­4   and   500µM   diaxozide.  
Following   each   condition   cells   were   spun   down   at   150g   for   90   seconds.   Supernatant  
was   collected   and   stored   at   -­20°C.   C-­peptide   ELISA   was   performed   using   the   ultra  
sensitive   c-­peptide   kit   following   the   manufacturers   instructions   (Mercordia).   For   the  
ELISA,  supernatant  was  thawed  to  room  temperature  and  diluted  8  to  30  fold.  
  
2.11  Perifusion  Of  β–Like  Cells  (Chapter  3)  
β-­like  cells  were  re-­aggregated  by  treatment  with  1mg/mL  dispase  into  suspension  
culture  16  to  24  hours  prior  to  perfusion.  The  β-­like  cells  were  placed  on  a  nylon  filter  in  
a  plastic  perifusion  chamber  (Millipore,  Bedford,  MA).  The  perifusion  apparatus  
consisted  of  a  water  bath  (37°C),  a  fraction  collector  (Waters  Division  of  Millipore),  and  a  
computer-­operated  high-­performance  liquid  chromatography  system  (Waters  625  LC  
System),  which  allowed  programmable  rates  of  flow  and  glucose  concentration  in  the  
perifusate.  The  perifusate  was  a  Krebs  bicarbonate  buffer  (pH  7.4)  containing  2.2  mmol/l  
Ca2+  and  0.25%  BSA  equilibrated  with  95%  O2/5%  CO2.  Cell  aggregates  were  perifused  
with  an  increasing  ramp  of  1  mmol/L  glucose  per  min.  The  maximal  insulin  secretion  
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response  was  tested  at  the  end  of  each  experiment  with  30  mmol/l  KCl  after  washout  of  
glucose.  
  
2.12  Electron  Microscopy  (Chapter  3)  
β-­like   cells   were   re-­aggregated   by   treatment   with   1mg/mL   dispase   into   suspension  
culture   16   to   24   hours   prior   to   fixation.   The   aggregates   were   fixed   in   2.5%  
glutaraldehyde,   2.0%  paraformaldehyde,   and   0.1  M   sodium   cacodylate   buffer   (pH  7.4)  
overnight  at  4°C.  After  subsequent  buffer  washes,   the  samples  were  postfixed   in  2.0%  
osmium  tetroxide   for  1  hour  at   room  temperature  and  rinsed   in  distilled  H2O  prior   to  en  
bloc  staining  with  2%  uranyl  acetate.  After  dehydration  through  a  graded  ethanol  series,  
the  tissue  was   infiltrated  and  embedded   in  EMbed-­812  (Electron  Microscopy  Sciences,  
Fort  Washington).  Thin   sections  were   stained  with  uranyl   acetate  and   lead  citrate  and  
examined  with  a  JEOL  1010  electron  microscope  fitted  with  a  Hamamatsu  digital  camera  
and  AMT  Advantage  image  capture  software.  
  
2.13  Flow  Cytometry  and  Cell  sorting    
A  list  of  primary  and  secondary  antibodies  can  be  found  Table  2-­2,  Table  2-­3  and  Table  
2-­4.  Single  cell   suspensions  were  prepared  by   treating  cells  with  0.25%  Trypsin/EDTA  
for  3  to  5  minutes.  For  intracellular  staining,  cells  were  fixed  with  1.6%  paraformaldehyde  
(Electron  Microscopy  Science)  for  30  minutes  at  37°C.  Cells  were  washed,  permabilized  
and   stained   with   saponin   buffer   (Biolegend).   Primary   and   secondary   antibodies   were  
diluted   to   the   appropriate   concentrations   in   100uL   of   saponin   buffer   and   cells   were  
stained   for   30   minutes   at   room   temperature.   Following   the   staining,   cells   were  
resuspended   in   FACS   buffer   (DPBS   with   0.1%   BSA   and   0.1%   sodium   azide).   For  
extracellular  staining,  cells  were  washed  twice  with  FACS  and  re-­suspended  in  100ul  of  
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Table  2-­2:  Conjugated  Antibodies  for  Flow  Cytometry  
  
  
Table  2-­3:  Unconjugated  Primary  Antibodies  
  
Antibody   Species   Dilution   Source  
GATA6     Rabbit  IgG   1:800  for  flow  cytometry  
1:1200  for  
immunofluorescence  






1:50  for  flow  cytometry  
1:50  for  immunofluorescence  
R&D  Systems  
FOXA1     Mouse  IgG2a   1:100  for  flow  cytometry   Santa  Cruz  
FOXA2   Mouse  IgG2a   1:100  for  flow  cytometry  
1:50  for  immunofluorescence  
Santa  Cruz  
Eomesdermin   Mouse  IgG2b   1:25  for  flow  cytometry   R&D  Systems  
C-­peptide   Rabbit  IgG  
polyclonal  
1:100  for  flow  cytometry   Cell  signaling  









1:50  for  flow  cytometry   R&D  Systems  





1:50  for  flow  cytometry   R&D  Systems  
Glucagon   Mouse  IgG1   1:1000  for  flow  cytometry   Sigma-­Aldrich  





Antibody   Dilution   Source  
SSEA3-­Alexa  647   1:50   Biolegend  
SSEA4-­PE   1:2000   Biolegend  
KDR-­APC   1:100   R&D  Systems  
CD18-­APC   1:20   BD  Pharmigen  
CD31-­PECy7   1:100   BD  Pharmigen  
CD41a-­PE   1:50   BD  Pharmigen  
CD41a-­APC   1:80   Biolegend  
CD42a-­PE   1:20   BD  Pharmigen  
CD43-­PE   1:50   BD  Pharmigen  
CD45-­Pacific  Blue   1:100   Biolegend  
CD235   1:10000   BD  Pharmigen  
CXCR4-­PE   1:50   Invitrogen  
CD117-­APC   1:50   Invitrogen  
SOX17-­PE   1:50   BD  Pharmigen  
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Table  2-­4:  Secondary  Antibodies  
  
Antibody   Dilution  
  
Source  
Goat-­anti-­Rabbit  IgG-­  Alexa488   1:400   Jackson  Immunoresearch  
Goat-­anti-­Rabbit  IgG-­  Phycoerythrin   1:400   Jackson  Immunoresearch  
Goat-­anti-­Rabbit  IgG-­  Alexa647   1:400   Jackson  Immunoresearch  
Goat-­anti-­mouse  IgG1-­Alexa488   1:400   Jackson  Immunoresearch  
Goat-­anti-­mouse  IgG1-­  Phycoerythrin   1:400   Jackson  Immunoresearch  
Goat-­anti-­mouse  IgG2a-­Alexa488   1:400   Jackson  Immunoresearch  
Goat-­anti-­mouse  IgG2a-­Alexa  647   1:400   Jackson  Immunoresearch  
Goat-­anti-­mouse  IgG2b-­  Alexa647   1:400   Jackson  Immunoresearch  
Goat-­anti-­guinea  pig  IgG-­Alexa488   1:400   Jackson  Immunoresearch  
Streptavidin-­  Pacific  Blue   1:400   Invitrogen  
Streptavidin-­  Alexa647   1:400   Invitrogen  
Goat-­anti-­rabbit  IgG-­HRP   1:8000   Biorad  

















	   43	  
FACS   buffer   containing   the   conjugated   primary   antibody   for   15   minutes   at   room  
temperature.   The   cells   were   washed   twice   with   FACS   buffer   prior   to   analysis.   All  
samples   were   analyzed   on   a   FACSCantos   II   flow   cytometer   (Becton   Dickinson)   and  
FlowJo   (Treestar)   software   program.   Cell   sorting   was   carried   out   on   single   cell  
suspension  using  BD  FACSAria  II  (Becton  Dickinson).  
  
2.14   Reverse   Transcription   and   Quantitative   Real   Time   Polymerase   Chain  
Reaction  (qRT-­PCR)  
Cells  were  harvested  by   treatment  with  0.25%  Trypsin/EDTA  (Invitrogen)   for  3  minutes  
followed   by   addition   of   fetal   bovine   serum   and   storage   in   RLT   lysis   buffer   at   -­80°C.  
Cellular  RNA  was  isolated  using  the  RNAeasy  micro  kit  (Invitrogen)  as  described  by  the  
manufacturer’s   instructions.   Random   hexamers   were   used   with   the   Superscript   II  
Reverse   Transcriptase   (Invitrogen)   to   synthesize   cDNA.   PCR   reactions   were   done   in  
triplicate   utilizing   either   SYBR-­GreenER   qPCR   Master   Mix   (Roche)   or   SYBR   select  
master  mix  (Invitrogen).  Quantitative  PCR  was  carried  out  on  a  LightCycler  480  II.  The  
primers  that  were  used  in  this  study  can  be  found  in  Table  2-­5.  Serial  dilutions  of  H9  ES  
cell  cDNA  were  used  to  generate  a  standard  curve  and  TBP  (Veazey  and  Golding,  2011)  
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2.15  Southern  Blot  (Chapter  4)  
Genomic   DNA   was   isolated   using   the   DNeasy   Blood   &   Tissue   kit   (Qiagen,   Valencia,  
CA).   Genomic   DNA   (5–10   µg)   was   digested   overnight   with   SPH1-­HF   (New   England  
Biolabs,   IPSwich,   MA).   The   genomic   DNA   was   separated   by   0.8%   agarose   gel  
electrophoresis   and   transferred   to   an   Amersham   Hybond-­N+   membrane   (GE  
Healthcare).   The   membrane   was   hybridized   with   a   32P-­α-­dCTP   labeled   probe  
synthesized   using   the   High   Prime   Random   Labeling   (Roche)   following   the  
manufacturers   instructions.  The  probe  used   for  Southern  blotting  was  a  480  base  pair  
BamH1  fragment  from  the  5’  arm  of  homology  in  the  vector  plasmid  AAVS1-­SA-­2A-­puro-­
PA.      
  
2.16  Western  Blot  (Chapter  5)  
A   list  of  primary  and  secondary  antibodies  can  be   found   in  Table  1  and  Table  3.  Cells  
were  harvested  at  day  4  of  definitive  endoderm  differentiation  with  0.25%  Trypsin/EDTA  
and   cell   pellets   were   stored   at   -­80°C.   Briefly,   protein   from   whole   cell   lysates   was  
extracted   using   the   NE-­PER   nuclear   and   cytoplasmic   extraction   reagents   (Thermo  
Fisher).  Combined  cell   lysates  were  run  on  a  4%-­12%  Bis-­Tris  SDS-­polyacrylamide  gel  
(Invitrogen)   and   transferred   to   a   PVDF   membrane   (Thermo   Fisher)   overnight.   The  
membrane   was   then   blocked   in   5%   nonfat   dry   milk   in   DPBS   for   1   hour   at   4°C.   The  
membrane  was  probed  with  primary  antibody  diluted  in  1%  nonfat  dry  milk  in  DPBS  with  
0.1%   Tween-­20   (PBST)   either   overnight   at   4°C   or   1   hour   at   room   temperature.   The  
membrane  was  washed  and  placed   in  a  horseradish  peroxidase  conjugated  secondary  
antibody   for   1   to   3   hours   at   room   temperature.   The   membrane   was   detected   by  
chemiluminescence   (Thermo   Fisher   Scientific)   and   exposed   onto   HyBlot   CL  
autoradiography  film  (Denville  Scientific)  for  visualization.      
	   47	  
2.17  Immunofluorescence  staining  (Chapter  5)  
PSCs   were   cultured   on   1:3   matrigel   coated   sterile   round   18mM   glass   coversliPS  
(Thermo   Fisher   Scientific)   and   differentiated   to   definitive   endoderm   as   described.   On  
day  4  of  definitive  endoderm  differentiation,  cells  were  fixed  in  4%  parafolmadlehyde  in  
DPBS  for  15  minutes  at  room  temperature.  Cells  were  blocked  for  one  hour  (5%  normal  
goat   serum,   0.3%   TritonX-­100   in   DPBS)   and   stained   in   primary   antibody   in   staining  
buffer  (1%  BSA,  0.3%  TritonX-­100  in  DPBS)  overnight  at  4°C.  After  washing,  cells  were  
stained   in   secondary   antibody   in   staining   buffer   for   2   hours   at   room   temperature.   The  
cover   slips   were   washed   mounted   onto   glass   slides   and   counterstained   with  
VECTASHIELD   containing   DAPI   mounting   media   (Vector   Labs).   Slides   were   viewed  
under   a   Leica   DMI   4000B   microscope   and   digital   images   were   captured   with   Leica  
Application   Suite   software.   A   list   of   primary   and   secondary   antibodies   can   be   found  
Table  1  and  Table  3.    
  
2.18  Lentiviral  vector  generation  and  transduction  (Chapter  5)  
GATA1,  GATA3,  GATA4,  GATA6,  truncated  GATA6  (containing  the  4  base  pair  ‘GTAC’  
patient   duplication)   cDNA   was   cloned   into   a   lenti   viral   transfer   vector.   The   lenti   viral  
vector  contains  an   inducible  Tet-­response  element   (TRE)  driving   the  expression  of   the  
GATA   factor   cDNA.   The   cDNA   is   followed   by   an   internal   ribosome   entry   site   (ires)  
driving   expression   of   red   fluorescent   protein   (RFP).   Lenti   virus   was   generated   in  
HEK293T   cells   by   transfection  with   2M  CaCl2   and  HEPES  with   the   transfer   vector,  G  
protein  of  the  vesicular  stomatitis  virus  (VSV),  Hgpm2,  Tat  and  Rev.  Virus  was  collected  
for  3  to  4  days  following  the  transfection  and  concentrated  by  high  speed  centrifugation.  
PSCs  were  transduced  at  40%  to  60%  confluency  with  lenti  virus  for  16  to  20  hours  with  
2µg/mL  polybrene  (Millipore).  Two  to  three  days  following  the  transduction,  PSCs  were  
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split.  Differentiation  of  these  cells  was  performed  for  a  maximum  of  4  passages  following  
the  lentiviral  transduction.    
  
2.19  Microarray  and  Bioinformatics  Analysis  (Chapter  5)  
Three  replicates  of  each  cell   line  were  prepared  by  differentiating  the  cells  for  24  hours  
toward   definitive   endoderm.   Total   RNA   was   extracted   from   the   cells   by   use   of   the  
PureLink  RNA  mini  kit  (Invitrogen)  following  the  manufacturers  instructions.  
  
2.20  Statistical  Analysis  
Results   from   multiple   experiments   are   expressed   as   the   mean   ±   standard   error.   An  
unpaired  two-­tailed  Student’s  t-­test  was  for  groups  with  equal  variance  were  performed  
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CHAPTER  3  
The  Characterization  of  Endodermal  Progenitor  Cell  Derived  β-­like  Cells  
  
3.1  Introduction  
The   use   of   primary   human   β   cells   in   research   is   limited   by   the   availability   of   human  
tissue,  which  makes  it  difficult  to  study  human  β  cell  development,  β  cell  proliferation  and  
β  cell  related  diseases  such  as  diabetes  using  primary  human  cells.  One  potential  model  
system  of  human  β  cells   that   is  currently  being  explored   is   the   in  vitro  differentiation  of  
pluripotent   stem   cells   (PSCs)   including   embryonic   stem   (ES)   cells   and   induced  
pluripotent  stem  (iPS)  cells  to  β  cells.  PSCs  can  be  directed  to  differentiate  into  various  
mature  cell   types   in  vitro,  by  mimicking  the  developmental  events   that  occur   in  vivo.   In  
an   in  vitro  pancreatic  differentiation,  PSCs  are  specified   through  sequential  stages  that  
mirror   in  vivo  development.  The  PSCs  progress   first   through  definitive  endoderm,   then  
pancreatic  progenitors,   then  endocrine  progenitors  and  eventually  β  cells   in  a  stepwise  
fashion  (Nostro  and  Keller,  2012).  
  
Adult   β   cells   should   be   monohormonal   for   insulin   and   secrete   insulin   in   response   to  
glucose   stimulation.   Initial   approaches   to   generate   β   cells   from   PSCs   in   vitro   were  
inadequate   as   they   resulted   in   poly-­hormonal   endocrine   cells   that   do   not   respond   to  
glucose   (D’Amour   et   al.,   2006).   In   these   early   studies,   glucose   responsive   β   cells  
derived   from   PSCs   could   only   been   generated   by   the   transplantation   of   PDX1+  
endocrine  precursors   into  mice   for   several  months   (Kroon  et   al.,   2008;;  Rezania  et   al.,  
2012).   More   recently,   a   number   of   laboratories   have   described   the   generation   of  
functional  PSC  derived  β  cells  in  vitro.  The  cells  that  are  generated  glucose  responsive  
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in  vitro  and  can  rescue  diabetic  mice  (Pagliuca  et  al.,  2014;;  Rezania  et  al.,  2014;;  Russ  et  
al.,  2015a)  .    
  
One  of  the  concerns  with  the  use  of  PSC  derived  β  cells  is  any  undifferentiated  PSCs  at  
the  end  of   the  differentiation  may  have   teratoma   forming  potential.  This   raises  serious  
safety  concerns  if  PSC  derived  endocrine  cells  are  ever  to  be  used  as  a  cell  replacement  
therapy.  Furthermore,   the  protocols   that  have  been  described   to  generate   functional  β  
cells  can  take  up  to  40  days  for  PSCs  to  reach  a  terminally  differentiated  β  cell  with  only  
limited  functionality.    
  
Our   laboratory  has  been  able   to  generate  a  population  of   endodermal  progenitor   (EP)  
cells   that   are   self-­renewing,   do   not   form   teratomas,   and   can   be   differentiated   into  
multiple   endodermal   cell   lineages.   More   importantly,   these   cells   can   be   differentiated  
into   pancreatic   β-­like   cells   that   are   mono-­hormonal   for   insulin   and   can   respond   to  
glucose  stimulation  in  vitro  by  utilizing  a  14  to  18  day  protocol  (Cheng  et  al.,  2012).    
  
As  EP  derived  β-­like  cells  (henceforth  referred  to  as  β-­like  cells)  are   insulin  expressing  
and  glucose  responsive  in  vitro  we  sought  to  determine  whether  β-­like  cells  are  a  viable  
model  system  for  the  study  of  human  β  cells.  By  gaining  an  increased  understanding  of  
the  similarities  as  well  as   the   limitations  of  β-­like  cells  when  compared   to  adult  β  cells,  
we  can   recognize   the  scope  of   the  conclusions   that  may  be  drawn   from  studies  using  
these   cells.   Here   we   describe   the   optimization   and   further   molecular   and   functional  
characterization  of  EP  derived  β-­like  cells.  
  
  
	   51	  
3.2  Results  
Differentiation  of  EP  cells  into  β-­like  cells  utilizes  a  differentiation  protocol  similar  to  that  
used  to  generate  endocrine  cells  from  ES  cells  (Nostro  et  al.,  2011).  However,  in  place  
of  starting  at  the  ES  cell  stage,  differentiation  from  EP  cells  is  initiated  at  the  primitive  gut  
tube  stage.  The  method  of  differentiation  is  step-­wise,  first  the  EP  cells  are  specified  into  
posterior   foregut   ,  pancreatic  endoderm  and   then  β-­like  cells   (Cheng  et  al.,  2012).  For  
these  experiments  we  chose  to  use  the  H9  ES  cell  derived  EP  cells  as  these  had  been  
previously  described  by  our  laboratory.  
  
3.2.1  Dispase  Aggregation  
At   the   final   stage   of   differentiation,   cells   are   harvested   for   analysis   and   further  
characterization.  At  this  stage,  the  β-­like  cells  are  positive  for  c-­peptide  and  negative  for  
glucagon  (Figure  3-­1A).  C-­peptide  is  a  small  peptide  that  is  produced  at  approximately  at  
a  1:1  ratio  to  insulin  during  the  cleavage  of  pro-­insulin  into  insulin,  thus  it  is  a  marker  of  
endogenous  insulin  production  (Rhodes,  2004b).  Insulin  is  not  used  directly  as  a  marker  
for  β  cells  as  insulin  is  present  in  the  differentiation  media  that  the  cells  are  cultured  in.  
To  determine  whether  a   three  dimensional  culture  can   improve   the  differentiation  of  β-­
like  cells,  the  cells  were  transitioned  from  an  adherent  culture  to  a  suspension  culture  on  
day  13  of  the  differentiation.  The  adherent  β-­like  cells  were  treated  with  1mg/mL  dispase  
for  a  short  period  of  time  to  partial  disaggregate  the  cultures.  In  the  suspension  culture,  
the   β-­like   cells   form   small   aggregates   (Figure   3-­1B).   Two   days   post   aggregation   in  
suspension   culture,   β-­like   cells   remain   c-­peptide   negative   and   glucagon   positive,  
additionally   it   is   observed   that   there   is   a   small   subpopulation   of   β-­like   cells  which   are  
double  positive   for   c-­peptide  and  somatostatin   (Figure  3-­1A).  Although   the  suspension  
culture  does  not  increase  the  absolute  yield  of  c-­peptide  positive  cells  (Figure  3-­1C),  it    










     
Figure   3-­1.  Dispase  aggregation   enriches   for   c-­peptide   positive  β-­like   cells.      EP  
cells   were   differentiated   as   an   adherent   culture   to   β-­like   cells.   At   day   13   of  
differentiation   dispase   treatment   was   use   to   reaggregate   the   cells   into   a  
suspension   culture.   Cultures   were   analyzed   for   c-­peptide   and   glucagon  
expression  prior  to  treatment  with  dispase.  Two  days  post  aggregation  cells  were  
analyzed  for  c-­peptide,  glucagon  and  somatostatin  by  intracellular  flow  cytometry.  
(B)   Bright   field   image   two   days   post   aggregation   of   β-­like   cells   from   adherent  
culture.   (C)   Quantification   of   percentage   c-­peptide   positive   cells   from   untreated  
adherent  cultures  and  aggregation  cultures  2  days  and  6  days  post  aggregation.  
(D)   Quantification   of   absolute   yield   of   c-­peptide   positive   cells   from   untreated  
adherent  cultures  and  aggregation  cultures  2  days  and  6  days  post  aggregation.  
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enriches  for  c-­peptide  positive  cells.  Two  days  post  aggregation  c-­peptide  positive  cells  
increased  by  2.1  ±  0.11  fold  and  6  days  post  aggregation  2.7  ±  0.38  fold  (Figure  3-­1D),  
suggesting  that  there  is  a  selective  advantage  for  the  survival  or  recruitment  of  c-­peptide  
positive  cells   into   the  aggregates  and  offers  a  simple  method   for  purification  of   the  EP  
derived  β-­like  cells.  
  
3.2.2  Gene  and  Protein  Expression  
Gene   expression   profiles   in   EP   derived   β-­like   cells   were   compared   to   primary   non-­
diabetic   adult   human   islets   to   determine   how   similar   EP   derived   β-­like   cells   are   to  
functional  adult  β  cells  (Figure  3-­2).  The  gene  expression  levels  of  endocrine  hormones  
correlated  with  the  protein  expression  levels  from  flow  cytometry  analysis.   Insulin  (INS)  
was  expressed  within   the  EP  derived  β-­like  cells  and   there   is   low  expression   levels  of  
somatostatin   (SST).   The   EP   derived   β-­like   cells   did   not   express   glucagon   (GCG)   or  
pancreatic   polypeptide   (PPY),   hormones   that   are   expressed   in   other   endocrine   cells  
within  the  islet.  To  determine  the  maturity  of  β-­like  cells  as  compared  to  a  human  adult  β  
cell,   four   β   cell   specific   genes,   NKX6.1,   urocortin3   (UCN3),   islet-­1   (ISL1)   and   v-­maf  
musculoaponeurtic  fibrosarcoma  oncogene  homology  A  (MAFA),  were  examined  (Blum  
et  al.,  2012;;  Hang  and  Stein,  2011;;  Schaffer  et  al.,  2013).  While  EP  derived  β-­like  cells  
expressed  UCN3  and  ISL1,  MAFA  and  NKX6.1  expression  is  low.  
  
In   β   cells   insulin   is   initially   synthesized   as   proinsulin   and   must   undergo   a   number   of  
cleavages   to   become   insulin   by   prohormone   convertase   1   (PCSK1),   prohormone  
convertase   2   (PCSK2)   and   carboxypeptidase   E   (CPE)   (Rhodes,   2004b).   In   the   β-­like  
cells  while  PCSK1  is  expressed  at  low  levels,  PCSK2  and  CPE  are  expressed  at    
  





































































































































Figure  3-­2.  Gene  expression  profile  of  β-­like  cells.  Quantitative  real  time  PCR  was  
done   to   examine   gene   expression   of   key   hormones,   transcription   factors,  
channels  and  processing  enzymes  in  β-­like  cells  and  primary  human  islets.  Gene  
expression  levels  are  normalized  to  an  adult  human  islet.    
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moderate   levels   compared   to   human   adult   islets.  When  β   cells   are   stimulated,   insulin  
release  in  response  to  glucose  begins  with  the  uptake  of  glucose  into  the  β  cell  via  the  
GLUT1  or  GLUT2  glucose  transporter  channels.  Glucokinase  (GCK)  then  breaks  down  
the   glucose   into   glucose-­6-­phosphate   and   through   glycolysis   and   the   citric   acid   cycle  
generates   an   increase   in   the   ATP/ADP   ratio.   The   high   ATP/ADP   ratio   causes  
depolarization   of   the   membrane   through   the   ATP-­potassium   channel,   of   which   Kir6.2  
(also   known   as   KJCN11)   and   SUR1   (also   known   as   ABCC8)   are   the  major   subunits.  
Depolarization   of   the   membrane   causes   the   influx   of   Ca2+   stimulating   insulin   release  
(Hou  et  al.,  2009).  With  the  exception  of  GLUT2  which  is  expressed  at  high  levels  in  β-­
like   cells,   GLUT1,   SUR1   and   Kir6.1   are   all   found   to   be   expressed   in   β-­like   cells   at  
comparable  levels  to  adult  human  islets.  GCK  is  expressed  but  at  lower  levels.  Another  
important  channel  in    β  cell  is  the  zinc  transporter  8  (ZNT8    or  also  known  as  SLC30A8),  
which   is   involved   in   transport   of   zinc   from   the   cytoplasm   into   insulin   granules  
(Wijesekara  et  al.,  2009).  In  β-­like  cells  the  expression  of  ZNT8  is  very  low  compared  to  
adult  islets.  Lastly,  GATA6  expression  level  was  examined  as  it  is  a  gene  of  interest  for  
us  (see  Chapter  5).  GATA6  is  expressed  at  similar  levels  in  β-­like  cells  when  compared  
to   adult   islets.   Based   upon   these   analysis   while   the   majority   of   genes   specific   for   or  
involved   in   β   cell   functionality   are   expressed   there   still   remains   a   few   that   have   low  
expression  levels  in  β-­like  cells.    
  
3.2.3  Glucose  Stimulation  Insulin  Secretion    
The  functionality  of  β-­like  cells  can  be  examined  using  a  static  glucose-­stimulated  insulin  
secretion   (GSIS)   assay.   In   this   assay,   the   glucose-­responsiveness   of   the   β   cells   is  
measured   by   incubating   in   a   low   glucose   basal   media   followed   by   a   high   glucose  
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stimulation   media.   C-­peptide   secretion   in   response   to   glucose   stimulation   is   then  
measured  by  ELISA.    
  
To   examine   the   functionality   of   the   β-­like   cells,   static   GSIS   was   performed   following  
aggregation  of  the  β-­like  cells.  The  absolute  amount  of  c-­peptide  released  per  c-­peptide  
positive  cell  was  found  to  be  lower  in  β-­like  cells  compared  to  per  c-­peptide  positive  cell  
in  adult   islets  (Figure  3-­3A).  The  fold  change  in  c-­peptide  secretion  between  basal  and  
glucose  stimulation  the  stimulation  index  is  2.4  ±0.48  similar  to  the  stimulation  of  human  
islets   at   2.8   ±0.66   (Figure   3-­3B).   This   data   shows   that   while   the   amount   of   insulin  
secreted   may   be   lower   in   β-­like   cells   as   compared   to   human   islets,   β-­like   cells   do  
function  similarly  in  terms  of  response  to  glucose  when  compared  to  an  adult  islet.    
  
In  addition  to  glucose,  β-­cells  also  respond  to  other  secretagogues  with  increased  insulin  
secretion.   To   examine   the   response   of   β-­like   cells   to   secretagogues,   the   cells   were  
stimulated   with   either   10mM   glucose   or   10mM   glucose   with   the   addition   of   a  
secretagogue  or  inhibitor  of  insulin  secretion  for  20  minutes.  To  study  the  functionality  of  
the   potassium   channel   in   β-­like   cells,   glibenclamide   and   diazoxide   was   used.  
Glibenclamide  is  a  sulfonylurea  drug  that  binds  to  the  SUR1  subunit  and  inhibits  the  KATP  
channel  resulting  in  depolarization  of  the  membrane  (Kramer  et  al.,  1995).  Diazoxide  is  a  
KATP   channel   activator   that   inhibits   insulin   secretion   by   hyperpolarizing   the  membrane  
and   increasing   calcium   flux   into   the   cell   (Alarcón   et   al.,   2002;;   Grimmsmann   and  
Rustenbeck,  1998).  Addition  of  100µM  glibenclamide   to  β-­like  cells   resulted   in  a  a  2.7  
±0.35  fold  statistically  significant   increase   in  stimulation  while  addition  of  diazoxide  has  
no  significant  effect  on  the  secretion  of  c-­peptide  from  the  β-­like  cells  and  the  stimulation    







     
Figure   3-­3.   Static   stimulation   of   β-­like   cells   (A)   Quantification   of   c-­peptide  
secretion   per   c-­peptide   positive   cell   of   β-­like   cells   and   primary   human   islets   in  
basal  glucose  (1  mM)  and  stimulation  glucose  (20  mM)  conditions.  (B)  Stimulation  
index   of   C-­peptide   secretion   from   A.   (C)   Stimulation   index   of   β-­like   cells  
challenged   with   the   secretagogues   arginine,   glibenclamide   extendin-­4   or   the  
inhibitor  diazoxide.  Stimulation   index  are  normalized  to   the  control   condition.  For  
statistical  analysis:  *  P<0.05,  **P<0.01,  ***P<0.001  
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index  was  1.1  ±0.28  relative  to  the  stimulation  index  of  glucose  stimulation  alone  (Figure  
3-­3C).  These  responses  of   the  β-­like  cells   to  glibenclamide  and  diazoxide  demonstrate  
that  in  β-­like  cells  the  KATP  channel  functions  appropriately  and  can  respond  to  drugs  that  
inhibit  or  activate  its  function.  Extendin-­4  is  an  analog  of  glucagon  like  peptide  1  (GLP1)  
that  binds   to   the  GLP1  receptor  and  causes  an   increase   in   insulin  secretion  (Young  et  
al.,   1999).   The   addition   of   0.1µM  extendin-­4   resulted   in   a   4.0  ±2.6   fold   increase   in   c-­
peptide   secretion   compared   to   stimulation  with   glucose   only.   The   amino   acid   arginine  
can   also   stimulate   the   release   of   insulin.   Arginine   is   transported   into   the  β-­cell   by   the  
mCAT2A  amino  acid  transporter   leading  to  the  depolarization  of  the  plasma  membrane  
and  an  increase  in   intracellular  calcium  concentrations  (Newsholme  et  al.,  2006).  β-­like  
cells   stimulated   with   the   addition   of   10mM   arginine   lead   to   statistically   significant  
increase   in   c-­peptide   secretion   of   2.4   ±0.28   fold.   Together   these   results   demonstrate  




An   alternative   way   to   understand   functionality   of   β-­like   cells   is   to   utilize   a   perifusion  
system.   Perifusion   systems   can   challenge   cells   with   glucose   or   other   stimulants   and  
measure  dynamic  insulin  secretion.  Insulin  secretion  in  vivo  is  biphasic,  when  β  cells  are  
stimulated   with   high   glucose   insulin   secretion   peaks   and   with   prolonged   stimulation  
decreases  and  plateaus  to  a  constant  level  until  normoglycemia  is  reestablished  (Gerich,  
2002;;   Straub   and  Sharp,   2002).   In   order   to   determine  whether  β-­like   cells   respond   to  
glucose   with   a   biphasic   secretion   of   insulin   and   the   glucose   concentration   where  
maximal  insulin  secretion  is  reached,	  β-­like  cells  were  perfused  with  a  glucose  ramp  of    





     















0 to 30mM ramp 0mM 30mM KCl0mM
Figure   3-­4.   Perifusion   of   β-­like   cells.   Quantification   of   insulin   secretion   from  
aggregated   β-­like   cells   perifused   with   a   0mM   to   30mM   glucose   ramp   for   40  
minutes   followed   by   a   30mM   potassium   chloride   treatment   at   the   end   of   the  
experiment  to  maximally  stimulate  the  cells.  
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0mM  to  30mM  over  a  period  of  40  minutes  (Figure  3-­4).  At  the  end  of  every  experiment,  
β-­like   cells   were   treated   with   30mM   potassium   chloride.   Samples   were   collected   at   1  
minute  intervals  and  analyzed  for  the  amount  of  insulin  secreted.      
  
Insulin   secretion   began   at   around   2mM  glucose   and  maximal   insulin   secretion  was   at  
approximately  6mM  glucose   (Figure  3-­4).  During   the  glucose   ramp   there  was  an   initial  
peak   in   insulin   secretion   indicating   the   first   phase   of   insulin   secretion   was   operative.  
However,  following  this  peak,  with  prolonged  stimulation,  there  was  a  decrease  in  insulin  
secretion   to   barely   detectable   levels   demonstrating   a   lack   of   a   robust   second   phase  
response  in  the  β-­like  cells.    Following  the  glucose  stimulation,  β-­like  cells  were  treated  
with   30mM  potassium  chloride  and  depolarization   of   the  membrane  was   confirmed  by  
secretion  of   insulin  suggesting   that   there  was  not  a  complete  depletion   insulin  present  
within  the  β-­like  cells.    While  functionality  of  EP  cell  derived  β-­like  cells  in  the  perifusion  
system   did   not   completely   mimic   primary   human   islets,   we   are   encouraged   by   these  
results   considering   that   even   the  best   published  beta   cell   differentiation  protocols  only  
show   functionality   in   static   GSIS   systems   and   fail   to   perform   in   the   perifusion   assay  
(Pagliuca  et  al.,  2014;;  Rezania  et  al.,  2014).    
  
3.2.5  Ultrastructure  
Electron  microscopy  can  be  used  to  visualize  the  intracellular  ultrastructure  of  the  cell.  In  
adult  human  β  cells,  there  is  an  abundance  of  mitochondria  and  insulin  is  found  in  dense  
core   granules   surrounded   by   a   white   ‘halo’   (Figure   3-­5C)   (Rhodes,   2004b).   As   β-­like  
cells  are  glucose  responsive,  we  questioned  whether  this  correlates  with  the  appropriate  
granule   morphology   and   mitochondrial   presence   in   the   cells.   Transmission   electron  
microscopy  (TEM)  on  β-­like  cells  revealed  the  presence  of  a  large  number  of    
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Figure  3-­5  
  
     
Figure  3-­5.  Ultrastrucutre  of  β-­like  cells.  Transmission  electron  microscopy  of  (A)  
primary  human   islets  cultured   in  differentiation  media   for  2  hours,   (B)  β-­like  cells  
cultured   in  differentiation  media,   (C)  primary  human   islets  cultured   in   islet  media  
and  (D)  β-­like  cells  cultured  in  human  islet  media  for  24  hours.  The  bottom  panel  
is  an  enlarged  view  of  the  boxed  section  from  the  top  panel.  
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mitochondria.  Dense  core  granules  were  observed,  however  these  granules  still  had  an  
abnormal   morphology   similar   to   an   immature   insulin   granule   (Rhodes,   2004b)   and  
lacked  the  characteristic  white  halo  (Figure  3-­5B).    
  
As  a  control,  primary  human  islets  were  placed  into  the  same  media  as  the  EP  derived  
β-­like   cells   for   several   hours.   Unexpectedly,   it   was   found   that   although   dense   core  
granules  were  present   in   the  β  cells   in   these   islets,   they  did  not  contain   the  white  halo  
(Figure  3-­5A).  This  suggests  that  the  presence  of  the  white  halo  and  correct  morphology  
of   the  dense  core  granules  may  be  dependent  upon  the  components  of   the  media  that  
the  cells  are  cultured  in.  To  test  this,  we  perform  TEM  on  β-­like  cells  that  were  cultured  
in   the  commercial   islet  media,  which   is  normally  used   to  culture  primary  human   islets.  
Improvement  of  granule  morphology  was  observed,  with  some  of  the  granules  displaying  
a  white  halo  around  the  dense  core  (Figure  3-­5D).  Thus,  it  is  likely  that  a  component  of  
the   commercially   available   media   is   lacking   from   the   differentiation   media   preventing  
formation  of  the  appropriate  dense  core  granule  morphology.    
  
3.2.6  Zinc  Sulphate  Treatment  
Knockout  ZNT8  mice  have  decreased  zinc  content   in  the   islet  but   this   is   found  to  have  
modest   effects   on   glucose   homeostasis.   Insulin   granules   present   in   these  mice   fail   to  
crystallize   to   form  a  dense   core  granule   (Davidson  et   al.,   2015;;   Lemaire  et   al.,   2009).    
Similarly,  β-­like  cells  are  functional  however  have  low  expression  of  ZNT8  and  a  lack  of  
dense   core   crystalline   granules.   Thus   a   lack   of   zinc   in   the   β-­like   cells   may   be   one  
explanation   for   why   dense   core   granules   do   not   form.   As   the   commercial   islet   media  
contains  zinc  and  the  differentiation  media  does  not,  it  was  hypothesized  that  the  lack  of  
zinc   in   the   differentiation   media   was   the   missing   component   preventing   the   correct  
	   63	  
morphology  of   the   insulin  granules.  To  address   this,  end  stage  differentiated  β-­like  cell  
media  was  supplemented  with  100µM  zinc  sulphate  (ZnSO4).    
  
The   ultrastructure   of   the  β-­like   cells   was   examined   following   4   days   of   treatment  with  
ZnSO4  by  TEM.  The  presence  of  zinc  did  not  affect   the  morphology  of   the  dense  core  
granules  present  in  the  β-­like  cells  and  these  granules  still  had  similar  morphology  to  the  
differentiation  media  control  conditions.  It  was  also  observed  that  there  small  dark  spots  
present   throughout   the  β-­like   cells   (some  of  which   are   indicated   by   the   arrow  head   in  
Figure  3-­6A)  which  had  been  cultured  in  the  presence  of  ZnSO4.  The  β-­like  cells  appear  
to  have   taken  up   the  ZnSO4from  the  culture  media  but  not   into   the   insulin  granule  and  
thus  this  did  not  rescue  the  granule  morphology.    
  
In  addition,   following   treatment  gene  expression  analysis  was  performed  every  2  days  
(Figure  3-­6B).  Treatment  with  ZnSO4  did  not  causes  changes  in  the  expression  of  insulin  
in   the   β-­like   cells.   Expression   of   the   zinc   transporter   SLC30A8   which   functions   to  
transport   zinc   out   of   the   cytosol   was   unaffected   and   compared   to   adult   human   islets  
levels  were  still   low.  SLC39A7,  a  zinc   transporter   channel   that   transports   zinc   into   the  
cytosol   from   extracellular   and   from   organelles   was   also   unchanged   with   ZnSO4  
treatment.   In  both   the   treated  and  untreated  conditions,  prolonged  culture  appeared   to  
have  the  most  dramatic  effect  on  increase  in  gene  expression  suggesting  that  prolonged  
culture  may  aid   in   the  maturation  of  β-­like  cells  and  expression  of   the  appropriate  zinc  
transporter  channels.    
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Figure  3-­6  
  
Figure  3-­6.  Zinc  sulphate  treatment  of  β-­like  cells.  End  stage  β-­like  cell  media  was  
supplemented  with  100  µM  zinc   sulphate.   (A)   Transmission  electron  microscopy  
of  β-­like  cells   following  2  days  of  zinc  sulphate   treatment.  The   lower  panel   is  an  
enlarged   view   of   the   boxed   section   in   the   top   panel.   (B)   Gene   expression   for  
insulin,  SLC30A8  and  SLC39A7  was  examined  every  2  days  on  control  and  zinc  
sulphate  treated  β-­like  cells.  
	   65	  
3.3  Discussion  
Here   we   have   further   examined   EP   derived   β-­like   cells   through   both   molecular  
characterization   and   functional   assays.   Gene   and   protein   expression   analysis   of  
hormones  have  demonstrated   that   although   low   levels   of   somatostatin   and   insulin   are  
co-­expressed  in  a  small  population  of  the  β-­like  cells,  unlike  PSC  derived  β  cells,  β-­like  
cells  never  co-­express  glucagon  and  insulin.  When  examining  gene  expression,  while  a  
number  of  crucial  β  cell  markers  such  as  PDX1,  ISL1  and  UCN3  are  expressed  in  the  β-­
like   cells,   two   other   β   cell   maturation  markers   which   are   expressed   at   low   levels   are  
NKX6.1  and  GLP1R.  Furthermore,  β-­like  cells  were  shown  to  express  the  majority  of  the  
genes   involved   with   the   processing   and   secretion   of   insulin   thus   corroborating   the  
functionality   of   the   cells.  However,  ZNT8,  a  gene   important   for   zinc   transportation   into  
the  cell  is  poorly  expressed  in  β-­like  cells  but  is  not  required  for  beta  cell  functionality  in  
vivo.    
  
Adult   β   cells   can   swiftly   respond   to   elevated   glucose   levels   with   the   fast   release   of  
insulin.   The   stimulation   index   of   β-­like   cells   in   response   to   glucose   during   static  
stimulation   is  2.4   (±0.48)   fold,   similar   to   the  stimulation   index  of  human   islets  which   is  
reported  to  be  in  the  range  of  2  to  4  fold  (Hilderink  et  al.,  2015;;  Lamb  et  al.,  2011;;  Street  
et  al.,  2004).  In  our  hands  the  stimulation  index  of  primary  human  islets  was  found  to  be  
2.8   (±0.66)   fold.   In   recently  described  ES  derived  β  cell  protocols,  both  PSC  derived  β  
cells  and  islets  were  shown  to  have  a  stimulation  index  of  approximately  2  fold  (Pagliuca  
et  al.,  2014;;  Rezania  et  al.,  2014;;  Russ  et  al.,  2015a).  While  β-­like  cells  can  respond  to  
glucose  stimulation  with  a  similar  stimulation  index  to  adult  islets,  some  deficiencies  still  
remain.  The  expression  of   insulin   in  β-­like  cells   is  2   fold   lower   than  adult   islets,  during  
	   66	  
both  basal  and  glucose  stimulation  the  amount  of  insulin  secreted  per  cell  is  several  fold  
lower   than   in   islets.   This   discordance   could   be   due   to   other   regulatory   mechanism  
present   within   β   cells   controlling   the   translation   of   insulin   or   defects   in   the   secretory  
mechanism  of  the  β-­like  cells.  Furthermore,  β-­like  cells  do  not  display  a  biphasic  insulin  
secretion  response  to  prolonged  glucose  stimulation.  In  order  to  be  able  to  recapitulate  
the   functionality   of   an   adult   islet,   these   two   deficiencies   must   be   addressed   and  
improved  in  our  β-­like  cell  differentiation.    
  
β-­like  cells  have  low  levels  of  NKX6.1  expression.  As  NKX6.1  is  known  to  be  important  
for   β-­cell   development   (Henseleit   et   al.,   2005;;   Schaffer   et   al.,   2013)   this  may   explain  
some  of   the  deficiencies  of   the  β-­like  cells.   In  adult  mice  a   loss  of  NKX6.1   in   the   islets  
causes   the   mice   to   become   diabetic   and   have   decrease   insulin   content   within   the  
pancreas.  In  vitro  static  GSIS  on  islets  derived  from  these  mice  demonstrated  that  they  
were   functional   in   terms   of   glucose   responsive   but   secreted   a   decreased   amount   of  
insulin  when   compared   to  wild   type   islets   (Taylor   et   al.,   2013).   These  phenotypes  are  
similar  to  what  has  been  observed  in  EP  derived  β-­like  cells  suggesting  that  although  the  
cells   are   glucose   responsive,   some   of   their   deficiencies   may   result   from   the   lack   of  
NKX6.1.  Additionally,  a   loss  of  NKX6.1   in   the  adult  mouse   islets   lead  to   the  decreased  
expression  of  GLP1R  suggesting  a  regulatory  mechanism  between  the  two  transcription  
factors   (Taylor   et   al.,   2013).   In   addition   to   low   expression   of  NKX6.1,  β-­like   cells   also  
have  low  expression  of  GLP1R.    
  
Addition   of   zinc   in   the   form   of   ZnSO4   to   the   β-­like   cell   differentiation   media   did   not  
enhance   insulin   granule   crystallization   in   the   β-­like   cells   suggesting   that   there   is   a  
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component   of   the   commercial   media   beneficial   to   insulin   granule   crystallization   that  
remains  to  be  identified.  Through  TEM  it  was  observed  that  zinc  was  able  to  enter  the  β-­
like  cell  but   failed  to  cause  crystallization  of   the   insulin  granule   indicating  that  zinc  was  
unable   to   enter   the   insulin   granule.  Examination  of  ZIP7   (also   known  as  SLC39A7),   a  
zinc   transporter   channel   involved   in   the   movement   of   zinc   into   the   cytoplasm   from  
outside   the   cell   or   intracellular   compartments   (Wijesekara   et   al.,   2009),   revealed  
expression   levels   similar   to   that   of   human   islets.   Thus   the   presence   of   ZIP7   allowed  
entry  of  the  zinc  into  the  cytoplasm  but  a  lack  of  ZNT8  lead  to  failure  in  transport  of  zinc  
into   the   insulin   granules.   In   murine   and   guinea   pig   studies,   global   or   β-­cell   specific  
knockout  of  ZNT8  have  been  studied  with  varying  results.  All  studies  agreed  that  a  lack  
of   ZNT8   lead   to   decreased   overall   zinc   content   within   the   islet.   The   insulin   granules  
observed  in  these  mice  were  diffuse  and  not  crystallized.  Results  of  in  vitro  GSIS  and  in  
vivo   glucose   tolerance   test   were   discordant,   with   some   studies   reporting   an  
improvement,  some  reporting  no  change  while  others  suggest  there  was  an  impairment  
in  β  cell  functionality  (Davidson  et  al.,  2014;;  Mitchell  et  al.,  2016).    These  studies  indicate  
that   a   lack   of   zinc   in   β   cells   lead   to   a   lack   of   crystalline   insulin   granules   but   is  
inconclusive  about  the  necessity  of  the  granules  for  full  β  cell  functionality.    
  
In   summary,   while   EP   derived   β-­like   cells   do   still   have   limitations   in   that   they   do   no  
express   β   cell   specific   markers   such   as   NKX6.1   and   do   not   respond   to   prolonged  
glucose  stimulation.  Unlike  PSC  derived  β  cells,  EP  derived  β  cells  do  not  pose  any  risk  
of  contaminating  PSCs  as  they  are  differentiated  from  a  pure  population  of  endodermal  
progenitor  cells.  While  there  remains  some  deficiencies  of  the  functionality  of  β-­like  cells,  
in  static  stimulation  β-­like  cells  can  respond  to  multiple  secretagogues  and  in  perifusion  
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assay   perform   better   than   any   of   the   other   currently   available   published   protocols  
(Pagliuca  et  al.,  2014;;  Rezania  et  al.,  2014).  The  main  function  of  a  β  cell   is  to  secrete  
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CHAPTER  4  
Utilization  of  the  AAVS1  Safe  Harbor  Locus  for  Hematopoietic  Specific  
Transgene  Expression  and  Gene  Knockdown  in  Human  ES  Cells  
  
4.1  Introduction  
In   human   ES   cells,   introduction   of   stable   genetic   modifications   by   homologous  
recombination  has  been  challenging  for  many  laboratories.  Most  commonly,  transgenes  
are   introduced   into   ES   cells   via   methods   such   as   viral   transduction   or   plasmid  
transfection.   However,   these   methods   lead   to   random   integration   within   the   genome  
(Tenzen   et   al.,   2010).   Although   clones   with   stable   transgene   expression   can   be  
selected,   most   clones   display   transgene   silencing   upon   ES   cell   differentiation.   For  
example,  even  the  very  well  characterized  and  strong  beta  globin  promoter  functions  to  
appropriately  induce  transgene  expression  in  only  a  minority  of  ES  cell  clones  generated  
using  a  random  integration  strategy  (Hatzistavrou  et  al.,  2009).  
  
The   use   of   zinc   finger   nucleases   (ZFNs)   is   one   way   in   which   transgenes   can   be  
introduced  at  specific   locations  within  the  genome  and  potentially  avoid  gene  silencing.  
ZFNs   cause   a   site-­specific   DNA   double   strand   break   and   enhance   homologous  
recombination  efficiency  to  introduce  a  construct  of  interest  using  gene  targeting  (Carroll,  
2011).  One  method  to  prevent  silencing  of  transgenic  constructs  is  to  target  genomic  loci  
of   constitutively   expressed   genes   for   gene   targeting.   One   such   site   in   the   human  
genome   is   the   AAVS1   “safe   harbor”   locus   which   encodes   the   PPP1R12C   gene   and  
when  targeted  with  transgenes  results  in  stable  gene  expression  (DeKelver  et  al.,  2010;;  
Hockemeyer  et  al.,  2009).  It  has  been  shown  that  transgenic  constructs  targeted  to  the  
AAVS1   locus   maintain   expression   in   hematopoietic   cells   differentiated   from   human  
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induced   pluripotent   stem   (iPS)   cells  when   using   constitutive   promoters   (Garçon   et   al.,  
2013;;  Zou  et  al.,  2011)  or  when  using  erythroid  specific  promoters  (Chang  &  Bouhassira,  
2012).   Therefore,   the   AAVS1   locus   offers   a   well-­characterized   site   for   transgene  
expression  for  use  in  human  pluripotent  stem  cells.  
  
Here   we   demonstrate   several   technical   advancements   for   using   the   AAVS1   locus   to  
generate  both   reporter  and  knockdown  constructs   in  human  ES  cells.     We  generate  a  
reporter   for   hematopoietic   cells   and   a   knockdown   construct   that   inhibits   myeloid   cell  
formation.   One   construct   is   designed   to   express   a   green   fluorescent   protein   (GFP)  
reporter   driven   by   a   human   CD43   promoter   fragment   that   accurately   reflects  
endogenous   CD43   gene   expression   in   hematopoietic   cells.   The   second   construct   is  
designed   to   express   short   hairpin   RNAs   driven   by   the   constitutive   chicken   actin   (CA)  
promoter.      By   using   hairpins   that   target   PU.1,   the   master   regulator   of   myeloid  
development,  we  demonstrate  an  efficient   and  stable  gene  knockdown   that   leads   to  a  
dramatic   inhibition   of   myeloid   development.   Finally,   we   show   that   a   simple   lipid  
transfection   method   can   generate   a   large   number   of   correctly   targeted   clones   much  
more   efficiently   and   easily   than   previously   published   reports   using   electroporation  
(Hockemeyer   et   al.,   2009).      These   techniques   provide   quick   and   reliable   tools   for  
expressing   transgenes   and   developing   reporter   and   knockdown   lines   to   study  
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4.2  Results  
  
4.2.1  Generation  of  a  CD43  Hematopoietic  Reporter  Cell  Line  
To   easily   quantify   hematopoietic   development   from   human   ES   cells,   we   created   a  
fluorescent   reporter   line.   The   pan-­hematopoietic   surface   marker,   CD43  
(leukosialin/SPN),   is   expressed   in   all   hematopoietic   lineages   beginning   at   the  
hematopoietic  progenitor  stage  during  in  vitro  human  ES  cell  differentiation  (Vodyanik  et  
al.,  2006).   In   the  adult,  CD43  is  considered  to  be  pan-­hematopoietic;;  however,   it   is  not  
expressed  in  mature  circulating  erythrocytes  and  a  subset  of  B-­cells  (Remold-­O’Donnell  
et   al.,   1987).   CD43   was   chosen   over   CD41   or   CD45   as   these   markers   are   only  
expressed   on   subsets   of   hematopoietic   progenitors   derived   from   human   ES   cells  
(Vodyanik  et  al.,  2006).      
  
A   construct   containing   the   CD43   promoter   region   driving   GFP   was   targeted   to   the  
AAVS1   locus   by   homologous   recombination   using   the   ZFN   technology   (Figure   4-­1A).  
Rather   than   electroporation,   which   is   known   to   be   toxic   to   ES   cells   (Zwaka   and  
Thomson,  2003),  a  lipid  transfection  reagent  was  used.  This  system  is  extremely  robust  
with  targeting  efficiencies  >90%  and  homozygous  targeting  in  roughly  50%  of  the  clones  
(Figure  4-­1C).    Approximately  25%  of  the  clones  had  a  single  integration  in  one  allele  of  
the  AAVS1  locus  without  additional  random  integrations  as  determined  by  Southern  blot  
(Figure   4-­1C   and   Figure   4-­2).   Furthermore,   a   PCR   screen   demonstrated   that   these  
clones  are  free  of  ZFN  construct   integration  (Figure  4-­3).  These  single  integrant  clones  
where  chosen  for  further  analysis.  
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Figure  4-­1.  AAVS1  safe  harbor  gene   targeting.   (A)  Schematics  of   the  constructs  
used   in   in   gene   targeting.   Both   constructs   contain   regions   of   homology   to   the  
AAVS1   locus   in   the   first   intron,  a   puromycin   resistance  gene   (Puro)   and  a  poly-­
adenylation  sequence   (PolyA).   (i)  The  CD43-­GFP   reporter  construct  contains  an  
approximately  2.1kb  promoter   from   the  human  CD43  gene   followed  by  GFP.   (ii)  
The   PU.1   knockdown   construct   contains   the   chicken   actin   promoter   (CA  
promoter),  GFP,   and   a   pair   of   short   hairpins   against   PU.1   in   the   context   of   the  
microRNA-­30  (mir30)  backbone.  (B)  Schematic  of  targeting  the  constructs  into  the  
AAVS1   locus.   Cells   were   transfected   with   a   high   concentration   of   plasmids  
containing   the   construct   and   the   FOK1   zinc   finger   nucleases.   Transfection   was  
done   in  6-­well   plates  with   lipid   transfection.  Single  clones  were   then   picked  and  
further  characterized.    (C)  Table:  Summary  of  the  efficiency  of  the  targeting  for  the  
CD43   reporter   construct   and   the   PU.1   knockdown   constructs.   (Het.  
Heterozygous;;   Homo.   Homozygous;;   Single   Int   w/o   random   int.   Single   Integrant  
without  random  integration)  
  









Figure  4-­2.  Southern  blot  analysis  of  targeted  clones.  (A)  Schematic  of  AAVS1  
locus  with  restriction  enzymes  sites  and  probe  used  in  Southern  blot  analysis.  (B)  
Southern  blot  analysis  of  SphI  digested  genomic  DNA.  
  












Figure  4-­3.  The  ZFN  contruct  is  non  integrating.  (A)  PCR  analysis  of  left  and  right  
ZFN   constructs   for   integration   into   the  genomic  DNA  of   the  AAVS1   targeted  ES  
cells.  (ZFN:  zinc  finger  nuclease)  
  











Figure  4-­4.  Generation  of  a  CD43-­GFP  reporter  ES  cell   line.   (A)  Flow  cytometric  
analysis   showing   the   differentiation   of   pluripotent   CD43-­GFP   ES   cells   to  
hematopoietic  progenitors.  Cells  were  analyzed  at  days  0,  5,  and  9  (non-­adherent  
cells  only)  of  differentiation  respectively.  (top)  Flow  cytometric  analysis  of  SSEA3  
versus   SSEA4,   CD31   versus   KDR,   and   CD41   versus   CD235.   (bottom)   Flow  
cytometric   analysis   of   CD43   versus   GFP   expression.   (B)   CD43-­GFP   ES   cells  
were  differentiated  as  in  A  and  examined  by  fluorescence  microscopy.  Bar  is  100  
um.      (C)  Day  9  non-­adherent  hematopoietic  progenitors   from   the  CD43-­GFP  ES  
cell  line  as  described  in  A  were  cultured  an  additional  4  days  in  cytokine  cocktails  
to   promote   erythroid,   megakaryocytes,   and   myeloid   development.   (top)   Flow  
cytometric   analysis   of   CD43   versus   GFP   expression.   (bottom)   Flow   cytometric  
analysis   of   CD235   versus   GFP,   CD42   versus   GFP,   and   CD18   versus   GFP  
expression.    
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To   test   the   specificity   of   the   CD43   reporter   construct,   the   CD43-­GFP   ES   cells   were  
differentiated   in  vitro   into  hematopoietic  progenitors.  Our   in  vitro  differentiation  protocol  
(Mills  et  al.,  2013)  generates  mesoderm  after  5  days  as  indicated  by  CD31  (PECAM-­1)  
and  KDR  (VEGF-­R2)  co-­expression  (O’Donnell  et  al.,  1987),  and  primitive  hematopoietic  
progenitors  appear   in   the  supernatant  by  day  9  as  demonstrated  by  CD235  and  CD41  
co-­expression   (Klimchenko   et   al.,   2009;;   Vodyanik   et   al.,   2006)   (Figure   4-­4A).    
Throughout   the   differentiation,   a   positive   correlation   is   observed   between   endogenous  
CD43   expression,   as   determined   by   staining   with   an   anti-­CD43   antibody,   and   GFP  
expression   from   the   CD43-­GFP   reporter   construct   (Figure   4-­4A   and   4-­4C).   In   our                
monolayer  differentiation  system,   the  CD43-­GFP  expressing  hematopoietic  progenitors  
are  easily  visible  as  they  bud  off  of  the  monolayer  (Figure  4-­4B).    
  
To  demonstrate  the  stability  of  transgene  expression,  the  hematopoietic  progenitor  cells  
were   expanded   in   liquid   culture   with   the   appropriate   cytokine   cocktails   to   induce  
maturation   to   erythroid   (CD235+),   megakaryocyte   (CD42+),   and   myeloid   (CD18+)  
lineages  (Figure  4-­4C).  In  all  of  the  induced  hematopoietic  lineages,  endogenous  CD43  
expression   correlated   with   GFP   expression   levels.   We   observed   that   the   CD235+  
erythroid   cells   eventually   expressed   lower   levels   of   CD43   and   concurrently   lost   GFP  
expression.  To  evaluate  the  specificity  in  expression  of  the  CD43  promoter,  CD43-­GFP  
ES   cells   were   differentiated   into   neuroectodermal   and   definitive   endodermal   lineages  
(Figure   4-­5A).   Neither   of   these   differentiated   cells   expressed   GFP   (Figure   4-­5B).  
Together   these   data   demonstrate   that   the   CD43-­GFP   transgene   is   effective   as   a  
hematopoietic   reporter   with   GFP   expression   corresponding   to   the   endogenous  
expression  of  CD43.    
  





     Figure   4-­5.  CD43-­GFP   reporter   line   does   not   show  mis-­expression   of   GFP.   (A)  
Gene  expression  analysis  of  neuroectoderm  and  definitive  endoderm  CD43-­GFP  
differentiated   cells  as   compared   to  ES   cells.   (B)   Flow   cytometry   analysis  CD43-­
GFP   ES   cells   for   GFP   expression   when   differentiated   to   neuroectoderm   and  
definitive  endoderm  lineages.  
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4.2.2  Knockdown  of  the  Myeloid  Specific  Transcription  Factor  PU.1  
We   next   determined   whether   the   AAVS1   targeting   system   could   be   used   to   stably  
knockdown   hematopoietic   genes   of   interest.   As   a   proof   of   principle,   the   transcription  
factor  PU.1  was  chosen  as  it  is  expressed  at  high  levels  in  monocytes,  granulocytes  and  
B  lymphoid  cells  and  plays  a  critical  role  in  the  regulation  of  the  myeloid  cell  fate  (Scott  
et   al.,   1997).   We   hypothesized   that   knockdown   of   the   PU.1   gene   would   prevent   the  
differentiation  of  ES  cells  into  myeloid  cells.  To  assure  high  levels  of  gene  knockdown,    
we   utilized   a  microRNA   based   system  where   two   hairpins   against   a   single   target   are  
present   in  the  miR-­30  backbone  (Stegmeier  et  al.,  2005;;  Sun  et  al.,  2006;;  Wang  et  al.,  
2007).     We  generated   two  constructs  each  containing   two  short  hairpin  RNAs   (shRNA  
set1   and   set2)   against   PU.1.      The   constitutively   expressed  CA   promoter  was   used   to  
drive  GFP  followed  by  the  shRNAs  (Figure  4-­1A.ii).    ES  cell   lines  expressing  these  two  
constructs   (shPU.1   set1   and   shPU.1   set2)   were   generated   with   efficiencies   similar   to  
that  achieved  with  the  CD43-­GFP  construct  (Figure  4-­1C).    These  data  demonstrate  the  
reliability   and   reproducibility   of   generating   a   variety   of   transgene   constructs   using   this  
system.  
  
To   test   the   efficiency   of   gene   knockdown,   the   ES   cell   lines   expressing   the   shPU.1  
constructs  were  differentiated   into  hematopoietic   cells.  The   transcription   factor  PU.1   is  
not  expressed   in  ES  cells  at  day  0  of  differentiation  and  becomes  expressed  by  day  9  
when  hematopoietic  progenitor  cells  are  generated  (Figure  4-­6A).  At  this  time  point,  the  
expression  of  PU.1  in  the  two  knockdown  cell  lines  was  >80%  lower  than  expression  in  
the  control  GFP-­expressing  ES  cell   line.  The  day  9  hematopoietic  progenitor  cells  were  
then   put   in   liquid   culture   for   an   additional   four   days   in   a   cytokine   cocktail   favoring  
myeloid  cell  generation.     At  day  13  of  differentiation,   the  expression  of  PU.1   in   the  two  
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knockdown  lines  was  >90%  lower  than  expression  in  the  control  cell   line  (Figure  4-­6A).  
These   data   demonstrate   that   constitutively   expressed   AAVS1-­targeted   knockdown  
constructs   against   PU.1   can   successfully   decrease   expression   levels   throughout  
differentiation.  
  
To   determine   the   effect   of   decreased  PU.1   levels   on   hematopoietic   cell   development,  
day  9  progenitor  cells  were  put  into  liquid  expansion  cultures  and  analyzed  for  erythroid  
(CD235+CD41-­)   and   myeloid   (CD18+CD45+)   lineages.      Both   knockdown   cell   lines  
expressed   almost   undetectable   levels   of   CD18   and   CD45   compared   to   ~50%   co-­
expression   of   these  markers   on   control   GFP-­expressing   cells,   indicative   of   a   block   in  
myelopoiesis   (Figure   3B).   Furthermore,   the   absolute   yield   of   myeloid   cells   in   the   two  
knockdown   lines  was  much   lower  compared   to   the  GFP  control  cell   line  (Figure  4-­6C).  
These   findings   were   confirmed   by   gene   expression   analysis   of   the   myeloid   marker  
cFMS,  which  was  also  drastically   reduced   in   the  PU.1  knockdown  cell   lines   (Figure  4-­
6D).      Analysis   of   the   erythroid   lineage   demonstrated   an   ~4-­fold   expansion   in   the  
percentage  of  CD235+  cells  (Figure  4-­6B)  with  a  concomitant  increase  in  absolute  yield  
of   cells,   especially   in   the   knockdown   line   set   2   (Figure   4-­6C).   These   findings   were  
confirmed  by  an  increase  in  gene  expression  of  the  erythrocyte  transcription  factor  EKLF  
in   the   two   knockdown   cell   lines   (Figure   4-­6D).   The   pan-­hematopoietic  marker  GATA1  
was   unaffected   and   there   was   a   minor   increase   in   the   megakaryocyte   marker   PF4.    
These  data  demonstrate  that  AAVS1-­targeted  knockdown  of  PU.1  specifically  decreases  

























Figure  4-­6.  Expression  of  PU.1  short  hairpin  RNAs  inhibits  myeloid  development.  The  
PU.1  shRNA  expressing  ES  cell   lines  (H9-­shPU.1  set  1  and  H9-­shPU.1  set  2)  along  
with  a  GFP  expressing  control  line  were  differentiated  into  hematopoietic  cells  and  at  
day  9,  non-­adherent  progenitors  were  harvested  and  cultured  an  additional  4  days  in  
a  cytokine  cocktail  to  promote  myeloid  development.     (A)  (top)  Quantitative  RT-­PCR  
of   PU.1.   expression   is   reported   relative   to   the   housekeeping   gene   TBP.   (bottom)  
Percentage  of  PU.1  expression  relative  to  the  control  GFP  construct  in  hematopoietic  
cells  at  day  9  and  day  13  of  differentiation.  (B)  Flow  cytometric  analysis  (CD18  versus  
GFP  and  CD41  versus  CD235)  of  H9-­GFP  and  PU.1  knockdown  cell   lines  at  day  13  
of   differentiation.   (C)   Absolute   cell   counts   of   myeloid   (CD18+CD45+)   and   erythroid  
(CD41-­CD235+)   cells   in  myeloid   lineage   conditions   (SCF  50ng,  GMCSF  200ng  and  
IL3   10ng).   Cell   counts   are   expressed   as   fold   change   from   the   number   of  
hematopoietic  progenitors  plated  at  day  9.  (D)  Quantitative  RT-­PCR  of  hematopoietic  
lineages  genes.  Gene  expression  levels  are  all  reported  relative  to  the  housekeeping  
gene  TBP.  
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4.3  Discussion  
The   CD43   promoter   fragment   we   describe   here   allows   tissue   specific,   controlled  
expression  of  a  transgene  specifically  in  cells  of  the  hematopoietic  lineages.    During  the  
differentiation   of   the  CD43-­GFP   hematopoietic   progenitors   into   the   erythroid   lineage   it  
was  observed  that  these  cells  began  to  lose  the  expression  of  GFP  over  time  in  culture.  
Since   endogenous   CD43   also   decreases,   this   observation   is   most   likely   due   to  
increased   sensitivity   of   the   CD43   antibody   over   GFP   and   not   due   to   silencing   of  
transgene   expression.   It   has   been   shown   that  mature   erythrocytes   lose   expression   of  
CD43,   hence   this   loss   of   expression   is   anticipated   (Remold-­O’Donnell   et   al.,   1987).    
Importantly,   myeloid   cells,   which   maintain   CD43   expression   in   the   adult,   do   not   lose  
GFP   expression   in   the   reporter   lines   with   culture   (Figure   4-­6C).      The   CD43   reporter  
represents  a  valuable  tool  to  easily  follow  hematopoietic  specification  from  ESCs  in  live  
cultures  with   specificity   that   rivals  CD41  or  CD45  as  all   hematopoietic   progenitors   are  
CD43+  (Vodyanik  et  al.,  2006).      
  
In  mouse  models,  a  homozygous  loss  of  PU.1  is  embryonic  lethal  (Scott  et  al.,  1994)  or  
if  mice  are  born  alive,  they  die  shortly  after  birth  (McKercher  et  al.,  1996).  Mice  that  are  
born  are  found  to  lack  any  mature  B  and  T  cells,  macrophages  and  neutrophils  but  have  
erythrocytes   and   megakaryocytes   (McKercher   et   al.,   1996)   indicating   that   PU.1   is  
required  for  myeloid  cell  lineage  development.  A  heterozygous  loss  of  PU.1  is  non-­lethal,  
however   it   leads   to  a   loss   in   the   formation  of  multipotent  myeloid  progenitors   (Scott  et  
al.,  1994).  We  demonstrate   that  a     >80%  knockdown  of  PU.1   in  human  hematopoietic  
cells  results  in  a  loss  of  myeloid  lineage  cells,  phenocopying  what  occurs  with  a  loss  of  
PU.1  in  the  mouse.  The  differentiation  of  ES  cells  into  primitive  hematopoietic  cells  can  
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be   considered   to  mimic   human   development   thus   our   data   suggests   that   during   early  
human  hematopoiesis  PU.1  is  also  required  for  myeloid  lineage  development.    
  
The   advent   of   new   technologies   such   as   TALENs   and   CRISPRs   offer   extremely  
powerful   methods   for   enhanced   gene   editing   (Gaj   et   al.,   2013).   Indeed,   these  
technologies   have   been   shown   to   target   the   AAVS1   locus   with   similar   efficiencies   as  
ZFNs  (Hockemeyer  et  al.,  2011;;  Mali  et  al.,  2013).  However,  targeted  gene  editing  and  
transgene   expression   to   a   novel   site  will   still   require   targeting   vector   construction,   the  
development   of   screening   protocols   and   the   labor   intensive   screening   of   potentially  
many  ES  cell  clones  which  will   vary  depending  on   the   targeting  construct  and  gene  of  
interest.      The   advantage   of   the   system   we   describe   here   is   that   the   same   targeting  
vector  and  screening  methodology  can  be  used  for  any  construct,  allowing  the  quick  and  
easy  generation  of  transgenic  pluripotent  stem  cell  lines  with  high  efficiency.    In  addition,  
we  have  adapted  the  use  of  a  simple  lipid  transfection  reagent  to  introduce  our  targeting  
constructs  which  allows  the  generation  of  sufficient  targeted  clones  from  a  single  well  of  
a  six  well  dish.  
  
We  have  shown  that  it  is  possible  to  have  site-­specific  integration  and  stable  expression  
of   a   transgene   throughout   hematopoietic   differentiation.   This   system   represents   a  
powerful  and  flexible  tool  to  study  hematopoiesis,  and  for  the  case  of  gene  knockdown  to  
study  the  requirement  of  a  particular  gene  in  the  context  of  any  cell  type  where  there  is  a  
differentiation  protocol  available.  Both   the  constructs  described  here  have   the  potential  
for   use   in   future   studies   involving   transgene   expression   in   differentiated   progeny   from  
pluripotent  stem  cells.  Together,   these  techniques  allow  the  easy  manipulation  of  gene  
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expression  and  will   strengthen   the  use  of  ES  cells  as  a  model  system   for   the  study  of  
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CHAPTER  5  
GATA6  Mutations  Reveal  a  Critical  Role  in  Human  Definitive  Endoderm  
Development  and  Pancreatic  β  Cell  Function  
  
5.1  Introduction  
Pancreatic   agenesis   is   a   rare   congenital   disease   caused   by   a   mutation   in   PDX1  
(Schwitzgebel  et  al.,  2003;;  Stoffers  et  al.,  1997),  PTF1A  (Sellick  et  al.,  2004;;  Weedon  et  
al.,   2014),   GATA4   (Amato   et   al.,   2010;;   Shaw-­Smith   et   al.,   2014)   or   most   commonly  
GATA6  (Bonnefond  et  al.,  2012;;  Chao  et  al.,  2015;;  De  Franco  et  al.,  2013;;  Lango  Allen  
et  al.,  2012;;  Nakao  et  al.,  2013;;  Stanescu  et  al.,  2014;;  Suzuki  et  al.,  2014;;  Yorifuji  et  al.,  
2012).   The  majority   of   GATA6  mutations   leading   to   pancreatic   agenesis   are   de   novo  
heterozygous   mutations.   Some   GATA6   mutations   have   incomplete   penetrance   as  
determined  by   patients   having   identical  mutations   to   pancreatic   agenesis   patients,   but  
displaying   either   adult   onset   diabetes   or   an   absence   of   pancreatic   abnormalities  
(Bonnefond   et   al.,   2012;;   De   Franco   et   al.,   2013;;   Yu   et   al.,   2014).   The   majority   of  
pancreatic   agenesis   patients   also   display   a   combination   of   other   defects   including  
congenital  heart  defects,  gut  abnormalities  and  intrauterine  growth  retardation  (Chao  et  
al.,  2015).  
  
GATA6  belongs  to  a  family  of  transcription  factors  consisting  of  six  members  that  bind  to  
the   consensus   sequence   (A/T)GATA(A/G).   GATA1,   GATA2   and   GATA3   are   mainly  
expressed   in   hematopoietic   cell   lineages,   while   GATA4,   GATA5   and   GATA6   are  
predominantly  expressed  in  the  heart,  gonads  and  endodermal  derived  tissues  (Viger  et  
al.,  2008).  GATA6  is  known  to  regulate  endodermal  gene  expression  and  development  
of   endoderm   derived   organs   (Molkentin,   2000).   In   mice,   GATA6   is   expressed   in   the  
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primitive   streak,   heart,   lung,   intestine,   gonads,   adrenal   and   pancreatic   tissues  
(Koutsourakis   et   al.,   1999;;   Liu   et   al.,   2002;;   Sartori   et   al.,   2014).   Within   the   adult  
pancreatic   tissue,   GATA6   is   expressed   in   both   the   exocrine   tissue   and   the   islets   of  
Langerhans  (Sartori  et  al.,  2014).    
  
In   contrast   to   the   severe   disease   phenotype   found   in   humans   having   GATA6  
heterozygous   mutations,   mice   with   GATA6   heterozygous   mutations   are   fertile   and  
phenotypically   normal.   Homozygous   GATA6   null   mice   are   embryonic   lethal   between  
E6.5   and   E7.5   (Morrisey   et   al.,   1998).   Using   tetraploid   complementation,   GATA6   has  
been  shown  to  be  essential   for  extra  embryonic  endoderm  development  explaining   the  
embryonic   lethality  (Koutsourakis  et  al.,  1999;;  Zhao  et  al.,  2005);;  however,  GATA6  null  
cells  can  contribute   to   the  definitive  endoderm   that   forms   the  primitive  gut.  Analysis  of  
GATA6   in   pancreas   progenitors   or   adult   β   cells   has   demonstrated  minimal   impact   on  
endocrine  function,  with  normal  numbers  of  β  cells  and  no  overt  signs  of  diabetes  even  
though  a  mild   impact  on  ER  stress  was  observed   in  one  study   (Carrasco  et  al.,  2012;;  
Decker  et  al.,  2006;;  Martinelli  et  al.,  2013;;  Sartori  et  al.,  2014;;  Xuan  et  al.,  2012).    
  
Due  to  the  major  differences  in  phenotype  between  human  and  murine  GATA6  disease  
models,  human  pluripotent  stem  cells  (PSCs)  offer  an  alternative  system  for  the  in  vitro  
study  of  GATA6.  With   recent  developments   in   the  genome  editing   field,   the  use  of   the  
clustered   regularly   interspaced   short   palindromic   repeats   (CRiPSR)/CAS9   technology  
(Hsu  et  al.,  2014;;  Ran  et  al.,  2013)  has  enabled  PSCs  to  become  an  even  more  powerful  
model  system  as  mutant  and  control   isogenic   lines  can  be  made   to  avoid  confounding  
results  due  to  differing  genetic  backgrounds.    
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Here,  we  study  GATA6  mutant  human  PSCs.  Induced  pluripotent  stem  (iPS)  cells  were  
generated   from   a   previously   described   pancreatic   agenesis   patient   having   a   novel  
heterozygous  GATA6  mutation   resulting   in  a   truncated  protein   (Stanescu  et  al.,  2014).  
Using   genome   editing,   PSC   lines   with   mutations   in   both   alleles   of   GATA6   were  
generated.   These   compound   heterozygous   GATA6  mutants   failed   to   differentiate   into  
definitive   endoderm   due   to   a   block   at   the   primitive   streak   stage   of   development.   Re-­
expression  of  GATA6  or  several  other  GATA  family  members  restored  this  defect.  Using  
endodermal  progenitor  (EP)  cells  as  a  tool  to  bypass  the  endoderm  defect,  pancreatic  β  
cell  differentiation  was  studied.  We   found   that  all  mutant   lines  maintained   the  ability   to  
differentiate  into  pancreatic  β-­like  cells  but  that  these  cells  were  functionally  defective  in  
glucose  responsiveness.  These  data  suggest  that  human  GATA6  plays  a  critical  role  in  
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5.2  Results  
  
5.2.1  Establishment  of  GATA6  PSC  lines  
To  study  the  role  of  GATA6  in  human  development,  mutant  and  control  PSC  lines  were  
generated   by   established   technologies   for   standard   reprogramming   and   CRISPR/Cas  
genome   editing.   An   iPS   cell   line   was   generated   from   cells   of   a   previously   described  
patient   expressing   a   heterozygous  GATA6  mutation   (Stanescu   et   al.,   2014).   The   four  
base   pair   duplication   in   the   second   exon   of   GATA6   caused   a   frame   shift   mutation  
resulting  in  a  truncated  protein  (Figure  5-­1A  and  5-­1B).  This  patient  derived  iPS  cell  line  
will   be  designated   iPS+/indel   (Table  5-­1).   To  generate   cell   lines  expressing  mutations   in  
both  alleles  of  GATA6,  CRISPR/Cas9  genome  editing  was  performed  using  the  patient  
iPS+/indel  cell  line  and  the  Mel1-­INS-­GFP  (Micallef  et  al.,  2012)  ES  cell  line  (Figure  5-­1C).  
The   iPS+/indel   cell   line  was   used   to  maintain   genetic   background   identity   to   the   patient  
cells   for   experimental   comparison.   The  Mel1-­INS-­GFP   ES   cell   line   (designated   ES+/+,  
Table  5-­1)  was  used   for   two  reasons   in  addition   to  confirming  phenotypes   in  a  second  
genetic  background.  First,  the  Mel1-­INS-­GFP  line  allowed  easy  purification  of  β-­like  cells  
as  it  contains  a  GFP  reporter  in  the  insulin  locus.  Second,  to  assist  with  inducible  gene  
expression  studies  we  generated  a  Mel1-­INS-­GFP  sub-­line  that  constitutively  expressed  
the   reverse   tetracycline   transactivator   (rTTA)   targeted   to   the  AAVS1  safe  harbor   locus  
(Figure   5-­2)   using   a   previously   described   methodology   (Hockemeyer   et   al.,   2009;;  
Tiyaboonchai   et   al.,   2014).   For   CRISPR/Cas   genome   editing,   the   guide   RNA   strands  
(gRNAs)  were  designed  to  target  the  second  exon  of  GATA6  near  the  patient  mutation  
site  (Figure  5-­1B)  creating  frame  shift  insertion  and/or  deletion  (Indel)  mutations  in  both  
alleles  of  GATA6  (Table  5-­1  and  Figure  5-­3A).    The  genome  edited  patient  iPS  cell  line  
will  be  designated  iPSindel/indel  and  the  genome  edited  Mel-­INS-­GFP  line  will  be    
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Figure  5-­1  
  
Figure  5-­1.  Generation  of  pluripotent  stem  cell  lines  with  GATA6  mutations.    
(A)   Schematic   of   GATA6   protein   with   site   of   patient  mutation.   (B)   Schematic   of  
GATA6  gene  with  location  of  GATA6  patient  mutation  and  site  of  guide  RNA  with  
the  PAM   sequence   indicated.   (C)  Western   blot   of  GATA6  protein   on   pluripotent  
stem   cell   lines   differentiated   towards   definitive   endoderm   for   4   days.   (D)  
Intracellular   flow   cytometric   analysis   of   mean   fluorescence   intensity   samples  
examined   in  C.  Expression   levels  were  normalized  to  1   in  wild   type  (+/+)  cells  of  
each   genetic   background.   (E)   QRT-­PCR   analysis   of   expression   of   GATA6   and  
GATA4   in   samples   examined   in   C.   (F)   Time-­course   analysis   of   GATA4   and  
GATA6  expression  during  definitive  endoderm  differentiation  of  GATA6+/+  cells  by  
qRT-­PCR.    For  all  statistical  analysis:  *  P<0.05,  **P<0.01,  ***P<0.001  
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Table  5-­1  
Name   Genetic  Background   Allele  1   Allele2  
ES+/+   Mel1-­INS-­GFP   Wild  type   Wild  type  
iPS+/+   CHOP.Panagenesis1   Wild  type   Wild  type  
iPS+/indel   CHOP.Panagenesis1   Wild  type   4bp  duplication  
ESindel/indel   Mel1-­INS-­GFP   1bp  deletion   20bp  insertion  




     
Table   5-­1.   Pluripotent   Stem   Cell   Lines.   The   name,   genetic   background   and  
mutations   in   the   two  alleles  of  GATA6   for  each   of   the   pluripotent   stem  cell   lines  
used  in  this  chapter  are  described  here.    
  
	  












Wild	  type	  allele	   
Targeted	  allele 
1 2 3 4 * 
A 
B 
Figure  5-­2.  Targeting  the  AAVS1  locus  in  Mel1-­INS-­GFP  ES+/+  cells.  
(A)   Targeting   of   the   AAVS1   locus   with   a   construct   containing   a   constitutive  
chicken   actin   (CA)   promoter   driving   the   expression   of   the   reverse   tetracycline  
transactivator  (rTTA)  by  use  of  a  pair  of  zinc  finger  nucleases.    (B)  Southern  blot  
of   targeted  clones   to  confirm   that  a   single  allele   has  been   integrated.   The  clone  
that  is  used  throughout  these  experiments  is  indicated  with  an  asterisk.  
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Figure  5-­3  
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Figure  5-­3:  Characterization  of  patient  IPS+/indel  CHOP.Panagenesis1  cells  
(A)  Generation  of  all   three  germ  layers  (ectoderm,  mesoderm  and  endoderm)  by  
teratoma  assay  to  confirm  pluripotency  in  the  patient  IPS+/indel.  (B)  Patient  IPS+/indel  
cells   were   subject   to   qRT-­PCR   analysis   of   common   pluripotency   markers:  




IPS+/+  (  Corrected  Patient  Derived  IPS):  46  XX  
IPSindel/indel    Compound  Heterozygous  Patient  Derived  IPS):  46  XX  
ESindel/indel    Compound  Heterozygous  Mel1-­INS-­GFP):  46  XY  
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designated   ESindel/indel   (Table   5-­1).      To   generate   an   isogenic   control   for   the   patient  
iPS+/indel   line,  genome  editing  was  also  used  to  correct  the  mutation  and  this  line  will  be  
designated  iPS+/+  (Table  5-­1).  The  iPS+/indel  line  was  confirmed  for  pluripotency  (Figure  5-­
4)  and  all  genome  edited  PSC  lines  were  confirmed  to  have  a  normal  karyotype  (Figure  
5-­3B).      
  
Because  GATA6  does  not  begin  to  be  expressed  until  primitive  streak  induction  and  not  
in  PSCs,  protein  and  transcript  levels  were  examined  in  control  and  mutant  cells  utilizing  
a  protocol   that   induces  definitive  endoderm  (Cheng  et  al.,  2012;;  D’Amour  et  al.,  2005;;  
Kubo  et  al.,  2004).  By  Western  blot  analysis,  full  length  GATA6  protein  was  detected  in  
the  control  lines,  ES+/+  and  iPS+/+,  and  in  the  patient  line,  iPS+/indel,  that  expressed  one    
normal  allele  of  GATA6.  The  patient   line,   iPS+/indel,  also  expressed  one  mutant  allele  of  
GATA6  that  generated  a  truncated  GATA6  protein  of  ~35kDa  that  was  the  only  form  of  
GATA6  detected  in  the  compound  heterozygous  mutant   lines,   iPSindel/indel  and  ESindel/indel  
(Figure   5-­1C).   Using   flow   cytometry,   GATA6   protein   was   also   quantified   by   mean  
fluorescence   intensity   (MFI)   normalized   to   wild   type   of   each   genetic   background.  We  
found  that   the  truncated  GATA6  protein   in   the  mutant   iPSindel/indel   line  was  expressed  at  
significantly  lower  levels  (0.27  ±  0.06  fold)  than  the  patient  iPS+/indel  (0.97  ±  0.13  fold)  and  
control   iPS+/+   lines.  The  same   results  were  observed   in   the  mutant  ESindel/indel   line,  with  
significantly  decreased  levels  of  GATA6  (0.30  ±  0.01  fold)  compared  to  the  control  ES+/+  




























       
Figure  5-­4.  Characterization  of  patient  iPS+/indel  CHOP.Panagenesis1  cells.  
(A)  Generation  of  all   three  germ  layers  (ectoderm,  mesoderm  and  endoderm)  by  
teratoma  assay  to  confirm  pluripotency  in  the  patient  iPS+/indel.  (B)  Patient  iPS+/indel  
cells   were   subject   to   qRT-­PCR   analysis   of   common   pluripotency   markers:  
NANOG,  OCT4,  REX1,  ABCG2,  SOX2  AND  DMNT3B.   (C)  Karyotype  of   patient  
iPS+/indel  cells.  
  
C          IPS+/indel  (Patient  Derived  IPS):  46  XX  
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In   addition   to  GATA6,  GATA4   is   another  member   of   the  GATA   family   of   transcription  
factors   that   is   up-­regulated   during   primitive   streak   and   definitive   endoderm   induction  
(Arceci  et  al.,  1993;;  Czysz  et  al.,  2015).  Both  GATA4  and  GATA6  transcript  levels  were  
measured   by   quantitative   PCR   in   cells   differentiated   to   definitive   endoderm.   GATA6  
transcript   levels   were   significantly   decreased   in   the   mutant   iPSindel/indel   cell   line   as  
compared  to  the  control  iPS+/+  cell  line  (Figures  5-­1E  and  5-­1F)  suggesting  that  GATA6  
may  be  part  of  a  self-­regulatory  feedback  loop.    GATA4  was  also  significantly  decreased  
in   the  patient   iPSindel/indel   line   (Figure  5-­1F).     A   time   course  analysis   of   both   transcripts  
during  endoderm  differentiation  in  iPS+/+  cells  showed  that  GATA6  was  expressed  prior  
to   GATA4   (Figure   5-­1G),   suggesting   cross-­talk   between   GATA4   and   GATA6.   These  
experiments   were   repeated   in   the   control   ES+/+   and   ESindel/indel   cells   and   found   to   be  
consistent  (Figure  5-­1E  and  5-­1F).  Together,  these  data  suggest  that  GATA6  may  be  the  
initial  GATA   family  member   to  be  expressed  maintaining  both   itself  and  GATA4  during  
endoderm  induction.  
  
5.2.2  Definitive  Endoderm  Differentiation  
To  analyze  the  impact  of  GATA6  on  differentiation  to  definitive  endoderm,  a  time  course  
analysis  was  performed  using  an  established  protocol  (D’Amour  et  al.,  2005;;  Kubo  et  al.,  
2004).   The   expression   of   developmentally   regulated   markers   at   different   stages   of  
differentiation   was   analyzed   using   the   corrected   patient   iPS+/+,   patient   iPS+/indel,   and  
mutant   iPSinde/indel   lines   (Figures   5-­5A).   These   experiments   were   also   repeated   in   the  
control   ES+/+   and   mutant   ESindel/indel   lines   (Figure   5-­6A).   In   all   lines,   the   pluripotency  
markers  NANOG,  SOX2  and  OCT4  were  down  regulated  by  day  2  of  differentiation  and  
the   primitive   streak   markers   brachyury   (T),   goosecoid   (GSC)   and   eomesodermin  
(EOMES)  were  expressed  at  the  appropriate  times  during  induction.  The  definitive    
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Figure  5-­5  continued  
  
	  
Figure  5-­5.  GATA6  is  required  for  definitive  endoderm  differentiation  of  pluripotent  
stem  cells.  Control  iPS+/+,  patient  iPS+/indel  and  mutant  iPSindel/indel  cells  described  in  
Figure  5-­1C  were  differentiated  into  definitive  endoderm.  (A)  Time-­course  analysis  
of  pluripotency  markers  (OCT4,  SOX2,  and  NANOG),  primitive  streak  markers  (T,  
GSC,  EOMES)  and  definitive   endoderm  markers   (SOX17,  HNF1B,  and  FOXA2)  
by  qRT-­PCR.  (B)  Analysis  of  the  definitive  endoderm  markers  FOXA1  vs.  SOX17  
at   day   4   of   differentiation   by   intracellular   flow   cytometry.(C)   Quantitation   of   the  
percentage   of   FOXA1+SOX17+   cells   in   B.   (D)   Immunofluorescence   analysis   of  
SOX17  and  FOXA2  at  day  4  of  differentiation.  For  all  statistical  analysis:  *  P<0.05,  
**P<0.01,  ***P<0.001  
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Figure  5-­6  
	  





     
Figure  5-­6.  Definitive  endoderm  differentiation  experiments  were   repeated   in   the  
ES   cell   background..   (A)   Time-­course   analysis   of   pluripotency   markers   (OCT4,  
SOX2,   and  NANOG),   primitive   streak  markers   (T,  GSC,  EOMES)   and   definitive  
endoderm   markers   (SOX17,   HNF1B,   and   FOXA2)   by   qRT-­PCR.   (B)  
Representative  analysis  of  the  definitive  endoderm  markers  FOXA1  vs.  SOX17  at  
day   4   of   differentiation   by   intracellular   flow   cytometry.   (C)   Quantitation   of   the  
percentage   of   FOXA1+SOX17+   cells   described   in   B.   (D)   Immunofluorescence  
analysis   of   SOX17   and   FOXA2   at   day   4   of   differentiation.   For   all   statistical  
analysis:*  P<0.05,  **P<0.01,  ***P<0.001  
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endoderm  specification  markers  SOX17,  FOXA2  and  HNF1B  failed  to  upregulate  in  the  
mutant   iPSindel/indel  and  ESindel/indel  cell   lines  compared   to   the  patient   iPS+/indel  and  control  
iPS+/+  and  ES+/+  lines  (Figures  5-­5A  and  5-­6A).  By  using  intracellular  flow  cytometry  and  
examining   the   co-­expression  of   the  definitive  endoderm  markers,  SOX17  and  FOXA1,  
these  data  were  confirmed  and  quantitated  (Figures  5-­5B,  5-­5C  and  FIgure  5-­6B,  5-­6C).    
Robust  co-­expression  of  SOX17  and  FOXA1  was  observed   in  both  control  ES+/+   (82%  
±7%)  and  iPS+/+  (82%  ±4%)  lines  and  patient  iPS+/indel  (75%  ±3%)  lines,  while  an  ~6-­fold  
decrease   was   observed   in   the   mutant   ESindel/indel   (14%   ±3%)   and   iPSindel/indel   (2.7%  
±0.7%)  lines.  These  data  were  confirmed  in  all  cell  lines  by  immunofluorescence  staining  
for   SOX17   and   FOXA2   (Figures   5-­5D   and   5-­6D).   These   data   show   that   GATA6   is   a  
critical   transcription   factor   required   during   definitive   endoderm   specification   in   human  
cells.  
  
To  determine   if  GATA6  affected  differentiation   to   the  other   two  germ   layers,  previously  
established   protocols   were   used   to   monitor   differentiation   of   control   ES+/+,   patient  
iPS+/indel,   and   mutant   ESindel/indel   and   iPSindel/indel   lines   (Greber   et   al.,   2011;;   Mills   et   al.,  
2014;;  Paluru  et  al.,  2013).  All  cell   lines  displayed  similar  differentiation  efficiency  to  the  
mesoderm  and  ectoderm  germ  layers  suggesting  that  GATA6  was  not  required  (Figure  
5-­7).  
  
5.2.3  Partial  Rescue  of  Definitive  Endoderm  by  the  Addition  of  Growth  Factor  
A   delay   in   proliferation   during   endoderm   induction   was   observed   with   the   mutant  
iPSindel/indel  and  ESindel/indel  line  as  compared  to  the  control  iPS+/+  and  ES+/+  as  well  as  the  
patient   iPS+/indel   lines   (Figure   5-­8A   and   5-­8B).   Between   day   1   and   day   2   of   the  
differentiation  there  was  a  decrease  in  cell  number  in  the  mutant  iPSindel/indel  and    








Figure   5-­7.   Differentiation   of   GATA6   mutants   to   mesoderm   and   ectoderm  
lineages.   (A)  Representative   flow  cytometry  analysis  of  ES+/+,   iPS+/indel,  ESindel/indel  
and   iPSindel/indel   cells   differentiated   toward   a   mesodermal   fate   confirmed   by   the  
expression   of   surface   antigens   KDR   and   CD31.   (B)   qRT-­PCR   analysis   of  
ectoderm  markers   SOX1   and   PAX6   in   ES+/+,   iPS+/indel,   ESindel/indel   and   iPSindel/indel  
cells  differentiated  toward  an  ectodermal  fate.    
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Figure  5-­8  
  
Figure  5-­8.  Partial  rescue  of  definitive  endoderm  differentiation  by  basic  fibroblast  
growth  factor.  All  cell  lines  were  differentiated  to  definitive  endoderm.  On  day  1  of  
the   differentiation   cells   were   treated  with   varying   concentrations   of   bFGF   for   24  
hours.   (A)  Quantitation  of  cell   yield  during  differentiation  without   treatment   in   the  
control   iPS+/+,   patient   iPS+/indel   and  mutant   iPSindel/indel   cell   lines.   (B)  As  well  as   in  
the   control   ES+/+   and   mutant   ESindel/indel   cell   lines.   (C)   Representative   flow  
cytometry   analysis   of   the   cell   lines   at   day   4   or   day   5   of   definitive   endoderm  
differentiation   with   either   5ng/mL   bFGF   treatment   or   50ng/mL   bFGF   treatment.  
(D)   Quantification   of   of   definitive   endoderm   cells   co-­expression   SOX17   and  
FOXA1   in   the   mutant   iPSindel/indel   and   (E)   mutant   ESindel/indel   cell   lines.   For   all  
statistical  analysis:*  P<0.05.  (bFGF:  basic  fibroblast  growth  factor)  
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ESindel/indel   cell   lines   while   the   control   iPS+/+,   ES+/+   and   iPS+/indel   cells   continued   to  
proliferate   and  expand   in   number.  As   the  differentiation  progressed,  mutant   iPSindel/indel  
and  ESindel/indel  cells  continued  to  proliferate  and  by  day  4  had  comparable  cell  numbers  
to   the   control   and   patient   cell   lines.      To   determine   whether   the   defect   in   definitive  
endoderm   differentiation   of   mutant   iPSindel/indel   and   ESindel/indel   cells   was   related   to   a  
proliferation  defect,  cells  were  treated  with   increasing  concentrations  of  basic   fibroblast  
growth   factor   (bFGF)   for  24  hours   from  day  1   to  day  2  of   the  differentiation.  This   time  
point   was   chosen   as   it   was   prior   to   the   observed   decrease   in   cell   number.   The   co-­
expression  of  FOXA1  and  SOX17  was  examined  at   the  end  of   the  definitive  endoderm  
differentiation.  While  there  was  no  change  in  the  efficiency  of  differentiation  in  the  control  
iPS+/+   and   ES+/+   cells   with   higher   bFGF   concentrations   (Figure   5-­8C)   there   is   partial  
rescue   of   the   definitive   endoderm   differentiation   in   both   the   mutant   ESindel/indel   and  
iPSindel/indel   cells   (Figure   5-­8C,   5-­8D   and   5-­8E).   As   a   pro-­survival   signal   can   partially  
rescue  the  phenotype,  this  is  suggestive  that  there  is  a  proliferation  or  cell  survival  defect  
in  the  mutant  ESindel/indel  and  iPSindel/indel  cells.  
  
5.2.4  Rescue  of  Definitive  Endoderm  by  GATA6  
To  confirm  that  GATA6  was  responsible  for  the  ~6-­fold  decrease  in  endoderm  induction  
from   the  mutant  ESindel/indel   line,  GATA6   rescue   experiments  were   performed.  Because  
the  mutant   ESindel/indel   line   constitutively   expressed   rTTA,   a   lenti-­viral   vector   containing  
the   tet   response   element   (TRE)   was   used   to   express   GATA6/RFP   in   a   doxycycline  
inducible  manner  (Figure  5-­9A).  By  adding  doxycycline  on  day  one  of  the  differentiation,  
robust  co-­expression  of  SOX17  and  FOXA1  was  observed   in  the  mutant  ESindel/indel   line  
only   after   rescue   with   full-­length   and   not   truncated   GATA6   (Figure   5-­9B   and   5-­9C).  
Compared  to  the  RFP  alone  vector,  we  observed  that  over  expression  of  the  truncated    
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Figure   5-­9.   Rescue   of   definitive   endoderm   differentiation   by   GATA   factor   re-­
expression.  ESindel/indel   infected   with   a   doxycycline   inducible   lentivirus   transgenic  
system   and   differentiated   into   definitive   endoderm.   (A)   Schematic   of   the  
doxycycline  inducible  lentivirus.  (B)  ESindel/indel  cells  were  transduced  with  lentivirus  
harboring  GATA1,  GATA3,  GATA4,  GATA6,   truncated-­GATA6   transgenes   or   an  
empty  vector  and  differentiated   into  definitive  endoderm.  Doxycycline  was  added  
on   day   1   of   the   differentiation   to   induce   gene   expression.   Representative  
intracellular  flow  cytometric  analysis  of  FOXA1  vs.  SOX17  expression  at  day  5  of  
differentiation.  Data  shown   is  gated  on  cells  expressing  RFP.   (C)  Quantitation  of  
the  percentage  of  FOXA1+SOX17+  cells  in  B.  (D)  Quantitation  of  the  percentage  
of   FOXA1+SOX17+   cells   in   cells   transduced   with   GATA6   or   a   empty   vector  
control   lentivirus   with   doxycycline   addition   beginning   at   various   days   during   the  
differentiation.   Data   shown   is   gated   on   cells   expressing   RFP   at   day   5   of  
differentiation.   (E)   Cells   treated   and   differentiated   as   described   in   B,   were   cell-­
sorted   for  RFP  expression  at  day  5  of  differentiation  and  subjected   to  qRT-­PCR  
analysis  for  SOX17,  FOXA2,  HNF1B  and  endogenous  GATA4  expression  levels.    
For  all  statistical  analysis:  *  P<0.05,  **P<0.01,  ***P<0.001  
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GATA6  protein  resulted  in  a  decrease  in  the  ability  of  the  ESindel/indel  cells  to  differentiate  
to  definitive  endoderm,  suggesting  a  possible  dominant  negative  activity  of  the  truncated  
protein  (Figure  5-­9B  and  5-­9C).  Gene  expression  analysis  of  other  endodermal  markers  
was  also  performed  in  cells  expressing  the  GATA6  and  truncated  GATA6  transgene  by  
sorting  the  RFP  positive  cells  at  day  5  of  differentiation.  The  expression  levels  of  SOX17,  
FOXA2  and  HNF1B   in  mutant  ESindel/indel  cells  rescued  with  GATA6  were  comparable  to  
normal  levels  in  control  ES+/+  cells  differentiated  to  definitive  endoderm  (Figure  5-­5A  and  
Figure   5-­6A).  Expression   levels   of   these  markers   in  mutant  ESindel/indel   cells   expressing  
truncated  GATA6  were  not  statistically  different  to  cells  expressing  the  empty  vector.    
  
To  address  a  temporal  requirement  of  GATA6  during  definitive  endoderm  specification,  
doxycycline   was   added   at   days   0,   1,   2,   or   3   of   differentiation   and   RFP+   cells   were  
analyzed   for   the   co-­expression   of   SOX17   and   FOXA1   at   day   five   of   differentiation  
(Figure   5-­9D).      These   time   points  were   chosen   as   they   represent   the   primitive   streak  
(days  0-­1)  and  endoderm  specification  (days  2-­3)  stages  of  development  (Figure  5-­6A).      
The  addition  of  doxycycline  at  days  0  and  1  of  differentiation  resulted  in  77%  ±  4.5%  and  
82%  ±  4.2%  of  cells  co-­expressing  SOX17  and  FOXA1  while  the  addition  of  doxycycline  
at  days  2  and  3  resulted  in  50%  ±  5.9%  and  30%  ±4.0%  of  cells  co-­expressing  SOX17  
and   FOXA1.   These   data   show   that   robust   endoderm   specification   required   GATA6  
expression  at  the  primitive  streak  stage  of  development.    
  
5.2.5  Rescue  of  Definitive  Endoderm  by  Other  GATA  Family  Members  
All   members   of   the   GATA   transcription   factor   family   share   fairly   conserved   DNA  
activation  and  zinc  finger  DNA  binding  domains  (Molkentin,  2000;;  Viger  et  al.,  2008).  To  
determine   if   other   GATA   family   members   can   contribute   to   definitive   endoderm  
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specification   and   compensate   for   a   loss   of   GATA6,   the   same   rescue   experiments  
described  above  were  performed  using   lenti-­viral  vectors  expressing  GATA1,  3,  and  4.  
GATA4  was  chosen  because   it   is   functionally   redundant  with  GATA6   in  animal  models  
(Holtzinger  and  Evans,  2005;;  Xuan  et  al.,  2012;;  Zhao  et  al.,  2008).  GATA1  and  GATA3  
are  not   typically  expressed   in  definitive  endoderm  and  were   initially  chosen  as  controls  
for  the  rescue  experiments.    As  shown  in  Figure  5-­9C,  rescue  with  GATA1,  GATA3,  and  
GATA4  resulted  in  cells  co-­expressing  53%  ±5.4%,  70%  ±3.6%,  and  76%  ±3.3%  SOX17  
and  FOXA1,  respectively.  The  rescue  of  definitive  endoderm  differentiation  with  GATA4  
was  expected,  but  the  ability  of  GATA1  and  GATA3  to  rescue  definitive  endoderm  was  
not  and  suggested  that  any  GATA  family  member,  even  those  not  typically  expressed  in    
endoderm,   may   compensate   for   GATA6.   These   data   were   confirmed   by   qRT-­PCR  
analysis  of  SOX17,  FOXA2  and  HNF1B  on  RFP+  sorted  cells  (Figure  5-­9E).  As  mutant  
ESindel/indel   have   significantly   lower  GATA4   expression   when   compared   to   control   ES+/+  
cells   in   definitive   endoderm   (Figure   5-­6C),   we   questioned  whether   other  GATA   family  
members  were  rescuing  the  differentiation  by  inducing  GATA4  expression.  We  show  that  
any  of   the  GATA   factors  can   rescue  expression  of  endogenous  GATA4   (Figure  5-­9E),  
although   further   experimentation   would   be   needed   to   formally   demonstrate   that   the  
rescue  seen  with  GATA1  and  GATA3  was  simply  due  to  GATA4  induction.    
  
5.2.6  Downstream  Targets  of  GATA6  During  Definitive  Endoderm  Specification  
To  determine  possible  targets  of  GATA6  during  differentiation  to  definitive  endoderm,  a  
gene  expression  microarray  was  performed  using  the  control  ES+/+  and  mutant  ESindel/indel  
lines.   The   cells   were   differentiated   for   24   hours   to   the   primitive   streak   stage   of  
development   when  GATA6   but   not   SOX17  was   upregulated   (Figure   5-­10A).      The   top  
candidates  of  differentially  expressed  genes  between  the  two  cell  lines  revealed  a    







Figure   5-­10.   Gene   expression   microarray   to   identify   downstream   targets   of  
GATA6.   (A)   Gene   expression  microarrays   were   performed   on   control   ES+/+   and  
mutant  ESindel/indel  cells  differentiated  toward  primitive  streak  for  24  hours  that  have  
begun   to   upregulate   GATA6   and   prior   to   the   upregulation   of   SOX17   as  
demonstrated   by   representative   intracellular   flow   cytometric   analysis.   (B)   Gene  
expression  was  analyzed  by  microarray  as  described   in  A.  The  top  8  genes  that  
were   enriched   in   ES+/+      cells   over   ESindel/indel   cells   are   shown.   (C)   Validation   of  
genes   from   the   microarray   in   mutant   ESindel/indel   and   iPS+/+   cells   compared   to  
control   ES+/+   and   iPS+/+   patient   cells   by   qRT-­PCR.   Expression   levels   were  
normalized   to   1   in   wild   type   (+/+)   cells   of   each   genetic   background.   For   all  
statistical  analysis:  *  P<0.05,  **P<0.01,  ***P<0.001  
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number   of   zinc   finger   (ZNF)   genes   (Figure   5-­10B).  We   chose   to   focus   on   genes   that  
were  down  regulated  in  the  mutant  ESindel/indel  line  compared  to  the  control  ES+/+  line  as  a  
loss   of   GATA6   prevented   definitive   endoderm   specification   (Figures   5-­6).   The   down  
regulated   genes   were   validated   by   qRT-­PCR   using   both   control   iPS+/+   and   mutant  
iPSindel/indel   lines  (Figure  4C  and  S6).    Two  of  the  six  genes,  ZNF844  and  ZNF594,  were  
down   regulated   in   both   mutant   ESindel/indel   and   iPSindel/indel   lines   (Figure   5-­10C).   The  
ZNF738,   linc000665   and   IL6ST   were   only   validated   in   the   mutant   ESindel/indel   line   and  
ZNF253  was  only  validated  in  the  mutant  iPSindel/indel  line  (Figure  5-­10C).      
  
5.2.7  Functional  Analysis  of  GATA6  Mutants  as  Endodermal  Progenitor  derived  β-­
like  Cells  
The  use  of  established  differentiation  protocols  to  study  the  role  of  GATA6  in  pancreas  
development  (D’Amour  et  al.,  2006;;  Kroon  et  al.,  2008;;  Pagliuca  et  al.,  2014;;  Rezania  et  
al.,   2014,   2012;;   Russ   et   al.,   2015b)   was   difficult   due   to   the   inability   of   the   mutant  
ESindel/indel   and   iPSindel/indel   lines   to   differentiate   efficiently   into   definitive   endoderm.   To  
overcome   this   developmental   block   and   generate   enough   cells   for   downstream  
applications,  we  utilized  our  protocol  to  establish  endodermal  progenitor  (EP)  cells  from  
the  corrected  iPS+/+,  control  ES+/+,  patient  iPS+/indel  and  mutant  ESindel/indel  lines  (Cheng  et  
al.,  2012).    GATA6  is  expressed  at  lower  levels  and  GATA4  and  GATA3  are  expressed  
at  higher  levels  in  EP  cells  compared  to  definitive  endoderm  making  the  establishment  of  
these  lines  feasible  (Cheng  et  al.,  2012).  Cells  were  differentiated  to  definitive  endoderm  
and  CXCR+CKIT+  co-­expressing   cells  were   sorted   for   the  generation  of  EP  cell   lines.    
All  lines  were  characterized  as  EP  cells  displaying  self-­renewal  capacity  to  greater  than  
20  passages  (data  not  shown)  and  expression  of  appropriate  markers  including  SOX17,  
EOMES,  FOXA1,  FOXA2,  TBX3,  MSX2,  MEIS2,  and  ID2  (Figure  5-­11).    














Figure  5-­11.  Generation   of   endodermal   progenitor   cells.   (A)  Representative   flow  
cytometry   analysis   of   SOX17,   FOXA2,   FOXA1   and   EOMSEDERMIN   in  
Endodermal   Progenitor   cells   derived   from   control   IPS+/+,   control   ES+/+,   patient  
iPS+/indel   and   mutant   IPSindel/indel   and   ESindel/indel   cells   (B)   Endodermal   Progenitor  
(EP)  cells  from  A  were  subject  to  qRT-­PCR  analysis  for  markers  that  are  known  to  
be  up-­reguated  in  EP  cells  as  compared  to  transient  definitive  endoderm  (DE)  and  
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Figure  5-­12  
  
Figure  5-­12.  GATA6  is  dispensable  for  differentiation  of  pancreatic  β-­like  cells  but  
necessary   for   functionality.   EP   cell   lines   were   generated   from   control   iPS+/+,  
control   ES+/+,   patient   iPS+/indel   and   mutant   ESindel/indel   pluripotent   stem   cells   and  
differentiated   to   β-­like   cells.   (A)   Representative   intracellular   flow   cytometric  
analysis   of  C-­Peptide  vs.  PDX1  at  day  14  of  differentiation.   (B)  Quantification  of  
the  percentage  of  C-­peptide+  cells   from  A.   (C)  Absolute  yield  of  c-­peptide+  cells  
from  A.   (D)   Quantification   of   C-­peptide   secretion   per   C-­peptide   positive   cell   on  
day  14   in  basal  glucose  (1  mM)  and  stimulation  glucose  (20  mM)  conditions.  (E)  
Stimulation   index   of   C-­peptide   secretion   from   D.   For   all   statistical   analysis:   *  
P<0.05,  **P<0.01,  ***P<0.001  
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To   study   pancreatic   cell   fate,   the   EP   cell   lines   were   differentiated   into   β-­like   cells  
following  our  published  protocol  (Cheng  et  al.,  2012).  All  EP  cell  lines  differentiated  into    
β-­like   cells   co-­expressing   c-­peptide   and   PDX1   (Figure   5-­12A).   The   efficiency   of  
differentiation  following  aggregation  of  the  cells  into  suspension  culture,  as  calculated  by  
the   percentage   of   c-­peptide+   cells,   was   comparable   between   all   lines   (Figure   5-­12B).  
However,  when   comparing   absolute   c-­peptide+   cell   yields   in   the   suspension   culture   of  
patient   iPS+/indel   to   corrected   iPS+/+   and   mutant   ESindel/indel   to   control   ES+/+   there   is  
decreased  β-­like  cell  yields  in  both  GATA6  mutant  lines  (Figure  5-­12C).    
  
To   analyze   the   functionality   of   these   β-­like   cells,   their   responsiveness   to   glucose  
stimulation   was   determined.   In   unstimulated   conditions,   the   corrected   iPS+/+,   control  
ES+/+,  patient   iPS+/indel,  and  mutant  ESindel/indel  β-­like  cells  secreted  similar  amounts  of  c-­
peptide  when  normalized  for  the  absolute  number  of  c-­peptide+  cells  per  culture  (Figure  
5-­12D).  Upon  glucose   stimulation,   the   increase   in   c-­peptide   secretion   of   the   corrected  
iPS+/+  EP  derived  β-­like  cells  was     1.7  ±  0.9   fold  over  basal   levels  and   in  control  ES+/+  
EP-­derived  β-­like  cells  was  2.1  ±  0.22  fold  over  basal  levels  (Figure  5-­12E).  The  patient  
iPS+/indel   and   mutant   ESindel/indel   EP-­derived   β-­like   cells   were   unresponsive   to   glucose  
stimulation  with  stimulation  indexes  of  1.1  ±  0.16  and  1.1  ±  0.08  respectively  (Figure  5-­
12D   and   5-­12E).      These   data   demonstrate   that   the   levels   of   GATA6   were   critical   in  
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5.2.8  Gene  Expression  Analysis  of  GATA6  Mutant  Endodermal  Derived  β-­like  cells  
By   cell   sorting   for  GFP+  β-­like   cells   from   the   control  ES+/+   and  mutant  ESindel/indel   lines,  
gene   expression   of   insulin   positive   cells   could   be   analyzed   (Figure   5-­13A).   While   a  
number  of  genes  were  not  differentially  expressed,  PDX1,  PCSK1  GLUT1  and  HNF4α  
were  significantly  lower  in  the  mutant  ESindel/indel  cells  compared  to  the  control  ES+/+  cells  
(Figure  5-­13B).  Decreased  levels  of  PDX1  in  mutant  ESindel/indel  compared  to  control  ES+/+  
were  confirmed  by  flow  cytometry.  However,   levels  of  PDX1  in  the  patient   iPS+/indel  was  
not  different  to  levels  in  the  control  iPS+/+  (Figure  5-­13C).  PCSK1  is  a  protease  important  
in   the   processing   of   proinsulin   to   insulin   (Steiner,   2004).   To   determine   whether  
decreased   levels  of  PCSK1   lead   to  defective  proinsulin  processing,   levels  of  proinsulin  
were  examined  by  intracellular  flow  cytometry.  Patient  iPS+/indel  cells  show  a  trend  toward  
increased   amounts   of   proinsulin   within   the   β-­like   cell   compared   to   control   iPS+/+   cells  
while  mutant  ESindel/indel  have  significantly  decreased  levels  of  proinsulin  present  (Figure  
5-­13D).   Proinsulin   secretion   was   also   examined   in   the   β-­like   cells.   Control   iPS+/+   and  
patient   iPS+/indel   displayed   no   difference   proinsulin   secretion,   however,   compared   to  
control   ES+/+   cells,   ESindel/indel   cells   had   significantly   increased   levels   of   proinsulin  
secretion   (Figure   5-­13E).   These   data   suggest   that   while   GATA6   does   not   affect   the  
ability   of   EP   cell   differentiation   into   pancreatic   β-­like   cells,   it   may   be   involved   in  
maturation  and  insulin  processing  of  the  β-­like  cells.    
  
5.2.9   Retinoic   acid   is   the   exogenous   signal   that   allows   patient   iPS+/indel   cells   to  
differentiate  in  vitro  
The  patient  from  which  the  iPS+/indel  cells  were  originally  derived  was  born  with  pancreas  
agenesis,   however   the   ability   to   generate   β-­like   cells   from   the   GATA6   mutant   lines  
suggests  that  pancreas  agenesis  may  be  due  to  cell  non-­intrinsic  mechanisms  that  can  
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Figure  5-­13  
     
Figure   5-­13.  Gene   Expression   Analysis   of   β-­like   cells.      (A)   The   Mel1-­INS-­GFP  
cells   contain   a   GFP   reporter   in   the   insulin   locus.   β-­like   cells   from   ES+/+   and  
ESindel/indel   were   purified   by   cell-­sorting   for   GFP+   cells   and   analyzed   for   gene  
expression.   (B)   QRT-­PCR   analysis   for   expression   of   the   indicated   genes.  
Expression  levels  are  normalized  to  ES+/+.  (C)  The  mean  fluorescence  intensity  of      
PDX1   in   c-­peptide   positive   control   iPS+/+,   control   ES+/+,   patient   iPS+/indel   and  
mutant   ESindel/indel   cells.   (D)   The   mean   fluorescence   intensity   of   proinsulin   in   c-­
peptide   positive   cells   was   determined   by   flow   cytometry.   (E)   Quantification   of  
proinsulin   secreted  per   c-­peptide  positive   cell.   For   these  experiments,   all   values  
are   normalized   to   the   wild   type   of   each   genetic   background.   For   all   statistical  
analysis:  *  P<0.05,  **P<0.01,  ***P<0.001  
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be   bypassed   using   a   differentiation   protocol   supplying   exogenous   inductive   signals.  
During   differentiation   of   EP   cells   to   β-­like   cells,   exogenous   signals   which   are   applied  
include  FGF  signalling,  inhibition  of  sonic  hedgehog  (SHH)  and  retionoic  acid  signalling.  
To   address   this,   concentration   so   FGF10,   cyclopamine   and   retinoic   acid  were   titrated  
down   during   the   differentiation.   Differentiated   cells   were   examined   at   the   pancreatic  
progenitor  stage  for  expression  of  PDX1  because  patients  who  have  pancreas  agenesis  
should   have   a   defect   in   the   formation   of   the   pancreatic   progenitor.   Furthermore,   to  
determine  the  final  outcome,  the  differentiation  was  examined  the  end  stage  in  adherent  
culture  for  expression  of  c-­peptide.    
  
Lowering  the  concentrations  of  FGF10  and  cyclopamine  did  not  affect  the  differentiation  
(data  not  shown).  However,  lower  retinoic  acid  concentrations  resulted  in  a  decrease  in  
the  differentiation  efficiency  of   the  patient   iPS+/indel   cells   compared   to   the   control   iPS+/+  
cells.  At  the  pancreatic  progenitor  stage  there  is  a  trend  toward  a  reduced  percentage  of  
PDX1   positive   patient   iPS+/indel   cells   in   low   (0.025   µM)   retinoic   acid   concentrations  
compared   to   the   control   condition   (2   µM)   retinoic   acid   (Figure   5-­14A   and   5-­14C).  
However,   lower   concentrations   of   retinoic   acid   did   not   affect   the   percentage   of   PDX1  
positive   control   iPS+/+   cells.   (Figure   5-­14A   and   5-­14B).   To   determine   whether   GATA4  
could  compensate  for  a  loss  of  GATA6,  GATA4  expression  levels  were  also  examined.  
At   control   concentrations   of   retinoic   acid,   GATA4   expression   was   lowered   in   IPS+/indel  
cells  compared  to  IPS+/+  cells  (Figure  5-­14D).  Both  GATA4  and  GATA6  can  be  induced  
by   retinoic   acid   (Arceci   et   al.,   1993;;   Mauney   et   al.,   2010)   and   with   decreased  
concentrations   of   retinoic   acid   there  was   decreased   expression   of  GATA4   in   both   the  
IPS+/indel  and  IPS+/+  pancreatic  progenitor  cells  (Figure  5-­14D).  These  findings  further    
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Figure   5-­14.   Retinoic   acid   overcomes   patient   iPS+/indel   cell   deficiency   during  
differentiation.    (A)  Representative  intracellular  flow  cytometry  analysis  of  PDX1  in  
control  iPS+/+  and  patient  iPS+/indel  at  the  pancreatic  progenitor  stage  differentiated  
in  different  concentrations  of  retinoic  acid.  (B)  Quantification  of  A  for  control  iPS+/+.  
(C)   Quantification   of   A   for   patient   iPS+/indel.   (D)   Quantitative   real   time   PCR   for  
expression   of   GATA4   at   the   pancreatic   progenitor   stage.   (E)   Representative  
intracellular   flow   cytometry   analysis   of   PDX1   and   C-­peptide   of   β-­like   cells   in  
adherent   culture   differentiated   in   different   concentrations   of   retinoic   acid.   (F)  
Quantification   of  D   for   control   iPS+/+.   (G)  Quantification   of  D   for   patient   iPS+/indel.  
For   all   statistical   analysis:   *   P<0.05,   **P<0.01,   ***P<0.001.  Statistical   significant  
was  calculated  compared  to  2uM  of  retinoic  acid.    
  
Figure  5-­14  
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confirm   the   observations   from   the   definitive   endoderm   stage   that   GATA4   may   be  
downstream  of  GATA6.  
  
At   the  β-­cell   stage,  without   retinoic   acid   c-­peptide   positive   cells   fail   to   develop   in   both  
control  iPS+/+  and  patient  iPS+/indel  cells.  Lowering  the  concentration  of  retinoic  acid  used  
during   the   differentiation,   patient   iPS+/indel   cells   lead   to   a   downward   trend   of   the  
percentage   of   c-­peptide   positive   cells   compared   to   the   control   condition   (2uM   retinoic  
acid)   (Figure   5-­14E   and   5-­14G).   The   differentiation   of   the   control   iPS+/+   cells   was  
unaffected  (Figure  5-­14E  and  5-­14F).  These  data  suggest   that   iPS+/indel  have   increased  
sensitivity  to  retinoic  acid  and  in  vitro,  under  normal  differentiation  conditions,  β-­like  cells  














	   120	  
5.3  Discussion  
This  study  established  a  human  in  vitro  PSC  model  system  to  study  the  loss  of  GATA6  
function.  Considering   that  GATA6  null  mice  are  embryonic   lethal  due   to  a   requirement  
for  extra-­embryonic  endoderm  (Morrisey  et  al.,  1998),  PSCs  are  advantageous  because  
extra-­embryonic  endoderm   is  unnecessary   for  maintenance  and  differentiation  of   these  
cells.   We   have   shown   that   while   patient   iPS+/indel   cells   have   no   defects   in   definitive  
endoderm   specification,   mutant   ESindel/indel   and   iPSindel/indel   cells   from   different   genetic  
backgrounds   failed   to   efficiently   differentiate   into   definitive   endoderm.   The   down  
regulation  of  pluripotency  markers  and  the  induction  of  primitive  streak  markers  in  these  
cells   remained   normal,   suggesting   a   defect   in   the   transition   of   cells   from   the   primitive  
streak  stage  of  development  to  definitive  endoderm.  Transgene  expression  of  GATA6  in  
the   mutant   ESindel/indel   cells   rescued   endoderm   differentiation   demonstrating   the  
importance  of  GATA6   in  definitive  endoderm  specification  and   that  off-­target  effects  of  
genome  editing  were  not  responsible  for  the  observed  phenotype.    
  
In   chimeric   mouse   models,   GATA6   null   cells   can   contribute   to   the   formation   of   the  
primitive  gut   tube  (Koutsourakis  et  al.,  1999).  The   inability  of   the  mutant  ESindel/indel  and  
iPSindel/indel   lines   to   generate   definitive   endoderm   (Figure   5-­5   and   5-­6)   suggested   that  
there  may  be  differences   in   the  role  of  GATA6  during  human  versus  mouse  endoderm  
development.  One  explanation  for  this  difference  could  be  the  timing  of  GATA6  induction  
in  the  human  system.    We  observed  the  expression  of  GATA6  preceding  GATA4  during  
endoderm   induction   from  PSCs  (Figure  5-­1G).  No  other  GATA  factors  were  expressed  
at  this  time  (data  not  shown).  In  mouse  models,  GATA4  and  GATA6  were  co-­expressed  
in  the  primitive  streak  (Morrisey  et  al.,  1997),   therefore   it   is  possible  that   in   the  mouse,  
GATA4  is  compensating  for  GATA6  leading  to  the  differences  in  phenotype.    
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In   the   mutant   ESindel/indel   and   iPSindel/indel   cell   lines,   there   was   significantly   decreased  
expression  of  both  GATA6  and  GATA4  (Figure  5-­1E  and  5-­1G)  suggesting  that  GATA6  
may  regulate   its  own  expression   in  addition   to  GATA4.  A  similar  observation  had  been  
made   in   the   visceral   and   primitive   endoderm   of   mouse   GATA6   knockout   embryos  
(Morrisey  et  al.,  1998).  However,  when  examining  a   loss  of  GATA6   in   the  heart   in   the  
embryo   proper,   there  was   no   decrease   in  GATA4  expression   levels   in  GATA6  mouse  
mutants   (Zhao  et  al.,  2005).  These  data  are  consistent  with   the  possibility   that  GATA6  
may   differentially   regulate   GATA4   expression   in   definitive   endoderm   in   human   and  
mouse  leading  to  the  observed  differences.    
  
Subsequently,   we   show   that   transgenic   expression   of   GATA4   rescued   the   definitive  
endoderm   differentiation   in   the   mutant   ESindel/indel   cells.   GATA4   has   been   shown   to  
compensate   for  a   lack  of  GATA6   in  zebrafish  and  murine  model  systems.   In  zebrafish,  
knockdown  of  GATA4  or  GATA6  by  morpholinos  led  to  the  formation  of  a  small  liver  bud  
that  did  not  expand;;  however,  with  a  loss  of  both  GATA  factors  the  liver  bud  completely  
failed  to  form  (Holtzinger  and  Evans,  2005).  In  mouse  models,  there  have  been  multiple  
studies   in  different   tissues   including  the  ovary,   intestinal  epithelium  and   liver  displaying  
similar   compensation   between  GATA4  and  GATA6   (Padua  et   al.,   2014;;  Walker   et   al.,  
2014;;  Zhao  et  al.,  2008).  Thus,  we  corroborate   that   in   the  human  system,  GATA4  can  
compensate  for  a  loss  of  GATA6.    
  
It  was  unanticipated   that  GATA3  and  GATA1  would  rescue  endoderm  differentiation  of  
mutant   ESindel/indel   cells   as   these   genes   are   not   normally   expressed   during   definitive  
endoderm   induction.   While   transgenic   expression   of   the   GATA   factors   rescued   the  
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differentiation,   GATA3   and   GATA4   did   so   more   robustly   than   GATA1.   These  
experiments  suggested   that   the  presence  of  any  GATA   family  member  at   the  primitive  
streak   stage   was   sufficient   for   definitive   endoderm   specification,   but   differences   in  
efficiency   were   seen.   GATA4   is   normally   expressed   in   endodermal   derived   tissues,  
GATA3   was   reported   to   be   expressed   in   endodermal   progenitor   cells   (Cheng   et   al.,  
2013)   and   GATA1   is   typically   expressed   in   hematopoietic   lineages   (Moriguchi   and  
Yamamoto,   2014).   In   addition   to   differences   in   tissue   expression,   there   may   also   be  
tissue   specific   functions   of   particular   GATA   family   members   explaining   efficiency  
variations  in  the  rescue  of  endoderm  induction.    
  
Similar   findings   of   compensation   were   reported   in   erythroid   cell   development.  
Transgenic   expression   of   GATA2   or   GATA3   could   rescue   erythroid   cell   development  
and  prevent  embryonic  lethality  in  GATA1  mutant  mice  (Takahashi  et  al.,  2000).  Despite  
the  fact  that  these  two  transcription  factors  were  expressed  in  hematopoietic  cells,  they  
were   not   normally   expressed   in   the   same   tissues   as   GATA1   (Bresnick   et   al.,   2012;;  
Orkin,  1995).  Transgenic  expression  of  GATA4  in  GATA1  mutant  mice  prolonged  the  life  
span  of   the  mice  but  did  not  prevent  death  due   to  anemia  revealing   that  GATA4  could  
not  completely  replace  GATA1  (Hosoya-­Ohmura  et  al.,  2006).  These  studies  corroborate  
our  own  findings  and  suggest  that  hematopoietic  and  endoderm  GATA  family  members  
may  have  distinct  functions.    
  
A  truncated  GATA6  protein  was  produced  in  the  GATA6  mutant  cell  lines  and  transgenic  
expression   of   this   protein   in   the   mutant   ESindel/indel   line   led   to   a   further   decrease   in  
definitive  endoderm  differentiation   (Figure  5-­9).     The  expression  of   this  protein  had  no  
impact   in   the   control   ES+/+   line   (data   not   shown).   These   data   suggested   that   the  
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truncated   GATA6   protein   may   have   mild   dominant   negative   activity.      Examination   of  
cells   with   GATA6   protein   null   alleles   will   be   important   to   determine   the   stage   and  
severity  of  the  endoderm  phenotype.  
  
All   of   the  GATA6  mutant  EP   lines  differentiated   into  pancreatic  β-­like  cells.  During   the  
differentiation  high  exogenous  addition  of  retinoic  acid  may  be  the  contributing  factor  that  
allows   the   differentiation   to   proceed   despite   any   intrinsic   deficiencies   that   may   result  
from  a   loss  of  GATA6.  Under   the   regular  concentration   (2  µM)  of   retinoic  acid,  patient  
iPS+/indel  cells  have  a  reduced  expression  of  GATA4  compared  to  to  control   iPS+/+  cells,  
corroborating   the   findings   of   a   decrease   in   GATA4   expression   in   cells   with   a   loss   of  
GATA6   at   the   definitive   endoderm   stage.   In   all   cell   lines   examined,   GATA4   is   further  
decreased  with  lower  concentrations  of  retinoic  acid  (Figure  5-­14C).  This  was  expected  
as  the  expression  of  both  GATA4  and  GATA6  can  be  induced  by  retinoic  acid  (Arceci  et  
al.,  1993;;  Mauney  et  al.,  2010).  One  explanation  for  the  differences  between  mouse  and  
human   phenotypes   that   result   from   a   heterozygous   loss   of   GATA6  may   be   lie   in   our  
findings  that  GATA4  is  downstream  of  GATA6.  In  mouse  models  with  a  conditional  loss  
of  GATA6  during  pancreatic  development  at  the  PTF1A  stage,  although  absolute  levels  
were   not   quantified,   GATA4   remained   express   in   the   adult   endocrine   pancreas  
(Martinelli  et  al.,  2013).  Furthermore,  a  conditional  loss  of  GATA6  in  the  jejunum  of  mice,  
revealed   that   a   loss   of   GATA6   did   not   affect   the   expression   of   GATA4   and   GATA4  
expression   levels   remained   comparable   to   wild   type   mice   (Walker   et   al.,   2014).      In  
contrast   to   in   vivo   mouse   models   of   a   loss   of   GATA6,   our   findings   suggest   that   in  
humans,  GATA4  may  be  downstream  of  GATA6  and   thus  a   loss  of  GATA6  cannot  be  
compensated  by  GATA4.    
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Figure   5-­15.   A   minimum   threshold   of   GATA4   and   GATA6   is   must   be   met   for  
pancreatic   progenitor   development.   (A)   Retinoic   retinoic   acid   can   induce   the  
expression   of   GATA6   and   GATA4.   GATA6   can   also   induce   the   expression   of  
GATA4.   Under   normal   conditions,   combined   expression   levels   of   these   GATA  
factors   is   above   the   minimum   threshold   for   pancreatic   progenitor   development.  
(B)  With  decreased   retinoic  acid  signaling   there   is  a  decrease   in  combine  GATA  
factor  expression.  However,   this   remains  above   the  minimum  threshold   required  
for  pancreatic  progenitor  development.  (C)  A  combination  of  reduced  retinoic  acid  
signaling   and  a   haploinsufficiency   in  GATA6  may   result   in   insufficient   combined  
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It  is  possible  that  in  vivo,  retinoic  acid  may  be  one  inducer  of  GATA4  and  GATA6  and  a  
minimum  combined  expression  level  of  GATA4  and  GATA6  is  necessary  for  pancreatic  
progenitor  development  (Figure  5-­15A).    Variability  in  endogenous  retinoic  acid  signaling  
in  different  people  can  result   from  differences   in  genetic  background.  Some   individuals  
may  have  slightly  decreased  retinoic  acid  and  thus  result  in  decreased  expression  levels  
of   GATA4   and   GATA6.   This   may   not   result   in   a   phenotype   as   GATA4   and   GATA6  
expression  may  still   remain  about   the  minimum  threshold   for  pancreatic  progenitor  cell  
specification   (Figure   5-­15AB).   However,   when   there   is   a   decrease   in   retinoic   acid  
signaling  combined  with  a  haploinsufficiency   in  GATA6,   the  expression  of  GATA6  from  
the  remaining  allele  and  induction  of  GATA4  expression  may  be  insufficient  to  meet  the  
minimum   threshold   for   combined   GATA   expression   levels.   Thus,   this   results   in   the  
inability  to  develop  pancreatic  progenitors  and  result  in  pancreas  agenesis  in  the  patient  
(Figure  5-­15C).  Furthermore,  variability   in  vivo  endogenous   retinoic  acid  signaling  may  
result   in  GATA6  mutations   that   have   incomplete   penetrance   as   displayed   by   different  
phenotypes  in  family  members  who  have  the  same  mutation  (Bonnefond  et  al.,  2012).      
     
When  examining  the  end  stage  β-­like  cell  differentiation,  the  patient  iPS+/indel  and  mutant  
ESindel/indel  β-­like  cells  had  decreased  β-­like  cell  yield.  Upon  examination  of  functionality,  
the  patient  iPS+/indel  and  mutant  ESindel/indel  β-­like  cells  did  not  secrete  insulin  in  response  
to   glucose   stimulation.      Gene   expression   analysis   of   mutant   ESindel/indel   β-­like   cells  
revealed   a   decreased   expression   of   PSCK1.   It   was   observed   that   these   cells   had   an  
increase   in   levels   of   proinsulin   within   the   cell   and   also   during   secretion   suggesting  
defective   insulin   processing.   These   data   in   both   the   patient   iPS+/indel   and   mutant  
ESindel/indel      lines   suggest   that   GATA6   is   a   critical   transcription   factor   for   the   robust  
differentiation  of  human  β  cells  and  their  full  functionality.  The  role  of  GATA6  in  the  β-­cell  
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functionality  in  the  patient  from  which  iPS  cells  were  generated  could  not  be  determined  
as   she   was   born   with   pancreatic   agenesis   (Stanescu   et   al.,   2014).   In   mice,   GATA6  
knockout   in  adult  β   cells  had  no  effect  on  β   cell  mass  or   function   (Sartori  et  al.,  2014)  
suggesting  similarities  and  differences  between  the  human  and  murine  systems.  
  
These  cell  lines  described  here  also  provide  an  important  model  for  studying  the  subset  
of   diabetic   patients   without   agenesis   who   have   GATA6   mutations.   The   in   vitro  
differentiation   of   GATA6   mutant   cells   will   provide   a   means   to   dissect   the   underlying  
disease   mechanism   at   different   stages   of   development.      The   PSC   lines   provided   a  
human  based  model  system  to  study  the  role  of  GATA6  in  endoderm  specification  and  
pancreatic   development.   The   utilization   of   an   intermediate   progenitor   population   was  
essential  for  defining  the  role  of  GATA6  in  pancreatic  β-­cell  functionality.  A  future  interest  
will  be  examination  of  pancreatic  β  cell  function  in  cells  expressing  heterozygous  GATA6  
mutations   from   patients   who   do   not   have   pancreatic   agenesis   but   present   with   adult  
onset  diabetes.      
  
In   this   study   the  use  of  PSCs  has  provided  a  powerful   human  based   system   to   study  
GATA6  mutations.  Important   insights  have  been  gained  into  the  role  of  GATA6  in  early  
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CHAPTER  6  
Summary  and  Speculations  
  
6.1  Comparing  ES  based  protocols  to  EP  derived  β-­like  cells  
Due   to   the   limited   availability   of   primary   human   islets   for   use   in   therapeutics   and  
research,  the  differentiation  of  β  cells  from  PSCs  that  faithfully  mimics  an  adult  β  cell  has  
long   been   one   of   the   goals   in   the   field.   One   of   the   main   concerns   with   the   original  
protocols   for   ES   cell   differentiation   to   endocrine   cells   is   that   the   resulting   cells   are  
polyhormonal,  lack  the  expression  of  NKX6.1  and  do  not  respond  to  glucose  with  insulin  
secretion  (D’Amour  et  al.,  2006;;  Kunisada  et  al.,  2012;;  Nostro  and  Keller,  2012).  These  
phenotypes  are  suggestive  of  a  cell   that  may  correspond  to  the  first  wave  of  endocrine  
cell  that  arises  in  vivo  during  the  primary  transition  of  fetal  pancreas  development.  First  
wave   endocrine   cells   arise   prior   to   the   expression   of   NKX6.1   and   co-­express   a  
combination  of   insulin,  glucagon  and/or  somatostatin   (De  Krijger  et  al.,  1992;;  Riedel  et  
al.,  2012)  but  lineage  tracing  studies  of  these  cells  have  shown  that  they  do  not  develop  
into   insulin  expressing  β  cells  (Herrera,  2000).  Furthermore,  unlike  adult  β  cells,   fetal  β  
cells  respond  poorly  to  glucose  stimulation  with  increased  insulin  secretion  (Blum  et  al.,  
2012;;  Hayek  and  Beattie,  1997;;  Hrvatin  et  al.,  2014).  The  phenotypes  of  the  ES  derived  
endocrine  cells  suggest  that  they  are  more  similar  to  fetal  β  cells  than  an  adult  β  cell.      
  
EP  cells  are  differentiated  into  β-­like  cells  under  the  same  protocols  used  in  the  original  
ES  cell  differentiation   to  endocrine  cells,  with  differentiated   initiated  at   the  primitive  gut  
tube   stage.   Differentiation   of   EP   cells   results   in   insulin   monohormal   and   glucose  
responsive  β-­like   cells.   Although   the   functionality   of   the  β-­like   cells   did   not   completely  
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replicate   primary   human   islets,   their   response   during   perifusion   is   as   good   or   better  
when   compared   to   the   functionality   of   ES   derived   β   cells   from   any   other   published  
protocols,   especially   by   perifusion   assay   (Pagliuca   et   al.,   2014;;  Rezania   et   al.,   2014).  
We  have  found  that  the  passaging  of  EP  cells  is  critical  for  this  to  occur.  Differentiation  of  
low   passage   EP   cells   results   in   a   subpopulation   of   polyhormonal   β-­like   cells   co-­
expressing  glucagon  and   insulin  with  poor  glucose  responsiveness.  The  percentage  of  
co-­expression   gradually   decreases   and   glucose   responsiveness   improves   as   the   EP  
cells   are   passaged   for   longer   periods   of   time   (data   not   shown).  We   hypothesize   that  
maintaining   EP   cells   in   culture   and   allowing   their   expansion   could   be   permitting  
epigenetic   changes   to   occur   in   the   EP   cells   that   are   important   for   their   later  
differentiation   to   glucose   responsive  β-­like   cells.   To   test   this,   chIP-­sequencing   can   be  
done  on  the  cells  to  examine  active  and  repressive  markers  on  chromatin.  Additionally,  
bisulfide  sequencing   for  observation  of  DNA  methylation  can  also  be  performed.  Using  
these   techniques  changes   in   low  passage  EP  cells   compared   to  high  EP  passage  EP  
cells  can  be  studied.  These  cells  can  also  be  compared   to  ES  derived  endocrine  cells  
and  ES  derived  β  cells  from  the  newer  protocols.    
  
6.2  Culturing  of  EP  cells  allows  for  their  maturation  
During  human  development,   the  first   insulin  positive  endocrine  cells  begin   to  appear  at  
approximately   7   weeks   of   fetal   age   (Jennings   et   al.,   2015;;   Piper   et   al.,   2004).      The  
original  ES  differentiation  protocols  take  approximately  18  days  (D’Amour  et  al.,  2006),  a  
relatively  condensed  amount  of  time  compared  to  in  vivo  development.  The  deficiencies  
that   result   in   endocrine   cells   differentiated   with   this   protocol   may   be   due   to   the  
insufficient  time  available  for  the  appropriate  maturation  of  the  cells.  Although  using  the  
same   differentiation   protocol,   EP   cells   may   be   able   to   overcome   some   of   these  
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deficiencies  as  they  have  been  expanded  as  an  endodermal  stem  cell  population,  which  
may  allow  for  the  maturation  of  the  endoderm.    
  
More   recently,  newer  protocols   for   the  differentiation  of  ES  cells  have  been  described.  
These   protocols   take   30   to   45   days   to   achieve   a   β   cell   that   has   improved   glucose  
responsiveness  with   a   subset   of   the   differentiated   cells  monohormonal   for   insulin  with  
the  co-­expression  of  NKX6.1   (Pagliuca  et  al.,   2014;;  Rezania  et  al.,   2014).  This   longer  
differentiation   protocol   may   allow   more   time   for   the   cells   to   mature   resulting   in   a  
functionally   superior   β   cell   compared   to   the   original   differentiation   protocols.   In   vivo,  
adult  β-­like  cells  develop  from  a  second  wave  of  endocrine  cell  development  that  occurs  
once   the   cells   have   begun   to   express  NKX6.1   (Nostro   and   Keller,   2012;;   Rieck   et   al.,  
2012).   The   newer  ES   based   protocols  may   result   in   superior  β   cells   compared   to   the  
original   ES   cell   protocols   as   they   more   closely   mimic   what   occurs   during   in   vivo  
development.  With  the  newer  differentiation  protocols,  NKX6.1  and  PDX1  cells  are  first  
derived   then   further   differentiated   to   insulin   positive   cells   more   closely   following   what  
occurs  in  vivo.  To  improve  upon  the  limitations  of  the  current  EP  derived  β-­like  cells,  the  
adaptation   and   optimization   of   these   newer   protocols   to   EP   cells   may   result   in   β-­like  
cells  with  enhanced  functionality  and  improved  maturity.    
  
6.3  The  Lack  of  NKX6.1  Expression  in  EP  derived  β-­like  cells  
It   is   interesting   that   EP   derived   β-­like   cells   are   glucose   responsive   despite   a   lack   of  
NKX6.1  expression.  Adult  mice  that  have  loss  NKX6.1  expression  become  diabetic  and  
have   decreased   insulin   content,   however   isolated   islets   remain   glucose   responsive   in  
vitro  (Taylor  et  al.,  2013).  It   is  possible  that  NKX6.1  is  not  necessary  for  functionality  in  
vitro  but   is  necessary   for   in  vivo   for  blood  glucose  homeostasis.  To  determine  whether  
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this   is  the  case,  EP  cells  could  be  targeted  in  AAVS1  locus  with  a  construct  containing  
NKX6.1  driven  by  an  inducible  promoter.  β-­like  cells  with  and  without  NKX6.1  expression  
could  then  be  transplanted  into  the  kidney  capsule  of  immune  compromised  mice.  Their  
functionality   in   vivo   can   then   be   examined   by   glucose   tolerance   test.   If   shown   to   be  
functional,   EP   derived   β-­like   cells   with   and   without   NKX6.1   expression   can   be  
transplanted  into  streptozotocin  induced  diabetic  mice  and  their  ability  to  maintain  blood  
glucose  homeostatic  in  vivo  can  be  tested.  One  current  limitation  that  would  first  have  to  
be  addressed  in  order  to  do  this  experiment,  is  that  the  current  method  of  differentiation  
does  not  allow  for  the  generation  of  a  sufficient  number  of  EP  derived  β-­like  cells  for  in  
vivo   transplantation.   Methods   for   scaling   up   of   the   differentiation   would   have   to   be  
explored.    
  
6.4  The  Function  and  Relationship  of  GATA  Family  Members  
While   patient   iPS+/indel   cells   can   robustly   differentiate   to   definitive   endoderm,   mutant  
iPSindel/indel   and   ESindel/indel   cell   differentiation   to   definitive   endoderm   is   inhibited.   This   is  
consistent  with   the   patient   phenotype;;   as   heterozygous   patients   have   the   presence   of  
other  endodermal  derived  tissues  suggesting  no  defects  in  endoderm  formation  (Chao  et  
al.,   2015).   We   show   that   re-­expression   of   GATA6   or   expression   of   GATA4   in   the  
ESindel/indel  cells  can  rescue  the  definitive  endoderm  differentiation.  It  has  been  shown  in  
other   model   organisms   that   GATA4   and   GATA6   can   compensate   for   the   loss   of   one  
another  (Holtzinger  and  Evans,  2005;;  Xuan  et  al.,  2012;;  Zhao  et  al.,  2008).  However,  in  
humans   there  have  been  reports  of  a   few  patients  who  have  pancreatic  agenesis  as  a  
result  of  a  mutation  in  GATA4  (Amato  et  al.,  2010;;  Shaw-­Smith  et  al.,  2014)  suggesting  
that  unlike  other  model  systems,  human  GATA4  and  GATA6  may  have  non-­redundant  
functionality.   In  our  experiments,  we  observe   that  a   loss  of  GATA6   leads   to  decreased  
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expression   levels   of   GATA4   during   definitive   endoderm   differentiation.   To   gain   an  
understanding   of   the   relationship   between   GATA6   and   GATA4,   PSCs   with   a  
heterozygous   and   homozygous   loss   of  GATA4   can   be   generated   by   use   of   CRISPR-­
cas9   genome   editing.   Differentiation   of   loss   of   GATA4   mutant   PSCs   to   definitive  
endoderm  and  observation  of  the  impact  on  expression  levels  of  GATA6  would  provide  a  
further   understanding   of   their   interactions.   Additionally,   if   a   loss   of   GATA4   leads   to  
decreased  efficiency  of  definitive  endoderm  differentiation,  similar  to  a  loss  of  GATA6,  it  
could   be   examined   whether   expression   of   GATA6   in   GATA4  mutants   can   rescue   the  
phenotype.    
  
In  addition   to  GATA6  and  GATA4,  we   found   that  GATA1  and  GATA3  can  also   rescue  
the  differentiation  to  definitive  endoderm.  It   is  possible  that   this  rescue  could  be  due  to  
these   GATA   factors   acting   through   GATA4   as   there   is   up-­regulation   of   endogenous  
GATA4.   To   investigate   if   GATA1   and  GATA3   can   directly   rescue   definitive   endoderm  
differentiation,  a  cell  line  with  the  double  knockout  of  both  GATA4  and  GATA6  could  be  
created  by  using  CRISPR-­cas9  genome  editing.  We  expect  that  with  a  double  knockout,  
the  cells  will  fail  to  differentiate  to  definitive  endoderm.    Expression  of  GATA1  or  GATA3  
can  then  be  introduced  during  definitive  endoderm  differentiation  and  examined  to  see  if  
they  can  rescue  the  differentiation  in  the  absence  both  GATA4  and  GATA6.    
  
6.5  Discrepancies  in  Phenotypes  of  GATA6  Mutations  
The   phenotypes   that   we   observed   in   our   differentiation   of   human   PSCs   to   definitive  
endoderm  and  β-­like  cells  are  different  to  those  that  are  observed  in  mouse  models  with  
a   heterozygous   and   homozygous   loss   of   GATA6.   In  mouse  models   GATA6   null   cells  
were   shown   to   contribute   to   the   endoderm   and   primitive   gut   tube   by   tetraploid  
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complementation  (Koutsourakis  et  al.,  1999;;  Zhao  et  al.,  2005).  One  reason  for  this  may  
be   the   differences  of   patient   specific  mutations   compared   to   loss   of   function   alleles   in  
mouse   models.   While   knockout   mice   are   generated   by   deletion   of   multiple   exons   of  
GATA6   resulting   in   unstable   mRNA   which   is   lost   (Morrisey   et   al.,   1998;;   Sodhi   et   al.,  
2006),  human  patients  often  have  point  mutations  or  small  insertions/deletions  leading  to  
the   presence   of   a   truncated   proteins   (Lango   Allen   et   al.,   2012).   In   some   cases,   the  
truncated   protein   may   be   non-­functional   and/or   lost   due   to   mRNA   degradation   and  
reflect  the  knockout  mouse  models.  However,  in  other  cases,  the  truncated  protein  may  
have   a   dominant-­negative   effect   and   thus   mutant   GATA6   mice   may   not   be  
representative   of   the   human   condition.   One   way   to   address   these   discrepancies   and  
determine  whether   it   is  a  species  specific  difference   is   to  generate  mouse  models  with  
the  same  heterozygous  GATA6  mutations  as  the  human  patient.  It  can  then  be  observed  
if  the  same  phenotypes  occur  with  the  same  mutations  across  different  species.    
  
Alternatively,  the  phenotypes  that  we  observe  may  be  due  to  differences  between  the  in  
vitro  and  in  vivo  systems.  To  study  whether  the  phenotypes  that  are  observed  in  human  
PSCs   are   due   these   differences,  mouse  PSCs  with   a   heterozygous   and   homozygous  
loss  of  GATA6  that  have  previously  been  generated  in  other  labs  (Sodhi  et  al.,  2006)  can  
be  obtained  and  differentiated  in  vitro  following  a  similar  protocol.    
  
Utilizing   the   in  vitro  differentiation  system  patient   iPS+/indel  and  ESindel/indel  EP cells could 
be differentiated to β-like cells, however, compared to their respective wild type control 
cells from the same genetic background, absolute β-like cell yield from iPS+/indel   and  
ESindel/indel   was significantly lower. While   these   findings   do   not   fully   recapitulate   the  
patient  phenotype  of  pancreas  agenesis,  a  decrease  in  β-­cell  mass  hints  at  a  defect  in  β-­
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cell   development.   We   find   that   decreased   concentrations   of   retinoic   acid   can   lead   to  
defective   β-­like   cell   differentiation   in   the   patient   iPS+/indel   cells.   During   in   vitro  
differentiation   retinoic   acid   may   be   supplied   at   a   much   higher   concentration   than  
conditions   that  are   found   in  vivo  overcoming  any  deficiencies   that   result   from  a   loss  of  
GATA6.   An   alternate   way   to   study   the   potential   of   GATA6   mutant   cells   is   by  
transplantation  of  endoderm  progenitor  cells  or  pancreatic  progenitor  cells   into   immune  
compromised  mice.  By  allowing  spontaneous  differentiation  to  occur  without  exogenous  
inductive  signals  driving  the  cells  toward  a  β  cell  fate,  it  can  be  determine  whether  a  loss  
of  GATA6  affects  the  ability  of  these  cells  to  differentiation  to  a  functional  β  cell.  
  
6.6  Down-­regulation  of  HNF4α  in  GATA6  mutant  β-­like  cells  
Heterozygous   mutations   in   HNF4α   cause   MODY1,   one   of   the   types   of   monogenic  
diabetes  (Steck  and  Winter,  2011).    It  is  a  possible  that  the  functional  defects  observed  
in   GATA6   mutant   β-­like   cells   are   due   to   the   decreased   expression   levels   of   HNF4α.  
Embryoid  bodies   formed  by  spontaneous  differentiation  of  mouse  GATA6  homozygous  
null  ES  cells  fail  to  express  HNF4α  which  is  one  of  the  genes  that  is  highly  upregulated  
in   wild   type   embryoid   bodies   (Morrisey   et   al.,   1998).  Moreover,   in   vitro   studies   in   the  
mouse   INS-­1   cell   line   show   that   in   the   presence   of   GATA6   with   patient   specific  
mutations,  GATA6  fails   to  bind  the  HNF4α  promoter  (Lango  Allen  et  al.,  2012)  and  the  
promoter  is  inactive  (Chao  et  al.,  2015).  To  address  whether  decreased  levels  of  HNF4α  
is   the  cause  of   the   functional  defects   in   the  GATA6  mutant  β-­like  cells,  HNF4α  can  be  
re-­expressed  in  iPS+/indel  and  iPSindel/indel  by  targeting  the  AAVS1  safe  harbor  locus.  If  re-­
expression  of  HNF4α   can   rescue  glucose   responsiveness   in   the  GATA6  mutant  β-­like  
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cells   this  would  suggest   that   the   loss  of   functionality   in   these  cells   is  due  to  decreased  
levels  of  HNF4α.  
  
6.7  Downstream  targets  of  GATA6    
To   gain   a   better   understanding   of   the   mechanisms   that   underlie   the   functionality   of  
human  β   cells,   it  would  be  beneficial   to  characterize  and   further  explore   the  molecular  
pathways   that   function   downstream   of   GATA6   in   β   cells.   Genome-­wide   transcriptome  
analysis  by  RNA-­seq  of   the  differentiated  β-­like  cells  can  be  performed.  β-­like  cells   for  
can  be  purified  by  either  utilization  of  the  Mel1-­INS-­GFP  reporter  cell  line  or  cell  sorting  
of  differentiated  cells  that  have  been  paraformaldehyde  fixed  and  stained  for  insulin.    By  
comparison   of   genes   that   are   differentially   regulated   in   GATA6+/+,   GATA6+/indel   and  
GATA6indel/indel  β-­like  cells,  we  can  investigate  the  mechanisms  by  which  a  loss  of  GATA6  
leads  to  a  functional  defect.  
  
6.8  Overcoming  the  limitations  of  EP  derived  β-­like  cells  
The  use  of  EP  cells  as  a  progenitor  cell  population  for  β-­like  cells  is  advantageous  over  
other  β  cell  differentiation  protocols  as  it  allows  us  to  overcome  the  developmental  block  
at   the  definitive  endoderm  stage   in   the  ESindel/indel  cells.  However,  one  deficiency  of  EP  
derived  β-­like  cells   is   that   they  do  not  express  NKX6.1.  Hence,  a  concern  of  using  EP  
derived  β-­like  cells  is  that  we  are  studying  a  phenotype  which  results  from  the  combined  
loss  of  both  GATA6  and  NKX6.1.  To  confirm  that  the  phenotype  observed  in  EP  derived  
β-­like   cells   is   reliable,   GATA6   mutant   cells   can   be   differentiated   with   other   β   cell  
differentiation   protocols.   However,   without   further   genetic   manipulation   this   would   be  
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difficult   with   the   ESindel/indel   and   iPSindel/indel   cells   due   to   the   developmental   block   at   the  
definitive  endoderm  stage.    
  
Although   lenti   viruses  could  be  used   to   rescue   the  phenotype  during  PSC   to  definitive  
endoderm   differentiation,   this   strategy   is   not   feasible   for   long-­term   differentiations   as  
lenti  viruses  are  silenced.  One  way  to  overcome  the  developmental  block  is  to  generate  
wild  type  PSCs  with  the  endogenous  GATA6  surround  by  loxP  sites.  The  AAVS1  locus  
can   be   targeted   with   a   CRE   recombinase   driven   by   the   insulin   promoter.   Upon  
differentiation  to   insulin  positive  cells,  GATA6  would  then  be  loss  through  cre-­mediated  
deletion.  Alternatively,  an  inducible  GATA6  construct  could  be  targeted  into  the  AAVS1  
safe  harbor   locus  of   the  ESindel/indel   and   iPSindel/indel   cells.  The  expression  of  GATA6  can  
then  be  modulated  to  levels  similar  to  wild  type  during  early  stages  of  the  differentiation  
and  removed  as  the  differentiation  progresses  beyond  the  definitive  endoderm  stage.  In  
addition,   the  differentiation  of   the  GATA6   inducible  ESindel/indel  and   iPSindel/indel  cells  using  
an  alternative  β  cell  differentiation  protocol  would  also  give  us  an  opportunity  to  examine  
if  GATA6  plays  a  role  in  regulating  the  expression  of  NKX6.1.    
  
6.9  Rescue  of  Functionality  in  β-­like  Cells  
In   addition   to   the  GATA6   inducible   iPSindel/indel,   the   introduction   of   an   inducible  GATA6  
construct   in   the   iPS+/indel   cell   lines   will   also   be   useful.  While   the   corrected   iPS+/+   cells  
have  improved  glucose  responsiveness  confirming  that  defective  functionality  is  due  to  a  
loss   of   GATA6,   it   would   be   beneficial   to   determine   whether   increased   expression   of  
GATA6   in   the   loss   of   function   GATA6  mutants   could   also   rescue   the   other   observed  
phenotype.   We   would   expect   that   with   induced   expression   of   GATA6,   both   the  
iPSindel/indel  and  iPS+/indel  cell  lines  would  have  increased  levels  of  PDX1  at  the  pancreatic  
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progenitor   stage   as  well   as   normal   glucose   responsiveness   and   proinsulin   processing  
upon  differentiation   to  β-­like  cells.  Additionally,   inducing  GATA6  expression  at  different  
stages   of   the   differentiation   would   also   allow   us   to   study   when   GATA6   is   needed.  
Utilizing   this   system   and   assessing   for   these   outcomes,   additional   cell   lines   with  
inducible  GATA4   could   also   be   created.   These   cell   lines  would   provide   further   insight  
into  the  degree  of  functional  redundancy  between  GATA  family  members  in  β  cells.    
  
6.10  Exploring  other  GATA6  patient  mutations  and  phenotypes  
In  this  work,  we  explore  one  specific  patient  mutation.  For  future  work  additional  patient  
mutations  should  be  studied  as  there  is  incomplete  penetrance  of  GATA6  heterozygous  
mutations.  Patients  with  the  same  mutation  have  been  shown  to  have  a  range  in  severity  
of   phenotypes   (Bonnefond   et   al.,   2012;;  De  Franco   et   al.,   2013;;  Yu   et   al.,   2014).  One  
reason   for   this   may   be   from   differences   in   genetic   background,   with   some   genetic  
backgrounds  resulting  in  a  higher  predisposition  for  a  more  severe  phenotype.  GATA4  is  
another  gene  which  results  in  pancreas  agenesis  with  varying  penetrance  (Amato  et  al.,  
2010;;  Shaw-­Smith  et  al.,  2014).  Mouse  model  studies  of  a  heterozygous  loss  of  GATA4  
in   different   strains   examined   for   cardiac   phenotypes   had   varying   penetrance   from   no  
disease   pathology   to   severe   cardiac   defects   suggesting   that   different   genetic  
backgrounds  may  play  a  role   in  penetrance  (Rajagopal  et  al.,  2007).  To  study  whether  
genetic  background  variations  affects  penetrance,  a  greater  number  of  patient  samples  
could  be  obtained  from  heterozygous  GATA6  patients  with  pancreas  agenesis  and  also  
from   adult   patients   who   have   diabetes   or   pancreas   phenotype.   Ideally,   the   same  
mutation  with  differing  phenotypes   in  different  patients  would  provide   the  most   insight.  
From  these  samples  iPS  cells  could  be  generated  and  differentiated  to  β  cells.  If  genetic  
background   did   play   a   role,   we   would   hypothesize   that   iPS   cell   lines   generated   from  
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samples  with  heterozygous  GATA6  mutations   that  did  not  have  a  phenotype  would  be  
glucose   responsive   and   express   higher   levels   of   PDX1   than   those   that   did   have   a  
pancreatic  phenotype.    
  
Furthermore,   an   understanding   of   the  mechanisms   that   regulate   penetrance   could   be  
studied   with   these   additional   patient   samples.   We   show   that   GATA4   is   able   to  
compensate   for  a   loss  of  GATA6  during  definitive  endoderm  differentiation.  Expression  
levels  of  GATA4  could  be  examined  in  these  additional  patient  samples  at  the  pancreatic  
progenitor  and  the  β-­like  cell  stage.    This  would  allow  us  to  investigate  whether  GATA4  
compensates   for   a   loss   of   GATA6   in   patients   with   milder   pancreas   phenotype.  
Additionally,   variability   of   retinoic   acid   signaling   could   be   examined   across   patient  
samples  of  different  genetic  backgrounds   to  determine  whether   this  plays  a   role   in   the  
penetrance.   By   titrating   different   concentrations   of   retinoic   acid   during   β-­like   cell  
differentiation,   we   would   expect   that   patient   samples   from   patients   with   pancreatic  
agenesis  will  be  more  sensitive  to  reduced  concentrations.  
	  
In   addition   to   pancreatic   agenesis,   GATA6   heterozygous   patients   often   have   other  
defects   including   biliary   atresia   and   heart   malformations   (Chao   et   al.,   2015).   Further  
studies   of   these   phenotypes   can   be   undertaken   by   differentiation   of   PSCs   to  
cholangiocytes  and  cardiomyocytes.  These  experiments  will  give  us  insight  into  whether  
in   these  other   tissues  GATA6  plays  a  cell   intrinsic  or  extrinsic  role   in   their  specification  
and  functionality.  Additionally,  it  will  provide  an  opportunity  to  examine  the  role  of  GATA6  
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